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1 Introduction 
 
1.1 The Ras superfamily of small GTPases 
The Ras superfamily, named after the most studied oncogene in human carcinogenesis, 
Ras, represents a group of small guanosine triphosphatases (GTPases), which comprises 
over 150 members in humans but can be found in all eukaryotes (Colicelli 2004, 
Wennerberg et al. 2005). The common feature of these proteins (with few exceptions) is 
their ability to bind and hydrolyse GTP due to the presence of a ~20 kDa G-domain. 
The G-domain consists of a six-stranded β-sheet and five α-helices and contains four to 
five conserved G-box motif elements (G1-G5), which are responsible for binding GTP. 
The so-called switch domains I and II bind γ-phosphate oxygens of GTP and after GTP 
hydrolysis and release of γ-phosphate, the switch domains relax into the GDP-specific 
conformation (Bourne et al. 1991).  
Ras proteins act as molecular switches, cycling between an active GTP-bound state 
and an inactive GDP-bound state. Guanine nucleotide exchange factors (GEFs) 
and GTPase activating proteins (GAPs) regulate the activation/inactivation cycle (Figure 
1.1). The dissociation of GDP from the inactive GDP-bound form is promoted by 
an upstream signal and conversion to the GTP-bound state is catalysed by GEFs. In the 
GTP-bound state, small GTPases are active and interact with downstream effector proteins. 
Hydrolysis of GTP to GDP is very slow and is accelerated by GAPs. In addition, GDP-
dissociation inhibitors (GDIs) regulate cycling of Rho and Rab GTPases between cytosol 
and membranes by capturing them in both GTP- and GDP-bound states (Colicelli 2004, 
Takai et al. 2001). 
 
 
 
Figure 1.1: Regulation of activity of small GTPases. In the active state, the GTPase binds GTP and 
interacts with effectors of signalisation. GAPs accelerate the hydrolysis of bound GTP. In GDP-bound state, 
small GTPases are inactive. GEFs catalyse the release of GDP. Due to the higher cytosolic concentration of 
GTP than GDP, the GTPase can again bind GTP. Taken from Colicelli (2004).   
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The Ras superfamily can be subdivided into five families according to the sequence 
and known functions of their members: Ras (Rat sarcoma oncoproteins), Rho (Ras 
homologous proteins), Rab (Ras-like proteins in brain), Ran (Ras-like nuclear protein), Arf 
(ADP-ribosylation factor) and Miro (mitochondrial Rho) (Colicelli 2004, Wennerberg 
et al. 2005). Members of the Ras superfamily are involved in a variety of cellular processes 
like gene expression (Ras, Rho), regulation of cell proliferation, differentiation 
and survival (Ras), actin organisation and cell cycle progression (Rho), vesicular transport 
and trafficking of proteins (Rab, Arf), transport between nucleus and cytoplasm 
and microtubule organisation (Ran) (Colicelli 2004, Takai et al. 2001, Wennerberg 
et al. 2005). 
 
1.2 The Rho-family  
The Rho family is characterised by an insertion (so-called Rho insert) of usually 13 
residues with high sequence variability between the fifth ß-strand and the fourth α-helix in 
the GTPase domain (Valencia et al. 1991). To date, 21 proteins of the Rho family have 
been described in vertebrates (Figure 1.2): Cdc42-like (Cdc42, TC10, TCL, Chp/Wrch2, 
Wrch1), Rac-like (Rac1-3, RhoG), Rho-like (RhoA-C), Rnd (Rnd1-2, Rnd3/RhoE), RhoD 
(RhoD und Rif), RhoH/TTF and RhoBTB (RhoBTB1-3) (Wennerberg and Der 2004). 
RhoBTB3 is very often not considered as a member of the Rho family because of its 
divergent GTPase domain. Members of the Rho family are present from lower eukaryotes 
up to mammals and have not been identified in eubacteria and archaea. 
The most studied Rho GTPases are RhoA, Rac1 and Cdc42. The members of the Rho, Rac 
and Cdc42 subfamilies are involved in regulation of cytoskeleton reorganisation in 
response to extracellular signals. Rho proteins are responsible for the formation of stress 
fibres and focal adhesions, Rac proteins for the formation of lamellipodia and Cdc42 
proteins are involved in filopodia formation. They also have been implicated in many other 
cytoskeleton-dependent processes like cell growth (G1 cell cycle progression), cytokinesis, 
morphogenesis, cell-cell interaction, cell polarity and cell migration. In addition, Rho 
proteins are involved in cellular processes such a membrane trafficking, endocytosis 
and gene expression (Jaffe and Hall 2005, Takai et al. 2001). Other Rho GTPases have 
been also identified in cytoskeleton-dependent processes like loss or formation of stress 
fibres (Rnd1, Rnd3, RhoD and Rif), focal adhesions (Rnd1, Rnd3, and RhoD), cell 
migration and cell-cell adhesion (Rnd3), formation of Cdc42-independent filopodia (Rif) 
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and cell migration and cytokinesis (RhoD) (Vega and Ridley 2007). For others, like Rnd2 
and RhoBTB1, 2 and 3 an effect on the actin cytoskeleton has not been observed. 
 
 
 
Figure 1.2: Phylogenetic tree of the Rho family of small GTPases. The family can be divided into six 
subfamilies: RhoA-related, Rac-related, Cdc42-related, Rnd proteins, RhoH/TTF and RhoBTB proteins. Note 
that RhoBTB3 is not shown in this tree because of its divergent GTPase domain. Taken from 
Burridge and Wennerberg (2004). 
 
Some of the members of the Rho family are referred to as atypical Rho GTPases because 
their structure and functional characteristics differ from those of the classical ones. 
The atypical GTPases are Rnd proteins, RhoH, Wrch1, Chp/Wrch2 and RhoBTB 
(Aspenström et al. 2007). One of the most striking features that make these Rho GTPases 
atypical is the difference in the cycling between the GTP- and the GDP-bound state. For 
example, RhoH has been shown to be constitutively in the GTP-bound state (Li et al. 
2002), as well as Rnd1 and Rnd3 (Chardin 2006). Wrch1 is predominantly in the GTP-
bound state (Saras et al. 2004, Shutes et al. 2004). RhoBTB proteins seem to be even more 
different – RhoBTB2 does not bind GTP (Chang et al. 2006) and it was shown recently 
that RhoBTB3 can bind and hydrolyse ATP (Espinosa et al. 2009). 
 
1.3 RhoBTB proteins 
The RhoBTB subfamily constitutes the more recent addition to the Rho family. It was 
identified during the study of Rho-related protein-encoding genes in Dictyostelium 
discoideum (Rivero et al. 2001). In humans, the RhoBTB subfamily is composed of three 
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isoforms: RhoBTB1, RhoBTB2 (also named DBC2, deleted in breast cancer 2) 
and RhoBTB3.  RhoBTB1 and RhoBTB2 are very similar to each other (79% similarity) 
and to the Drosophila orthologue (Dm RhoBTB), whereas RhoBTB3 (43% similarity to 
human RhoBTB1 and RhoBTB2) and the Dictyostelium discoideum orthologue (RacA) are 
the most divergent members. Orthologues of RhoBTB have been found in numerous 
eukaryotes, but they are absent in fungi and plants.  
 
1.3.1 Structure of RhoBTB proteins 
RhoBTB proteins consist of a GTPase domain followed by a proline-rich region, a tandem 
of two BTB domains and a C-terminal domain (Figure 1.3).  
 
 
 
Figure 1.3: Domain architecture of RhoBTB proteins.  The GTPase domain of RhoBTB3 is barely 
recognisable as such. The first BTB domain is interrupted by an insertion of variable length. Only RhoBTB3 
has a CAAX motif at the C-terminus. The simplified phylogenetic tree on the left illustrates the relationship 
among the proteins. Figures denote overall percentage similarity between branches, but the degree of 
similarity is higher when the comparisons are restricted to particular domains (not shown). Asterisks denote 
the positions of mutations in RhoBTB2 found in tumours. Hs: Homo sapiens, Dm: Drosophila melanogaster, 
Dd: Dictyostelium discoideum. Taken from Berthold et al. (2008a). 
 
1.3.1.1 The GTPase domain 
The GTPase domain is perhaps the region where most divergence is found among 
members of the RhoBTB subfamily. Early analyses revealed that this domain is typically 
Rac-like in RacA and divergent, but recognisable as Rho-related in RhoBTB1 
and RhoBTB2 as well as in Dm RhoBTB (Rivero et al. 2001).  
The GTPase domain of RhoBTB proteins other than RhoBTB3 and RacA also contains 
a Rho insert, which is characteristic for Rho proteins. This insert is longer than usual 
(18 residues or more) and rich in charged residues. Moreover, the GTPase domain of these 
RhoBTB proteins contains two insertions and one deletion, as well as a few deviations 
from the GTPase consensus of most Rho GTPases (Rivero et al. 2001). The deletion 
affects the phosphate/magnesium binding region within the switch II; in particular, one of 
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the deleted residues is the glutamine equivalent to Q61 in Ras. Also of importance, the 
glycine residue equivalent to G12 in Ras appears substituted by asparagine in RhoBTB1 
and RhoBTB2 or threonine in Dm RhoBTB. Because these two residues are essential for 
GTP hydrolysis, these proteins would predictably display impaired enzyme activity. 
Indeed, using a blot overlay approach, Chang et al. (2006) have shown that the GTPase 
domain of RhoBTB2 appears not to bind GTP at all. 
In RhoBTB3, the GTPase domain appears extensively erased, to the point that it is 
virtually unrecognisable as a GTPase. Only a short stretch at the end of the domain can be 
reliably aligned to the GTPase domain of other subfamily members. Interestingly, it has 
been shown recently that RhoBTB3 can bind and hydrolyse ATP (Espinosa et al. 2009). 
Small GTPases usually contain the sequence NKXD in the G4 box motif within 
the GTPase domain and the aspartic acid confers specificity for guanosine (Hwang 
and Miller 1987, Zhong et al. 1995). In RhoBTB3 this aspartic acid is mutated to 
asparagine and this is the crucial residue for ATP binding and hydrolysis (Espinosa et al. 
2009).  
In phylogenetic analyses, the GTPase domain of RacA groups together with GTPases of 
the Rac subfamily and all relevant residues for nucleotide binding and enzymatic activity 
are conserved (Rivero et al. 2001). In RacA the so-called Rho insert is shorter (6 amino 
acids) than the usual 13 amino acids of most Rac proteins. As far as it has been examined, 
the GTPase domain of RacA behaves like other Rac proteins (see section 1.3.3.4). 
 
1.3.1.2 The proline-rich region 
The proline-rich region links the GTPase to the first BTB domain. Sequences rich in 
proline are very common recognition motifs involved in protein-protein interactions. 
Among the modules that bind proline-rich regions are the SH3 (Src homology 3) domain, 
the WW domain, the Ena/VASP homology 1 domain, profilin, the GYF domain, ubiquitin 
enzyme variant (Uev), and the cytoskeleton-associated protein glycine-rich domain (Kay 
et al. 2000, Li 2005). The SH3 domain is often present in proteins involved in signal 
transduction and cytoskeleton organisation. The proline-rich region of some RhoBTB 
proteins could act as a SH3 domain binding site (Figure 1.4). Nevertheless, albeit 
the sequence analysis strongly suggests that the proline-rich region of several RhoBTB 
proteins is a potential SH3 domain-binding site, this still needs to be verified 
experimentally. 
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DdRacA SVPIPPVMPPAGKAPWIDIITS-       
HsRhoBTB1  PLLQAPFLPPKAPPPVIKIPECP 
HsRhoBTB2  PLLQAPFLPPKPPPPIIVVPDPP 
DmRhoBTB PLLQAPFRPPKPPPPEVTVMVG- 
HsRhoBTB3  HGIRPPQLEQPEKMPVLKAEAS-  
 
Figure 1.4: Alignment of proline-rich region sequences of RhoBTB proteins. The PxxP motif (where x 
denotes any amino acid) described initially as the core binding motif of the SH3 domain can be found in 
RhoBTB1, RhoBTB2, DmRhoBTB and Rac1. In RhoBTB3 this region is very poorly preserved. Subsequent 
analyses have defined proline-rich motifs for a number of different SH3 domains more precisely as +xFPxFP 
(class I ligands), FPxFPx+ (class II ligands) and R/KxxK/R (class III ligands); where F is a hydrophobic and + 
is in most cases a basic residue) (Kay et al. 2000, Li 2005, Mayer 2001). RhoBTB1 and RhoBTB2 have 
a conserved class II motif and DmRhoBTB has class III motif. Proline residues are marked in grey 
background. Class II motif and RxxK sequence are underlined. 
 
1.3.1.3 The BTB domain 
The BTB domain (Broad-Complex, Tramtrack, Bric à brac) was named after Drosophila 
transcription factors where this domain was first described. It is also known as a poxvirus 
and zinc finger domain (POZ). The BTB domain is an evolutionarily conserved domain 
that is widespread among eukaryotes. In humans, nearly 200 different proteins bear BTB 
domains, in most cases in combination with other domains. The BTB domain is a protein-
protein interaction domain participating in homomeric and heteromeric associations with 
other BTB domains (Aravind and Koonin 1999) and RhoBTB proteins are also capable of 
forming homodimers and heterodimers (Berthold et al. 2008b). The crystal structure of 
some BTB domains has been solved. The BTB core fold consists of a 95 amino acid 
globular cluster of 5 α-helices flanked by 3 short β-strands (Figure 1.4). The BTB domain 
of the RhoBTB proteins contains an N-terminal extension that folds into one α-helix 
and one β-strand, and this extension mediates the formation of dimers and oligomers 
(Stogios et al. 2005). 
More recently, it was shown that proteins containing BTB domains are components of 
cullin 3 (Cul3)-dependent ubiquitin ligase complexes (Furukawa et al. 2003, Geyer 
et al. 2003, Pintard et al. 2003, Xu et al. 2003) (see section 1.4.2). The role of RhoBTB 
proteins as components of Cul3-dependent complexes will be also discussed below (see 
section 1.4.3). 
The BTB domains of RhoBTB have some special features. A tandem of two BTB domains 
as in RhoBTB is not found within the BTB protein family. Moreover, the first BTB 
domain is bipartite, being interrupted by an extension of unknown function that is rich in 
charged residues.  
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Figure 1.4: Structure of the BTB domain. The BTB core folds from the structures of BTB-Zinc-Finger 
(BTB-ZF), Skp1, Elongin C and T1 are shown on the left hand panel. The core of the BTB fold consists of 
three conserved β-strands (B1 to B3) and five α-helices (A1 to A5). The 'long form' of BTB proteins has 
additionally one α-helix α1 and one β-strand β1. Skp1 protein has two additional α-helices at the carboxyl 
terminus (α7 and α8). Taken from Stogios et al. (2005). 
 
1.3.1.4 The C-terminal region 
Following the second BTB domain, there is a region conserved in all members of the 
RhoBTB subfamily that may constitute a novel domain, but has not been found so far in 
any other protein apart from RhoBTB. The core of the C-terminal domain consists of 
approximately 80 amino acids that predictably folds as four consecutive α-helices. The last 
helix ends close before the prenylation signal of RhoBTB3, but prolongs further in 
a predicted β-strand in RhoBTB1, RhoBTB2, and Dm RhoBTB (Ramos et al. 2002). 
RhoBTB are atypical Rho GTPases – in contrast to the classical Rho family members they 
do not undergo any known post-translational modification, and almost all of them lack 
the C-terminal CAAX prenylation motif that is recognised by a set of enzymes that 
introduce a post-translational modification, isoprenylation, responsible for the targeting of 
the modified protein to membranes. Only RhoBTB3 ends with the CAAX prenylation 
motif. Closely upstream of this motif is an additional cysteine residue, which suggests that 
RhoBTB3 might be also palmitoylated (Ramos et al. 2002).  
 
1.3.2 Expression of RhoBTB proteins 
The expression of both, mouse and human RHOBTB genes has been studied using different 
approaches. All three RHOBTB genes are ubiquitously expressed although with notable 
differences in the pattern of tissue levels among the three genes. Interestingly, while 
RHOBTB1 and RHOBTB3 showed high expression levels in many tissues examined, 
RHOBTB2 was very weakly expressed in both, human and mouse tissues. RHOBTB genes 
are also expressed in foetal tissues (Nagase et al. 1998a, Nagase et al. 1998b, Ramos et al. 
 15
2002). In addition, the expression of one or more RHOBTB genes has been reported in 
numerous human and mouse cell lines using RT–PCR. RHOBTB3 was found expressed in 
human cancer cell lines: in leukaemia cell lines, in cervical carcinoma and in colorectal 
carcinoma (Ramos et al. 2002). 
Expression of RHOBTB2 has been also studied during mammogenesis. St-Pierre et al. 
(2004) found that during mammary gland development in mice, RHOBTB2 transcripts are 
expressed at low but constant levels. However, attempts to study the spatial pattern of 
the expression of RHOBTB2 in the mammary gland using in situ hybridisation were 
inconclusive because of undetectable mRNA levels. 
 
1.3.3 Function of RhoBTB proteins  
Over the past years it has been shown that RhoBTB is involved in several cellular 
processes. However, the connection between these processes is largely unknown. The role 
of RhoBTB proteins as components of the Cul3-dependent complexes will be discussed 
below (see section 1.4.3). 
 
1.3.3.1 RhoBTB, cell growth, and apoptosis  
Overexpression of RhoBTB2 in the breast cancer cell line T-47D (a cell line that lacks 
RhoBTB2 transcripts) effectively suppressed cell growth in vitro (Hamaguchi et al. 2002). 
More recently, Freeman and co-workers have shown that the overexpression of RhoBTB2 
leads to a short-term increase in cell cycle progression and proliferation, but long-term 
expression has a negative effect on proliferation (Freeman et al. 2007). The growth arrest 
effect of RhoBTB2 has been explained by the downregulation of cyclin D1. Cyclin D1 is 
upstream of cyclin E, and the overexpression of any of both prevented the growth arrest 
effect of RhoBTB2 (Yoshihara et al. 2007). The effect on cyclin D1 is only partially 
dependent on proteasomal degradation. Moreover, it has not been investigated whether 
cyclin D1 is degraded by Cul3-dependent complexes through direct binding to RhoBTB2. 
The downregulation of cyclin D1 is essential for the cell proliferation suppression effect of 
RhoBTB2, but this works for T-47D cells and not for 293 cells. It therefore appears that 
the regulation of cyclin D1 is not a universal tumour suppressive mechanism used by 
RhoBTB2. The explanation has been put forward that resistance to RhoBTB2 in some cell 
lines may be achieved by rapid destruction of the protein through 26S proteasome-
mediated degradation (Collado et al. 2007). Further support for the roles in cell cycle 
regulation has been provided recently with the identification of RHOBTB2 as a target of 
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the E2F1 transcription factor (Collado et al. 2007). E2F1 is a member of a class of E2F 
implicated in the transcription of genes necessary for DNA replication and cell cycle 
progression and can also promote apoptosis (DeGregori and Johnson 2006). RhoBTB2 
levels increase upon initiation of prophase and decrease at telophase, and this effect 
depends on E2F1 (Freeman et al. 2007). RhoBTB2 levels also increase during drug-
induced apoptosis in an E2F1-dependent manner, and the downregulation of RHOBTB2 
delays the onset of apoptosis (Freeman et al. 2007). In agreement with an implication in 
this process, RhoBTB was found in Drosophila as one of several genes whose expression 
was significantly upregulated in a DNA microarray analysis aimed at identifying genes 
associated with cell death induced by the steroid hormone ecdysone (Lee et al. 2003). 
However, the role of RhoBTB as a possible cell death regulator was not investigated 
further. 
 
1.3.3.2 RhoBTB and chemokine expression 
It was shown recently that downregulation of RHOBTB2 by RNA interference in primary 
lung epithelial cells causes a decrease in mRNA expression of CXCL14 (a chemokine that 
controls leukocyte migration and angiogenesis). The same effect was observed in 
keratinocytes. Apparently, this effect is independent of Cul3-mediated protein degradation 
(McKinnon et al. 2008). 
 
1.3.3.3 RhoBTB and vesicle transport  
Chang et al. (2006) have addressed the potential role of RhoBTB2 in vesicle transport in 
a fluorescent recovery after photobleaching analysis with the help of a vesicular stomatitis 
virus glycoprotein (VSV-G) fused to GFP. VSV-G is extensively used to study anterograde 
transport from the endoplasmic reticulum (ER) to the Golgi apparatus (GA). Knockdown 
of endogenous RhoBTB2 hindered the ER to GA transport and resulted in the altered 
distribution of the fusion protein.  
More recently, it was reported that RhoBTB3 binds the GTP-bound conformation of Rab9 
through the second BTB domain and the C-terminal domain (Espinosa et al. 2009). Rab9 
localises to late endosomes and vesicles travelling towards the Golgi apparatus (GA). It is 
required for the trafficking of the mannose 6-phosphate receptors (MPRs) from late 
endosomes to the GA (Lombardi et al. 1993, Riederer et al. 1994). Using siRNA depletion 
of RhoBTB3 Espinosa et al. (2009) demonstrated that RhoBTB3 is required for retrograde 
transport of MPRs to the GA. Interestingly, these authors did not observe any alteration in 
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transport of VSV-G from ER to GA as it was reported for RhoBTB2 (Chang et al. 2006). 
By measuring ATPase activity of purified proteins Espinosa et al. (2009) demonstrated that 
Rab9 enhances ATP hydrolysis of RhoBTB3. Moreover, RhoBTB3 binds TIP47 (tail-
interacting protein of 47 kDa), that is recruited by Rab9 from the cytosol to late endosomes 
to package MPRs cargo for transport (Carroll et al. 2001, Ganley et al. 2004). Espinosa 
et al. (2009) proposed a model in which Rab9 activates RhoBTB3 on the GA, which 
removes TIP47 from the vesicles and permits membrane fusion of vesicles with the GA. 
Further, in support of a role in vesicle trafficking, RhoBTB has been identified as one of 
the genes that suppress the neuromuscular junction overgrowth phenotype induced in 
Drosophila larvae by the expression of a dominant negative form of the N-ethylmaleimide 
sensitive factor (NSF) (Laviolette et al. 2005). NSF is an ATPase that participates in 
vesicle trafficking through binding to the SNARE complex and is also important for 
the regulation of receptor trafficking (Zhao et al. 2007).  
 
1.3.3.4 RhoBTB and the actin filament system  
Although very atypical, RhoBTB proteins are members of the Rho family, therefore, 
the first aspect that was investigated was their effect on the organisation of the actin 
filament system. Aspenström et al. (2004) observed only a moderate influence on 
the morphology and actin organisation of porcine aortic endothelial cells upon the ectopic 
expression of RhoBTB1 and RhoBTB2. Not surprisingly, neither RhoBTB1 nor RhoBTB2 
were found to interact with the GTPase-binding domain of WASP, PAK1, or Rhotekin, 
three well-known effectors of many typical Rho GTPases. Confirming that, at least in 
metazoa, RhoBTB proteins do not play a major role in the organisation of the actin 
filament system, Dm RhoBTB was found among the proteins whose depletion had no 
effect on lamellae morphology in Drosophila S2 cells (Rogers et al. 2003). Unlike 
metazoan RhoBTB, the Dictyostelium orthologue RacA may be directly implicated in 
the regulation of the actin cytoskeleton. The GTPase domain of RacA, which is very 
closely related to members of the Rac subfamily, is able to interact with the Rac-binding 
domain of WASP and kinases of the PAK family in yeast two-hybrid assays (de la Roche 
et al. 2005, Han et al. 2006, Park et al. 2004). Unlike metazoan RhoBTB, RacA is 
susceptible to regulation by RhoGEF and RhoGAP, and in vitro interaction with 
a RhoGEF, GxcDD, has been reported recently (Mondal et al. 2007). RacA probably 
represents a “primitive” cytoskeleton-regulating stage of the RhoBTB subfamily that was 
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replaced in the evolved metazoan RhoBTB proteins by roles in cell proliferation 
and vesicle trafficking. 
 
1.3.4 RhoBTB in human diseases 
Since the first report proposing RHOBTB2 as a tumour suppressor gene, evidence is 
accumulating in support of members of the RhoBTB subfamily being implicated in 
tumorigenesis. The RHOBTB2 gene was identified as the gene homozygously deleted at 
region 8p21 in breast cancer samples (Hamaguchi et al. 2002). This is a region commonly 
associated with loss of heterozygosity (LOH) in a wide range of cancers. Alterations found 
in RHOBTB genes in tumour tissues and cell lines are summarised in Table 1.1 and are 
also depicted in the Figure 1.3.  
 
Tumour 
type 
Genomic 
alterations 
 (% cases) 
Mutation and effect Decreased 
expression  
(% cases) 
Reference 
RHOBTB1 
Head and 
neck  
23% LOH  
(n=52 tumours) 
None  
n = 52 tumours 
37%  
(n=46 tumours) 
(Beder et al. 2006) 
RHOBTB2/DBC2 
Breast 
 
 
3.5% HD  
(n=200 tumours) 
E5  G>A   D299N     No growth inhibition when re-
expressed 
E9  C>A   P647T      Unknown effect 
E5  A>C   D368A   Unknown effect 
n = 65 tumours + 65 cell lines of breast and lung cancer 
42%  
(n=19 cell lines) 
(Hamaguchi et al. 
2002)  
Lung  NA E5  T>G   Y284D    Abolished binding to Cul3 
n = 65 cell lines of breast and lung cancer 
50% 
(n=14 cell lines) 
(Hamaguchi et al. 
2002) 
(Wilkins et al. 2004) 
Breast 
(sporadic)  
NA Promoter    –238G>A   Altered expression? 
Promoter    –121C>T        Altered expression? 
5’ UTR        +48G>A        Altered expression? 
n = 100 tumours 
NA (Ohadi et al. 2007) 
Breast 
(familial)  
NA None 
n = 17 tumours 
NA (Ohadi et al. 2007) 
Stomach 29% LOH  
(n=95 tumours) 
E5  C>T     R275W     Unknown effect 
n=95 tumours 
NA (Cho et al. 2007) 
Bladder  
 
42% LOH 
 (n=54 tumours) 
38% LOH 
 (n=32 cell lines) 
E5  G>C   E349D      Unknown effect 
E7  G>A  G561S*   Unknown effect 
(only cases with SSCP mobility shift were sequenced) 
75%  
(n=12 cell lines) 
(Knowles et al. 2005) 
 
Table 1.1: Alterations found in RHOBTB genes in tumour tissues and cell lines. Only changes identified 
either as mutations or as polymorphisms that could result in functional alterations are shown in the table. The 
genomic structure of the RHOBTB genes is described in Ramos et al. (2002). Note that in the table exons are 
numbered from the first transcribed exon, whereas in Ramos et al. exon 1 was considered the exon with the 
ATG codon. RHOBTB1 is placed in 10q21.2, RHOBTB2/DBC2 in 8p21.3 and RHOBTB3 in 5q15. HD - 
homologous deletion; LOH - loss of heterozygosity; NA - not analysed; SSCP - single strand conformation 
polymorphism; *Polymorphism with possible effect. Modified from Berthold et al. (2008a). 
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In some of these studies decreased expression of RHOBTB1 and RHOBTB2 in tumour 
samples was observed (Beder et al. 2006, Hamaguchi et al. 2002, Knowles et al. 2005). 
Although we still have limited information on the status of RHOBTB genes in tumours, 
the picture that emerges from the reports is one of rare mutations but common reduced or 
extinguished expression. This observation can be made extensive to the third family 
member, RHOBTB3. Berthold et al. (2008b) determined the expression of RHOBTB3 in 
an array of tumour tissues and their matched normal tissues and have found a moderate but 
significant decrease of RHOBTB3 expression in the breast, kidney, uterus, lung, and ovary 
tumours.  
Recently, RhoBTB3 was proposed by Kurian et al. (2009) as a blood biomarker for 
psychosis that are accompanied by hallucinations, as decreased expression of RhoBTB3 
mRNA in patients with high hallucinations states was observed. 
 
1.4 RhoBTB proteins and proteasome-dependent degradation 
1.4.1 General overview of the proteasome-dependent degradation pathway 
Until 1980’s, protein degradation was an unexplored area of cell biology. This process was 
considered as an unspecific phenomenon. Today it is clear that destruction of proteins is 
as important as their synthesis to achieve homeostasis in living organisms. The key 
molecule in this process is ubiquitin, a small (8.6 kDa) globular protein. It is highly 
conserved among eukaryotes (e.g. human and yeast ubiquitin differ only in three amino 
acids), but is absent in eubacteria and archaea. It is necessary to mention that besides 
degradation of proteins, ubiquitination is also involved in other non-proteolytical cellular 
processes like histone modification (Shukla et al. 2009) and viral budding (Patnaik et al. 
2000, Schubert et al. 2000, Strack et al. 2000). 
Degradation of unwanted or misfolded proteins by the proteasome-dependent degradation 
pathway is accomplished in two consecutive steps: 1) substrate tagging by a polyubiquitin 
chain and 2) recognition of the polyubiquitinated protein by the 26S proteasome. First, 
the ubiquitin-activating enzyme E1 activates ubiquitin in an ATP-requiring reaction to 
generate a high-energy E1-thiol-ester~ubiquitin intermediate E1-S~Ub (Haas et al. 1982). 
This activated thiol moiety is transferred to the ubiquitin-conjugating enzyme E2 (also 
called ubiquitin-carrier protein, UBC), forming a high-energy thiol ester intermediate E2-
S~Ub (Hershko et al. 1983). Activated ubiquitin is then transferred from E2 to 
the substrate by the third enzyme called ubiquitin-ligase E3 (Hershko et al. 1983). It is the 
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E3, which specifically interacts with different substrates. E3s mediate this transfer by 
different mechanism and can be grouped in several classes. The two best known classes are 
HECT (homologous to the E6-AP COOH terminus) ligases and RING (Really Interesting 
New Genes) finger-containing ligases. In the case of HECT ligases, activated ubiquitin is 
transferred first to the E3 before it is conjugated to the ligase-bound substrate. RING 
finger-containing ligases catalyse the direct transfer of the ubiquitin to the substrate 
(Glickman and Ciechanover 2002) (Figure 1.5).  
 
 
 
 
Figure 1.5: Proteasome-dependent degradation pathway. E1 activates ubiquitin in an ATP-requiring 
reaction. Activated ubiquitin is then transferred to E2 and from E2 to the substrate by the third enzyme called 
ubiquitin-ligase E3. RING finger-containing ligases catalyse the direct transfer of ubiquitin from E2 to 
a lysine-residue on the substrate protein. HECT-domain E3 enzyme transfers ubiquitin from E2 to a cysteine-
residue on E3 and then to a lysine-residue in the substrate protein. Taken from Jung et al. (2009).  
 
The ubiquitin molecule has seven lysine residues (K6, K11, K27, K29, K33, K48 and K63) 
and it has been shown that for formation of ubiquitin chains in vivo all lysine residues are 
used (Peng et al. 2003). Ubiquitin is attached to the protein substrate by a covalent 
isopeptide bond between the C-terminal glycine of ubiquitin and the ε-NH2 group of 
a lysine residue of the substrate protein (Hershko et al. 1980). A polyubiquitin chain is 
formed by subsequent attachment of the C-terminal glycine of the next ubiquitin to 
the lysine of the previous ubiquitin. The minimal and sufficient length of polyubiquitin 
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chain that serves as a tag for degradation in the proteasome is four ubiquitin molecules 
(Thrower et al. 2000). Up to date, the best described and characterised polyubiquitin chains 
are the Lys48- and Lys63-linked chains. Lys48-linked polyubiquitin chains constitute 
the major signal for targeting the substrates to the proteasome for degradation (Pickart 
1997). Lys63-linked ubiquitination was believed to be involved in proteasome-independent 
processes such as DNA repair (Spence et al. 1995) and receptor endocytosis (Acconcia 
et al. 2009). However, nowadays there is also evidence that polyubiquitin chains linked 
through Lys63 to the protein may also serve as a signal for proteasome-dependent 
degradation (Kim et al. 2007, Saeki et al. 2009). 
Ubiquitin-mediated degradation is a very complex process that is undoubtedly crucial for 
proper cell function. It has been implicated in a variety of cellular processes, like cell-cycle 
regulation, signal transduction, transcription factor regulation (Glickman and Ciechanover 
2002, Weissman 2001), the quality control of newly synthesised proteins (ERAD) (Hirsch 
et al. 2009) and immune response (Bhoj and Chen 2009). Dysfunction of components of 
this pathway leads to the development of diseases like cystic fibrosis, atherosclerosis, 
diabetes, several neurodegenerative illnesses (e.g. Parkinson’s disease, Alzheimer’s 
disease) and has been linked also with the process of aging (Jung et al. 2009). 
 
1.4.2 Cullin (Cul)-dependent E3 ligases 
Cullins (of which there are 7 in mammals) function as scaffolding proteins that bring 
together the ubiquitin-conjugating enzyme and substrate-recognition components. 
The crystal structure revealed that they are composed of three repeats of five helix bundles 
and a globular C-terminal domain (Angers et al. 2006, Goldenberg et al. 2004, Zheng et al. 
2002). Cullins belong to the group of RING-finger containing ligases. The core ligase of 
a Cul-dependent complex consists of a cullin protein that binds the RING-finger protein 
Roc1 (which recruits the ubiquitin-conjugating enzyme) through its C-terminus and 
a linker protein through its N-terminus. An adaptor protein then acts as a bridge between 
the linker protein and the substrates. The complex is positively regulated by covalent 
attachment of the Nedd8 ubiquitin-like protein to the cullin subunit. Each cullin family 
member interacts with a specific linker. The Cul1 complex contains the Skp1 linker and 
an F-box-containing adaptor (called SCF complex: Skp1/Cul1/F-box). The Cul2 and Cul5 
complexes contain the linker Elongin C (along with Elongin B) and a SOCS-box-
containing protein (called ECVcomplex: EloB/C-Cul2-VHL-box protein or ECS complex: 
EloB/C-Cul5-SOCS-box protein). The Cul3 complexes contain a BTB domain-bearing 
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protein that functions simultaneously as linker and adaptor (Petroski and Deshaies 2005) 
(Figure 1.6). Interestingly, comparison of the structure of the BTB domain with Skp1 and 
Elongin C demonstrated that Skp1 and Elongin C are in fact BTB proteins that display 
a similar interface for interaction with the corresponding cullin, despite a low degree of 
primary sequence conservation (Stogios et al. 2005). 
 
 
 
 
Figure 1.6: Cullin-dependent ubiquitin ligases share a similar architecture. A)  The archetypal SCF 
complex contains Cul1, Skp1 and Rbx1/Roc1/Hrt1 and an F-box protein. B) ECV/ECS complex contains 
Cul2 (or Cul5), Elongin B/C, Rbx1/Roc1/Hrt1 and a BC-box protein. C)  In the ubiquitin-ligase complex 
containing Cul3, Rbx1/Roc1/Hrt1 and BTB-domain protein, the BTB protein associates directly with Cul3 
through its BTB domain without the help of a linker protein. Taken from Krek (2003).  
 
1.4.3 RhoBTB proteins as adaptors of Cul3-dependent ubiquitin ligases 
The identification of the BTB domain as adaptor in Cul3-dependent ubiquitin ligase 
complexes prompted Wilkins and co-workers to investigate whether RhoBTB2 may also 
take part in the formation of such complexes (Wilkins et al. 2004). They identified the N-
terminal region of murine Cul3 as an interacting partner of RhoBTB2 in a yeast two-hybrid 
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screening (Wilkins et al. 2004). RhoBTB2 interacts specifically with Cul3, but not with 
other cullin family members in vivo. The interaction was mapped to the first BTB domain 
in a series of pull-down experiments with deletion constructs. Wilkins et al. (2004) also 
provided evidence that RhoBTB2 is itself a substrate for Cul3-based ubiquitin ligase 
complexes, as treatment with proteasomal inhibitor MG132 or shRNA ablation of Cul3 
resulted in increased levels of RhoBTB2, and RhoBTB2 was polyubiquitinated by Cul3 
complexes in vitro. RhoBTB3, similar to RhoBTB2 interacts with Cul3 through the first 
BTB domain and upon proteasomal inhibition accumulates in the cells (Berthold et al. 
2008b). RHOBTB2 was proposed as a candidate tumour suppressor gene based on the fact 
that its re-expression in T-47D (a breast cancer cell line that lacks RHOBTB2 transcripts) 
caused growth inhibition, whereas the expression of the somatic mutant D299N did not 
have the same effect (Hamaguchi et al. 2002). This mutation is placed in the first BTB 
domain immediately before the insertion. In fact, it is interesting that almost all missense 
mutations found in the RHOBTB2 locus reside in the first BTB domain of the protein 
(Figure 1.3). The question arises whether one or more of those mutations result in impaired 
interaction with Cul3. This has been investigated by Wilkins et al. (2004) who found that 
the Y284D mutant, but not the D299N and D368A mutants, failed to co-immunoprecipitate 
with Cul3, and consequently, had a longer half life than the wild-type protein. The Y284D 
mutation resides in the dimerisation interface of the first BTB domain and could prevent 
proper folding. Analogous mutants have been shown to abrogate function by impairing 
folding of the BTB domain, for example, in the transcription factor PLZF (Melnick et al. 
2000).  
 
1.5 MUF1/LRRC41 
To date, no substrates have been shown to be degraded by RhoBTB-Cul3-dependent ligase 
complexes. Previous experiments performed in our laboratory identified a list of potential 
binding partners of RhoBTB3 that includes MUF1, kindlin-2 and Uev1a (S. Ramos, 
personal communication). However, these interactions have not been investigated 
extensively and are the object of this thesis. 
MUF1/LRRC41 (leucine-rich repeat containing 41) is a largely uncharacterised protein 
that has an N-terminal SOCS-box motif and a C-terminal leucine-rich repeat (LRR) region 
(Figure 1.7A). It has been shown that MUF1 interacts with Elongin B/C through the BC-
box subdomain of the SOCS-box. This interaction mediates binding to Cul5 and 
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the MUF1-Elongin B/C-Cul5-Rbx1 complex has ubiquitin ligase activity (Kamura et al. 
2001). The expression, subcellular localisation and function of MUF1 have not been 
addressed so far.  
 
 
Figure 1.7: Domain composition of MUF1. A) Schematic representation of MUF1. Numbering of amino 
acids is in respect to the murine MUF1. The SOCS-box is at the N-terminus of MUF1 and the leucine-rich 
repeat (LRR) region is C-terminal. B) Sequence alignment of MUF1 SOCS-box with representative SOCS-
box sequences and SOCS-box consensus. Amino acids at position A42-P71 of MUF1 are shown. Red arrows 
indicate amino acid residues crucial for interaction with EloB/C. SOCS3, SH2 domain-containing SOCS-box 
protein 3; WSB1, WD repeat-containing SOCS-box protein 1; ASB2, ankyrin repeat-containing SOCS-box 
protein 2; RAR, Ras-related SOCS-box protein; SSB1, SPRY domain-containing SOCS-box protein. 
Modified from Kamura et al. (2001). C) The LRR of murine MUF1. The conserved regions LxxLxLxxN/CxL 
are highlighted in grey.  
 
1.5.1 The SOCS-box 
The SOCS-box is a structural motif that has been initially characterised in the members of 
the suppressors of cytokines signalling (SOCS) family (Hilton et al. 1998). SOCS proteins 
have been originally identified as negative regulators of the JAK-STAT signalling pathway 
induced by cytokine stimulation (Endo et al. 1997, Naka et al. 1997, Starr et al. 1997). All 
SOCS proteins (SOCS1-7, CIS) share structural similarities: an N-terminal region of 
IGEVACGALDGSDPSCLGLPALEASQRFRSISTLELFTVPLSTEAALTLCHLLSSWV
SLESLTLSYNGLGSNIFRLLDSLRALSGQAGCRLRALHLSDLFSPLPILELTRAIVR
ALPLLRVLSIRVDHPSQRDNPAVPENAGPPGHIVGDEEIPENCLEQLEMGFPRGAQP
APLLCSVLKASGSLQQLSLDSATFASPQDFGLVLQTLKEHNLSLKRLSFHDMNLADC
QSEVLFLLKNLTLQEITFSFCRLFEKRPVQFLPEMVAAMKGNSTLKGLRLPGNRLGN
AGLLALADVFSEDSSSSLCQLDISSNCIKPDGLLEFAKRLERWGRGAFGHLRLFQNW
LDQDAVTAREAIRRLRATCHVVSDSWDSTQAFADYVSTM 
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variable length is followed by an SH2 domain and the SOCS-box, which is located at 
the C-terminus (Hilton et al. 1998, Starr et al. 1997). The SOCS-box is a ~40 amino acid 
motif composed of two well conserved blocks separated by 2 – 10 non-conserved residues 
(Figure 1.7B). The C-terminal conserved region is a cullin box motif, and the N-terminal 
conserved region is a consensus BC-box, a ~10 amino acid degenerate sequence motif with 
the consensus sequence (A,P,S,T)LxxxCxxx(A,I,L,V), where leucine at position 2 and 
cysteine at position 6 are highly conserved. SOCS-box proteins bind to the Elongin C 
through the BC-box (Kamura et al. 1998, Zhang J.G. et al. 1999), which is structurally 
similar to Skp1 and the BTB fold as already mentioned (Stogios et al. 2005). Binding of 
Elongin C to the BC-box is mediated by interaction with the highly conserved leucine at 
position 2 (Stebbins et al. 1999) and point mutations at conserved residues within the BC-
box abolish this interaction (Kamura et al. 1998, Kamura et al. 2001). Elongin C interacts 
with ubiquitin like protein Elongin B (Garrett et al. 1994) and the whole complex can bind 
to Cul2 or Cul5, depending on the specific cullin box (Kamura et al. 2004). The ECV 
complex (EloB/C-Cul2-VHL-box) and the ECS complex (EloB/C-Cul5-SOCS box) 
resemble SCF complex and have ubiquitin ligase activity (De Sepulveda et al. 2000, Iwai 
et al. 1999, Kamizono et al. 2001, Kamura et al. 2001). A large number of SOCS-box 
containing proteins accommodate additional domains like WD-40 repeats, SPRY domains 
and ankyrin repeats (Hilton et al. 1998, Masuhara et al. 1997). In all these proteins the 
SOCS-box domain is C-terminal. With an N-terminal SOCS-box, MUF1 seems to be 
unique. 
 
1.5.2 The LRR 
The leucine-rich repeat (LRR) is a structural motif that has been implicated in mediating 
protein-protein interactions. It has been identified in thousands of proteins in eukaryotes, 
bacteria, viruses and archaea. LRRs are usually 20-29 residues long sequences repeating 
multiple times within the protein (2 to 52 times). LRRs are usually composed of a so-called 
conserved segment, which shows significant similarities in all known LRR containing 
proteins, and a variable segment whose sequence varies among the members of different 
subfamilies (Bella et al. 2008). The sequence of the conserved region is LxxLxLxxN/CxL, 
where x denotes any amino acid. Later it has been shown that there is certain variability in 
the conserved region and leucine can be substituted by valine, isoleucine or phenylalanine; 
asparagine/cysteine can be substituted by either serine or threonine (Kajava 1998). 
The first LRR protein that has been crystallised was the ribonuclease inhibitor (RI). RI 
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adopts a curved solenoid structure where the LRRs form β-sheets on the concave side of 
the solenoid and are connected by loops with α-helices that align on the convex side 
(Figure 1.8A) (Kobe and Deisenhofer 1993). Since the 3D structure of RI has been solved, 
nearly 90 structures of other LRR proteins have been determined indicating that all LRRs 
adopt a more or less perfect solenoid conformation (Bella et al. 2008).  
LRR containing proteins have been implicated in wide range of cellular processes as cell 
adhesions, signalling, extracellular matrix assembly, platelet aggregation, neuronal 
development, RNA processing, invasion of pathogenic bacteria to the cell and immune 
response (Bella et al. 2008). Mutations in genes encoding LRR proteins have been 
associated with several human diseases such as schizophrenia, Parkinson’s disease and 
Crohn’s disease (Matsushima et al. 2005). 
 
Figure 1.8: 3D structure of LRR proteins. A) 3D structure of ribonuclease inhibitor (RI). The LRR 
domains are shown in cyan, the other domains are shown in magenta. Taken from Kobe and Kajava (2001). 
B) 3D structure of decorin core protein (DCN). DCN is capable of homodimerisation, where the surface on 
the concave side is used as a homodimerisation interface. Taken from Bella et al. (2008). 
 
It is the concave side of LRR domain that is mainly involved in protein-protein interactions 
and moreover, it has been demonstrated that proteins containing a LRR region form very 
often homo- and heterodimers (Figure 1.8B) (e.g. Toll-like receptor ectodomain, Ran 
GTPase-activating protein, monocyte differentiation antigen CD14) or even larger 
assemblies like tetramers (Yersinia outer membrane protein M, YopM) (Bella et al. 2008). 
Examination of the leucine rich repeat region of mouse MUF1 revealed at least four 
conserved 11 amino acids long LxxLxLxxN/CxL motifs (Figure 1.7C). 
 
1.6 The kindlin protein family 
The kindlin family consists of three members: kindlin-1, kindlin-2 and kindlin-3 (Siegel 
et al. 2003). Kindlins are encoded by the FERMT (fermitin family homologue) genes 
FERMT1, FERMT2 and FERMT3. The first identified member of this family was kindlin-
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2, which was identified among serum-inducible genes in serum-starved quiescent human 
fibroblasts and was initially named Mig-2 (mitogen-induced gene 2) (Wick et al. 1994). 
Kindlins are composed of a FERM (4.1, ezrin, radixin, moesin) domain, which is 
subdivided into four subdomains named F0, F1, F2 and F3 (Figure 1.9). The N-terminally 
localised F0 subdomain adopts an ubiquitin-like fold. The F1 subdomain is interrupted by 
an insert that has a similar size in kindlin-1 and kindlin-2, but is shorter in kindlin-3 (Goult 
et al. 2009). The F2 subdomain is interrupted by a pleckstrin homology (PH) domain 
and the F3 subdomain contains a phosphotyrosine binding fold (PTB) that is capable of 
recognising β integrin tails (Kloeker et al. 2004, Shi et al. 2007). 
 
 
 
 
Figure 1.9: Domain structure of kindlins. Kindlins are composed of a FERM (4.1, ezrin, radixin, moesin) 
domain, which is subdivided into subdomains named F0, F1, F2 and F3. The F2 subdomain is interrupted by 
a pleckstrin homology domain (PH). This insertion does not interfere with FERM domain function.  
A nuclear localisation signal has been described in the F0 subdomain of kindlin-2.  
 
1.6.1 The role of kindlins in integrin activation 
All three kindlins have been shown to bind directly to cytoplasmic tails of β1 and β3 
subunits of integrins (Figure 1.10) and have been identified as key regulators of integrin 
activation, together with talin (Harburger et al. 2009, Moser et al. 2008, Ussar et al. 2008). 
Integrins are heterodimeric transmembrane receptors that are composed of α and β 
subunits. There are 18 α and 8 β subunits in mammals that combine with each other to 
form 24 specific dimers.  Each integrin subunit has a large extracellular domain, a short 
transmembrane domain and a cytoplasmic tail (Hynes 2002). Inactive integrins assume 
a bent conformation and are in a low affinity binding state for ligands; they shift to a high 
affinity state during activation (Moser et al. 2009). Integrins are localised in focal 
adhesions and interact with proteins of the extracellular matrix (ECM) through their 
extracellular domain and, via talin, with the actin cytoskeleton through their cytoplasmic 
tail (Zhang et al. 2008). Through these interactions integrins constitute a fundamental 
connection for bi-directional communication between the ECM and the intracellular 
environment. Talin, similarly to kindlins, bears a FERM domain composed of F0, F1, F2 
and F3 subdomains. The F3 subdomain contains a PTB that is the major integrin binding 
site (Wegener et al. 2007). Both talin and kindlin are crucial for integrin activation by 
binding to the cytoplasmic tail of β integrins. The F3 subdomain of talin binds to 
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the membrane proximal NPxY motif and induces separation of integrin tails, whereas 
kindlin binds to the membrane distal NxxY motif (Moser et al. 2009). 
 
 
 
Figure 1.10: A model of kindlin binding to β integrin cytoplasmic tails. Kindlin prefers to interact with 
a membrane distal (T/S)TxxNxxY amino acid sequence but interaction with the membrane proximal NPxY 
motif has been also reported. The N-terminal region corresponds to the F0 subdomain Taken from Meves 
et al. (2009). 
 
1.6.2 Expression and localisation of kindlins 
Human kindlin genes show distinct differences in expression. Expression of kindlin-1 is 
restricted to the skin epithelial cells (keratinocytes) and intestinal epithelial cells (Lai-
Cheong et al. 2008, Siegel et al. 2003, Ussar et al. 2006), while kindlin-2 is ubiquitously 
expressed with the exception of the hematopoietic cells, where kindlin-3 was found (Ussar 
et al. 2006). Kindlin-1 and kindlin-2 localise predominantly to focal adhesions in 
keratinocytes (Kloeker et al. 2004, Siegel et al. 2003, Tu et al. 2003, Ussar et al. 2006) but 
cytoplasmic localisation of kindlin-1 has also been reported, including the perinuclear area 
(Kloeker et al. 2004, Lai-Cheong et al. 2008, Siegel et al. 2003). Localisation of kindlin-2 
to stress fibres has also been reported (Tu et al. 2003). Kindlin-2 is the only member of 
the kindlin family that contains a nuclear localisation signal (Ussar et al. 2006) 
and endogenous kindlin-2 was visualised in the nuclei of smooth muscle cells (Kato et al. 
2004). Contrary to this, kindlin-1 but not kindlin-2 was found in the nucleus of normal 
human keratinocytes (Lai-Cheong et al. 2008). Mouse kindlin-3 localises to the podosomes 
of macrophages and dendritic cells that are integrin-dependent adhesion sites in 
hematopoietic cells (Ussar et al. 2006). 
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1.6.3 Kindlin in human diseases 
All three kindlins have been implicated in human diseases and cancer. This family is 
named after dermatologist Theresa Kindler who described a patient with traumatic bulla 
formation, atrophy of the skin and congenital poikiloderma. Today this disease is named 
Kindler syndrome, an autosomal recessive genodermatosis caused by loss-of-function 
mutations in the FERMT1 gene. These mutations are predicted to reduce expression and 
function of kindlin-1. It was reported that patients with Kindler syndrome have 
a predisposition to non-melanoma skin cancer and expression of kindlin-1 and kindlin-2 is 
altered in many cancer cell lines. Mutations in the FERMT3 gene cause so called LAD-III 
syndrome (leukocyte adhesion deficiency), which is characterised by bleeding problems 
and life-threatening infections (Lai-Cheong et al. 2009). 
 
1.7 Uev1a 
Uev1a (ubiquitin-conjugating E2 enzyme variant, also called CROC1, CIR1, UBE2V) was 
originally identified as a signal transducing molecule able to activate the human FOS 
proto-oncogene promoter (Rothofsky and Lin 1997). Uev1a resembles ubiquitin-
conjugating enzymes in sequence as well as structure, but lacks the ability to transfer 
ubiquitin to the substrate due to the absence of a catalytic cysteine residue (Sancho et al. 
1998). Uev1 interacts with Ubc13 (Andersen et al. 2005), which is the only ubiquitin-
conjugating enzyme identified so far that mediates the assembly of Lys63-linked 
polyubiquitination chains (Hofmann and Pickart 1999). For this process both of 
the proteins are required; neither Ubc13 nor Uev1a alone is able to promote Lys63 
polyubiquitination chain formation (Hofmann and Pickart 1999, McKenna et al. 2001). 
The crystal structure of Uev1a has been solved recently. Based on this, a structural model 
of the Ub-Ubc13-Uev1a~Ub tetramer has been proposed that elucidates the mechanism 
how specificity in forming Lys63-linked polyubiquitin chains is achieved (Hau et al. 
2006). 
An increasing line of evidence supports the role of Ubc13-Uev1a complex in activation of 
NFκB (Deng et al. 2000, Shi and Kehrl 2003, Wang et al. 2001). One of the pathways that 
lead to the activation of NFκB is TNFα (tumour necrosis factor α) signalling. Briefly, 
the proinflammatory cytokine TNFα binds to the TNFR (TNFα receptor), which causes 
aggregation of the receptor and allows binding of TRADD (TNFR-associated death 
domain protein). TRADD recruits multiple adaptor proteins like TRAF (TNF-receptor-
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associated factor) and RIP (receptor interacting protein 1) that subsequently recruit IκB 
kinase complex (IKK). IKK is composed of two kinase subunits IKKα and IKKβ and one 
regulatory subunit IKKγ (also called NEMO, NFκB essential modifier). Activated IKKβ 
phosphorylates IκBα (inhibitor of NFκB complex) that serves as a signal for SCF-ligases to 
ubiquitinate IκBα. Proteasomal degradation of IκBα frees the NFκB dimer, which 
translocates to the nucleus where it binds to the promoter or enhancer regions of target 
genes (Hayden and Ghosh 2004). It has been shown that the family of TRAF proteins, 
which contain a RING-domain, have ubiquitin-ligase activity and upon binding of the Ubc-
Uev1a complex catalyse the synthesis of Lys63-linked polyubiquitin chains (Deng et al. 
2000). This complex ubiquitinates RIP (Ea et al. 2006) as well as NEMO (Andersen et al. 
2005), which leads to the activation of IKK (Figure 1.11).  
 
 
 
Figure 1.11: Model depicting the function of Ubc13-Uev1a ubiquitin conjugating enzyme in NFκB 
signalling pathway. TNFα binds to the TNFR that promotes the interaction between TRADD, RIP1 and 
TRAF2/6. Ubc13-Uev1a is involved in ubiqitination of NEMO and RIP by forming Lys63-linked 
polyubiquitin chains. Activated IKKβ phosphorylates IκBα. Phosphorylated IκBα is modified by Lys48-
linked polyubiquitin chain that results in its degradation in proteasome. Activated NFκB dimer translocates to 
the nucleus. Taken from Syed (2006). 
 
Activation of the NFκB signalling pathway leads to anti-apoptotic response (Kucharczak 
et al. 2003) and its constitutive activation is frequently observed in many cancer cells 
(Lin and Karin 2003). Uev1a has been proposed as a candidate proto-oncogene based on 
the observations that its expression is up-regulated in immortal cell lines in comparison to 
pre-immortal counterparts as well as in all cancer cell lines examined (Ma et al. 1998, Xiao 
et al. 1998). Consistent with this, Syed et al. (2006) have demonstrated that overexpression 
of Uev1a alone is capable of evoking NFκB signalling and protects cells from stress-
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induced apoptosis. Thus, up-regulation of Uev1a seems to be sufficient to drive cells 
towards tumourigenesis. 
 
1.8 Aims of the study 
RhoBTB proteins constitute a subfamily of atypical Rho GTPases. They consist of 
a GTPase domain followed by a proline-rich region and two BTB domains. BTB domains 
are involved in the formation of Cul3-dependent ubiquitin ligase complexes, therefore 
the function of RhoBTB proteins seems to be distinct from that of the classical Rho 
GTPases. Since RhoBTB proteins have been described relatively recently, still little is 
known about their function and significance in cellular processes.  
Connecting to previous research in our laboratory, we aim to further characterise 
the subcellular localisation of RhoBTB3, one of the RhoBTB isoforms, by counterstainig 
with various cellular markers. We will also explore the localisation of RhoBTB3 relative to 
the cytoskeleton. RhoBTB2 has been shown to act as an adaptor in multicomponent Cul3-
dependent ligase complex and previous observations from our laboratory indicate that this 
feature might be shared also by RhoBTB3. Therefore the next aim of this study is to 
further characterise the function of RhoBTB3 in Cul3-dependent ligase complexes, namely 
its interaction with Cul3, heterodimerisation, ubiquitination and degradation. Potential 
binding partners (and therefore possible substrates of RhoBTB3-Cul3-dependent ligase 
complexes) have been identified previously in a two-hybrid screening. Another aim is to 
verify the interaction of RhoBTB3 with three of those candidate binding partners, MUF1, 
kindlin-2 and Uev1a. Because MUF1 is, like RhoBTB, involved in the formation of Cul-
dependent ligase complexes, we will focus on the relationship between MUF1 
and RhoBTB3. We will analyse the expression and subcellular localisation of MUF1, 
the latter one also with respect to RhoBTB3, and will address the interaction of both 
proteins by domain mapping. We will explore the significance of MUF1-RhoBTB 
interaction within Cul-ligase complexes and the mechanism of MUF1 degradation. We will 
also examine whether MUF1 is able to dimerise similarly to other LRR containing 
proteins. Finally, since MUF1 interacts with Cul5 and it has been described recently that 
cullins can form dimers, we will also explore a possible heterodimerisation of Cul3 
and Cul5. 
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2 Material and Methods 
 
2.1 Material 
2.1.1 Cell lines and strains 
Name Origin/Source Description 
Mammalian cell lines 
COS7 Cercopithecus aethiops African green monkey fibroblast-like 
cell line, isolated from kidney, contains 
large T antigen of SV40 
293T HEK Homo sapiens Human embryonic kidney cells 
transformed with large T antigen of 
SV40 
HeLa Homo sapiens Cervix carcinoma 
Bacterial strains 
E. coli XL1-Blue  Bullock (1987) 
Yeast strains 
Y190  Flick and Johnston (1990), Harper et al. 
(1993) 
 
2.1.2 Vectors 
Vector Features Source 
pEGFP-C2 
pEGFP-C3 
4.7 kb; GFP N-terminal, kanamycin resistance, 
for transient expression in mammalian cells 
Clontech 
pCMV-Myc 3.8 kb; Myc N-terminal, ampicillin resistance, for 
transient expression in mammalian cells 
Clontech 
pcDNA3.1.(-) 5.4 kb; ampicillin resistance, for transient 
expression in mammalian cells 
Invitrogen 
pcDNA3-Myc3 5.4 kb; 3x Myc N-terminal, ampicilin resistance, 
for transient expression in mammalian cells 
Ohta et al. (1999)
pRK5-Myc 5.4 kb; Myc N-terminal, ampicillin resistance, for 
transient expression in mammalian cells 
Aspenström et al. 
(2004) 
pGBKT7 7.3 kb; kanamycin resistance, for expression in 
yeast cells, GAL4-binding domain 
Clontech 
 
2.1.3 Oligonucleotides for siRNA 
The oligonucleotides for Cul3 silencing along with ON-TARGETplus Non-targeting 
siRNA were obtained from ThermoScientific. 
 
siCul3 
Target sequence: NNGAAGGAAUGUUUAGGGAUA 
Sense sequence: GAAGGAAUGUUUAGGGAUAUU 
Antisense sequence: UAUCCCUAAACAUUCCUUCUU 
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2.1.4 Oligonucleotides for RT-PCR 
MUF1/fwd/E5_E6 GAGAGCCTTACACTTTCCTACAATGGTC (Sigma) 
MUF1/rev/ E9_E10 CTAATAGGCCAGCGTTCCCCA (Sigma) 
 
Reaction ReadyTM Mouse GAPD Internal Normaliser - Primer set (Super Array Bioscience 
Corporation) 
 
2.1.5 Oligonucleotides for PCR 
The oligonucleotides listed below were obtained from Sigma. Engineered cloning sites are 
underlined. 
Gene Name Sequence 
Mm MUF1 MUF1/FL/fwd/EcoRI GAATTCATGGAGGCCACGTCCCGGGA
GGCGGCGCCAGCGAAGAGCTCGGCCT
CGGGCCCCAGCGCTCCCCCCG  
Mm MUF1 MUF1/mt/fwd GAGCTCGGCCTCGGGCCCCAGCGCTC
CCCCCGCCCCGTTCGAGCTGTTCGGG
CGG 
Mm MUF1 MUF1/fwd/ΔSOCS/ 
EcoRI 
GAATTCATGTATTACTTGGAGAGGAT
TGAGGAAACTGCT  
Mm MUF1 MUF1/fwd/LRR/ 
EcoRI 
GAATTCATGGAGGCCACGTCCCGGGA
GGCGGCGCCAGCGAAGAGCTCGGCCT
CGGCCCCAGCGCTCCCCCCG  
Mm MUF1 MUF1/1110_1137/ 
rev/HindIII 
AAGCTTAGACCCCTGACGGGTGCGGG
GCCCTTTC 
Mm MUF1 MUF1-FL/rev/Hind3 AAGCTTTCACATGGTGCTGACATAAT
CTGCAAAGGC 
Mm MUF1 MUF1-FL-
flag/fwd/NheI 
GCTAGCGCCGCCACCATGGACTACAA
AGACGATGACGATAAAATGGAGGCC
ACGTCCCGGGAG 
Mm MUF1 MUF1/fwd/IPl/EcoRI GAATTCGCCGCCACCATGGAAAACAG
TACCACCACCATTTCTCGGGAGGAGC
TTGAAGAGCTACAAGAAGCGGGATCC
ATGGAGGC CACGTCCCGGGAG 
Mm MUF1 MUF1/rev/IPl/HindIII AAGCTTTCAGTCAGTCAGGATCCTCA
CATGGTGCTGACATAATCTGCAAAGG
C 
Mm RhoBTB3 RBTB3-Rho-
fwd/EcoRI 
GAATTCTTATGTCCATCCACATCGTGG
CGTTG  
Mm RhoBTB3 RhoBTB3-H270L fwd AGCCCTCAAGATCGTTCTCTGCTCTGT
AAGCCATGTTTTC 
Mm RhoBTB3 RhoBTB3-H270L rev GAGCAGAGAACGATCTTGAGGGCTTC
CACGACGCCCGTCAC 
Mm RhoBTB3 B3-C/rev/EcoRI GAATTCAGTCAGTCAAGCTTAGATCT
CATGACTAAACAGCGACATTTCCGGG 
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2.1.6 Constructs 
Construct Insert 
extension
Backbone Author 
Constructs for expression in mammalian cells 
Mm Flag-MUF1 23-807 pcDNA3.1.(-) This work 
Mm Flag-MUF1ΔSOCS 82-807 pcDNA3.1.(-) This work 
Mm MUF1 25-807 pcDNA3-Myc3 This work 
Mm MUF1/N 23-575 pcDNA3-Myc3 This work 
Mm MUF1ΔSOCS 82-807 pcDNA3-Myc3 This work 
Mm MUF1/C (587-786) 609-807 pcDNA3-Myc3 Marion Kopp 
Mm MUF1/C (587-716) 609-735 pcDNA3-Myc3 Marion Kopp 
Mm MUF1/C (702-786) 724-807 pcDNA3-Myc3 Marion Kopp 
Mm MUF1-FL 25-807 pEGFP-C3 This work 
Mm MUF1(L46P,C50F) 23-807 pEGFP-C3 This work 
Mm MUF1ΔSOCS 82-807 pEGFP-C2 This work 
Mm MUF1-LRR 403-807 pEGFP-C2 This work 
Empty vector with I-Plastin 
tag I-Pl* 
- pcDNA3.1.(-) This work 
Mm I-Pl-MUF1-FL 23-807 pcDNA3.1.(-) This work 
Mm RhoBTB1-C 583-695 pEGFP-C1 Jessica Berthold 
HsRhoBTB2-FL 1-728 pEGFP-C1 Berthold et al. (2008b) 
Mm RhoBTB3-FL 1-611 pEGFP-C1 Berthold et al. (2008b) 
Mm RhoBTB3(H270L) 1-611 pCMV-Myc This work 
Mm RhoBTB3-GTPase 1-204 pEGFP-C1 Berthold et al. (2008b) 
Mm RhoBTB3-B1 236-402 pEGFP-C1 Berthold et al. (2008b) 
Mm RhoBTB3-B2 396-592 pEGFP-C1 Berthold et al. (2008b) 
Mm RhoBTB3-C 522-611 pEGFP-C1 Berthold et al. (2008b) 
Mm RhoBTB3-PB1B2C 196-611 pEGFP-C1 Berthold et al. (2008b) 
Mm RhoBTB3-B1B2C 236-611 pEGFP-C1 Berthold et al. (2008b) 
Mm RhoBTB3-B2C 396-611 pEGFP-C1 Farshad Khademi 
Hs RhoBTB3-FL 1-611 pRK5-Flag Berthold et al. (2008b) 
Hs RhoBTB2-FL 1-728 pRK5-Flag Berthold et al. (2008b) 
Hs RhoBTB1-FL 1-696 pRK5-Flag Pontus Aspenström 
Hs RhoBTB3 1-611 pRK5-Myc Berthold et al. (2008b) 
Hs RhoBTB2 1-728 pRK5-Myc Aspenström et al. (2004) 
Hs RhoBTB1 1-696 pRK5-Myc Aspenström et al. (2004) 
Mm RhoBTB3-GTPase 1-204 pRK5-Myc Jessica Berthold 
Hs Cullin 3 (Cul3) 1-768 pcDNA3-FlagJ Ohta et al. (1999) 
Hs Cullin 3 DN (Cul3 DN) 1-457 pcDNA3.1.-Flag Pontus Aspenström 
Hs Cullin 3 (Cul3) 1-768 pcDNA3-Myc3 Ohta et al. (1999) 
Hs Cullin 5 (Cul5) 1-780 pcDNA3-Myc3 Ohta et al. (1999) 
Hs Cullin 5 ΔNΔC  
(Cul5ΔNΔC) 
100-541 pEGFP-C2 This work 
Hs Roc1 1-108 pRK5-Myc This work 
Mm RBPMS1 1-606 pcDNA3-FlagJ This work 
Mm RBPMS3 1-675 pcDNA3-FlagJ This work 
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Mm Uev1a 1-147 pcDNA3-Myc3 Jessica Berthold 
Mm Uev1a 1-147 pEGFP-C2 Francisco Rivero 
Mm kindlin-1 1-677 pEGFP-C Reinhard Fässler 
Mm kindlin-2 1-687 pEGFP-C Reinhard Fässler 
Mm kindlin-1 1-677 Flag Reinhard Fässler 
Mm kindlin-2 1-687 Flag Reinhard Fässler 
Hs kindlin-1 (258-677) 258-677 pcDNA-Flag Lindsey Anderson 
Hs kindlin-1 (1-495) 1-495 pcDNA-Flag Lindsey Anderson 
Mm kindlin-1/N (1-446) 1-446 pEGFP-C Reinhard Fässler 
Mm kindlin-1/C (471-677) 471-677 pEGFP-C Reinhard Fässler 
Rt MyoIXb 1-1980 pUHD-6xHis-Flag Martin Bähler 
 
Constructs for expression in E. coli 
Hs Rac1 1-192 pGEX-2TK Berthold et al. (2008b) 
Mm RhoBTB3-GTPase 1-204 pGEX-2T Berthold et al. (2008b) 
GST-Ub 2-76 pGEX-4T-1 Michael Gmachl 
 
Constructs for yeast two-hybrid experiments 
Hs Cullin 3 (Cul3) 1-768 pGADT7 Berthold et al. (2008b) 
Hs Cullin 5 (Cul5) 1-735 pGBKT7 This work 
 
*AACAGTACCACCACCATTTCTCGGGAGGAGCTTGAAGAGCTACAAGAAGCG 
 
2.1.7 Enzymes 
• Calf intestine alkaline phosphatase (CIP) (Roche) 
• Klenow fragment (DNA polymerase I) (Roche) 
• Lysozyme (Sigma) 
• M-MLV reverse transcriptase (Promega) 
• Restriction enzymes (Amersham, Fermentas, Jena Biosciences, New England 
Biolabs) 
• Ribonuclease A (RNase A) (Roche) 
• Shrimp alkaline phosphatase (SAP) (Roche) 
• T4 DNA ligase (Invitrogen) 
• Taq DNA polymerase (Roche) 
• Trypsin (Biochrom) 
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2.1.8 Antibodies and fluorescent dyes 
2.1.8.1 Primary antibodies 
Antibody  Source WB IF 
β-Actin mouse Sigma 1:5000 - 
Cullin 3  rabbit Manabu Furukawa 1:1000 - 
EEA1 mouse Transduction Laboratories - 1:100 
Emerin rabbit ProSci 1 μg/ml - 
I-Plastin rabbit Grimm-Günter et al. (2009) - 1:300 
GAPDH mouse Sigma 8 μg/ml - 
GFP mouse Angelika A. Noegel non-diluted - 
GM130  mouse Markus Plomann - 1:50 
GST rabbit Angelika A. Noegel 1:5000-1:50,000 - 
Myc  mouse Angelika A. Noegel, Biomol non-diluted - 
Flag (anti-ECS) rabbit Novus Biologicals 1:1000 1:200 
Flag M2 mouse Sigma 1:1000 - 
α-Tubulin mouse Calbiochem - 1:1000 
  
2.1.8.2 Secondary antibodies 
Antibody Source WB IF 
Goat anti-rabbit IgG, peroxidase-
conjugated 
Sigma 1:10,000 - 
Goat anti-mouse IgG, peroxidase-
conjugated 
Sigma 1:10,000 - 
Goat anti-mouse IgG, Alexa 488 
conjugate 
Molecular Probes, Invitrogen - 1:1000 
Goat anti-mouse IgG, Alexa 568 
conjugate 
Molecular Probes, Invitrogen - 1:1000 
Goat anti-mouse IgG, Alexa 568 
conjugate 
Molecular Probes, Invitrogen - 1:1000 
Anti-mouse Cy5 conjugated Invitrogen - 1:1000 
 
2.1.8.3 Fluorescent dyes 
• 4´, 6´- diamidino - 2 phenylindol (DAPI) (Sigma) 
• MitoTracker® Red CMXRos (Molecular Probes) 
• Hs Transferrin-Alexa Fluor 546 (Invitrogen) 
• TRITC-Phalloidin (Sigma) 
 
2.1.9 Inhibitors 
• Benzamidine (Sigma)  
• Colchicine (Sigma) 
• Cycloheximide (Sigma) 
 37
• Latrunculin B – (Merck Biosciences (Calbiochem-Novabiochem) 
• MG132 (Sigma) 
• Phenylmethylsulfonyl fluoride (PMSF) Sigma  
• Protease Inhibitor Cocktail (Sigma)  
• RNasin RNase Inhibitor (Promega) 
• Taxol (Biochemika) 
 
2.1.10 Transfection reagents 
• DharmaFECT®1 Transfection Reagent (ThermoScientific) 
• Lipofectamine 2000 (Invitrogen) 
 
2.1.11 Antibiotics 
• Ampicillin (Sigma) 
• Kanamycin monosulphate (Melford Laboratories) 
 
2.1.12 Molecular weight markers 
• PageRulerTM Plus Prestained Protein Ladder SM1811 Mw 
250/130/100/70/55/35/27/15/10 kDa (Fermentas) 
• High molecular weight marker 250/150/100/75/50/37/25/20 kDa (Amersham 
Biosciences)  
• EZ-RunTM Prestained Rec Protein Ladder  130/95/72/55/43/34/26/17 kDa (Fisher 
Scientific) 
• EZ-RunTM Prestained Rec Protein Marker 118/85/47/36/26/20 kDa (Fisher 
Scientific) 
• DNA Ladder 12216; 11198; 10180; 9162; 8144; 7126; 6108; 5090; 4072; 3054; 
2036; 1636; 1018; 506; 396; 344; 298; 220; 201; 154; 134; 75 bp (Life 
Technologies) 
• 1kb Full Scale DNA Ladder 10000, 8000, 6000, 4000, 3000, 2000, 1550, 1400, 
1000, 750, 500, 400, 300, 200, 100, 50 bp (Fisher Scientific) 
• 100 bp Scale DNA Ladder 2000, 1550, 1400, 1000, 750, 500, 400, 300, 200, 100, 
50 bp (Fisher Scientific) 
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2.1.13 Chemicals 
Laboratory reagents and materials were obtained from following suppliers: Amersham, 
Biomol, Fluka, Invitrogen, Melford Laboratories, Merck, National Diagnostic, Pharmacia, 
Promega, Sigma, Serva, Roche and Roth. 
 
2.1.14 Kits 
Pierce® BCA Protein Assay Kit Pierce (ThermoScientific) 
pGEM-T easy Cloning Kit Promega 
High Pure Plasmid Purification Kit Roche 
μMACSTM Epitope Tag Protein Isolating Kit Miltenyi Biotec  
Nucleobond AX 100 Macherey Nagel 
NucleoSpin Extraction Kit Macherey Nagel 
ProFoundTM Mammalian c-Myc Tag IP/CoIP Application Set  Pierce (ThermoScientific) 
SuperSignal® West Pico Pierce (ThermoScientific) 
   
2.1.15 Laboratory material 
3mm filter paper Whatman 
6-well plates Nunc 
24-well plates Nunc 
Cell scraper 25 cm Sarstedt 
Coverslips: 12/15/18 mm in diameter Menzel-Gläser 
Cryotubes 1 ml Nunc 
Eppendorf tubes: 0.5 ml, 1.5 ml, 2 ml Eppendorf  
Falcon tubes: 15 ml, 50 ml Greiner Bio-one Cell Star 
Filters: 0.20 μm, 0.45 μm Millipore 
Glass Pasteur pipettes Brand 
Glass slides Menzel-Gläser 
Hyperfilm ECL 18x24 cm Amersham 
Microscope slides 76x26 mm Menzel-Gläser 
Needles BD Plastipak 
Neubauer improved chamber depth: 0.100 mm; 0.0025 mm2 Labor Optik 
Nitrocellulose transfer membrane Pall 
Parafilm Pechiney 
PCR reaction tubes: 0.2 ml VWR 
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Petri dishes: 60x15 mm, 100x20 mm, 140x20 mm Nunc 
Pipettes: 1-10 µl, 1-20 µl, 20-200 µl und 200-1000 µl Gilson 
Pipette tips Greiner Bio-one Cell Star 
PVDF transfer membrane Pall 
Serological pipettes: 5 ml, 10 ml, 25 ml Sarstedt 
Steritop bottle top filter 0.22 µm Millipore 
Syringes BD Plastipak  
  
2.2 Sterilisation 
Media and buffers were sterilised by autoclaving at 120ºC. If sterilisation by autoclaving 
was not possible, 0.2 μm or 0.45 μm filter units were used. 
 
2.3 Cell culture methods 
Mammalian cells were cultivated at 37˚C in a humidified incubator supplied with 5% CO2. 
The cells were grown in Dulbeccos´ Modified Eagle (DME) medium enriched with fetal 
bovine serum (FBS).  
 
Culture medium for HeLa, COS7 and 239T HEK cells 
DME medium ´high glucose´ (4.5 g/l) (Sigma) 
10% heat inactivated FBS (Biochrom) 
2 mM Glutamine (Sigma) 
100 U/ml Penicillin, 100 μg/ml Streptomycin (PAA) 
 
The medium for HeLa and 239T HEK cells contains additionally 1 mM sodium pyruvate 
(Sigma). 
 
2.3.1 Defrosting of mammalian cell stocks  
Mammalian cells were stored in medium containing DMSO (dimethylsulfoxide) (see 
section 2.3.7) in liquid nitrogen. To defreeze the cells, the vial was warmed in a 37˚C water 
bath and the cells were immediately resuspended in medium to dilute the DMSO. Cells 
were centrifuged (1000 × g, 10 min, 4˚C), the medium was removed and the cells were 
resuspended in fresh medium and seeded on a 10 cm plate. Next day cells were split.   
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2.3.2 Passaging of mammalian cells 
All mammalian cell lines were split in the same way. After aspirating of medium, cells 
were rinsed with PBS and incubated at 37˚C with 0.05% trypsin and 0.53 mM EDTA in 
PBS until they were detached from the culture dish. The cells were resuspended in fresh 
medium and split. 293T HEK cells were split every 1-2 days when they reached 70-80% 
confluency at a ratio of 1:3 – 1:5. COS7 cells were split every 3 days when the plate was 
almost confluent at a ratio of 1:10. HeLa cells were split every 3-4 days at a ratio of 1:10.   
 
2.3.3 Transfection of mammalian cells 
Cells were split 24 h before transfection to the wells of a 6-well plate. The quantity of 
reagents used is calculated for one well of a 6-well plate. Transfection was performed with 
Lipofectamine 2000 as follows: 4 μg of DNA and 10 μl of lipofectamine were separately 
mixed with 250 μl of pre-warmed DME medium without FBS and after 5 min mixed 
together and incubated for 20 min at room temperature. Lipofectamine-DNA complexes 
were then added to the cells with 2 ml freshly changed DME medium (2 ml) containing 
10% FBS.  
If larger amounts of transfected cells were needed, cells were split to bigger plates and 
the amount of reagents was adjusted according to the size of the plate as recommended by 
manufacturer. 
 
2.3.4 Drug treatment 
Where indicated, cells were treated with the following drugs: taxol, colchicine or 
latrunculin B. Taxol and colchicine were added to the cells 20 h after transfection for 4 h 
(20 μM taxol, 25 μM colchicine). Latrunculin B was added to the cells 23.5 h after 
transfection for 30 min (final concentration 2.5 μM). Appropriate solvents were used as 
a control (DMSO/Ethanol). 
 
2.3.5 Determination of protein stability (Wilkins et al. 2004) 
6×106 293T HEK cells were seeded the day before transfection on a 10 cm Petri dish. 
Transfection of the appropriate plasmids was done with Lipofectamine 2000. 16 h after 
transfection cells were trypsinised and distributed into 4 wells of a 6-well plate. When 
the cells had re-attached (after 3-4 h), they were treated with 100 μM cycloheximide to 
arrest protein biosynthesis and either with 10 μM MG132 or DMSO. Cells were collected 
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at different time points and lysed (see section 2.7.1). Lysates were analysed by the SDS-
PAGE electrophoresis (see section 2.7.3).  
 
2.3.6 Gene silencing 
To silence the expression of endogenous Cul3, ThermoScientific DharmaFECT®1 for 
transfection of oligonucleotides was used according to the manufacturers’ protocol. 
Oligonucleotides targeting the Cul3 sequence were designed and used along with non-
targeting siRNA as a negative control (see section 2.1.3).  
293T HEK cells were cultivated during the duration of the whole experiment in antibiotics-
free medium as these have large cytotoxic effects on the cells. 24 h prior to experiment, 
cells were trypsinised and 6.25×105 cells were seeded into one well of a 6-well plate. On 
the day of the experiment, 100 μl of 2 μM siRNA solution was mixed with 100 μl serum-
free medium in one tube and 4 μl of DharmaFECT® solution was mixed with 196 μl 
serum-free medium in a second tube. After 5 min incubation, the content of both tubes was 
mixed together and incubated for another 20 min. During this time old medium was 
removed and 1600 μl of fresh medium was added to the cells. When incubation was 
completed, the silencing mixture was pipetted drop wise to the plate. Following controls 
were included in this experiment: 1. Untreated cells, 2. Mock-transfection (no siRNA), 3. 
Negative control siRNA 
 
2.3.7 Cryostocks preparation 
To prepare the cells for cryoconservation in liquid nitrogen, a confluent monolayer from 
a 10 cm plate was trypsinised and resuspended in cold DME medium and incubated for 
30 min on ice. The cells were then centrifuged (1000 × g, 10 min, 4˚C) and the pellet was 
resuspended in 1 ml freezing medium. Cryotubes were placed into a cryorack Nalgene® 
Mr. FrostyTM Cryo (with special filling soaked in isopropanol) and left in -80˚C overnight. 
The cryotubes were transferred to liquid nitrogen following day.  
Freezing medium 
70% DMEM  
20% FCS  
10% DMSO  
  
 42
2.4 Bacterial culture methods 
2.4.1 Media for bacterial cells cultivation  
The Luria Bertani (LB) media were prepared with deionised water and sterilised by 
autoclaving at 120˚C. After cooling down antibiotics were added to the final concentration 
of 100 mg/l (ampicillin) or 50 mg/l (kanamycin). The pH of the LB medium was set with 
5 M NaOH. For the blue-white selection of E. coli transformants, 10 μl of 1 M IPTG 
solution (isopropyl β-D-1-thiogalactopyranoside) and 40 μl X-Gal solution (20 mg/ml 
solution of 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside dissolved in N,N´-
dimethyl-formamide) were spreaded on  agar plates. The SOC medium was sterilised 
through a 0.2 μm filter unit. 
 
LB medium (pH 7.0 at 37˚C) 
1% (w/v) Bacto-Trypton 
0.5 % (w/v) Yeast Extract 
0.5 % (w/v) NaCl 
 
LB agar plates (pH 7.0 at 37˚C) 
1 % (w/v) Bacto-Trypton 
0.5 % (w/v) Yeast Extract 
0.5 % (w/v) NaCl 
1.5 % (w/v) Agar-Agar 
 
SOC medium (pH 7 at 37˚C) 
2 % (w/v) Bacto-Trypton 
0.5 % (w/v) Yeast Extract 
10 mM NaCl 
2.5 mM KCl 
20 mM Mg2+ (1:1 MgCl2·6H2O and MgSO4·7H2O) 
20 mM glucose 
 
2.4.2 Preparation of E. coli XL-1 blue competent cells  
A single bacterial colony was picked from an LB agar plate and pre-cultured overnight in 
20 ml LB medium. 250 ml LB medium were inoculated with this overnight culture 
and allowed to grow to an optical density of OD600 = 0.4-0.5. The culture was then cooled 
down on ice for 20 min and centrifuged 10 min at 2500 × g at 4˚C. The pellet was 
resuspended in 80 ml ice cold TB buffer and again incubated on ice for 10 min. After 
centrifugation, the pellet was resuspended in 20 ml TB buffer and mixed with 1.6 ml 
DMSO. The cell suspension was aliquoted, frozen in liquid nitrogen and stored at -80˚C. 
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TB buffer 
10 mM PIPES 
15 mM CaCl2 
250 mM KCl 
The pH 6.7 was set with KOH and then MnCl2 was added to the final concentration of 
55 mM. 
 
2.4.3 Transformation of E. coli XL-1 blue competent cells 
50 μl of competent cell suspension was thawed on ice for 10 min. Plasmid DNA or 
a ligation reaction was added to the bacterial cells and incubated for another 30 min on ice. 
A thermal shock of 42˚C was applied for 45 sec and the cells were subsequently cooled on 
ice for 1-2 min. After incubation in SOC medium without antibiotics (37˚C, 1 h), the cells 
were spreaded on agar plates with the appropriate antibiotic selection and incubated 
overnight at 37˚C. 
 
2.4.4 Preparation of glycerol stocks 
850 μl of an overnight culture were mixed with 150 μl of glycerol and stored at -80˚C.  
 
2.5 Yeast two-hybrid system 
2.5.1 Media for yeast cells cultivation 
Media were sterilised by autoclaving, adenin solution and glucose by filtration.  
 
YEPD-medium 
2% (w/v) Difco Pepton 
1% (w/v) Yeast extract 
2% (w/v) Glucose 
 
 
YEPD-agar plates 
2% (w/v) Difco Pepton 
1% (w/v) Yeast extract 
2% (w/v) Glucose 
1.8% (w/v) Agar-Agar 
Selection plates 
0.7% N base without amino acids 
2% glucose 
0.064% TL dropout (amino acid mix without tryptophan and leucine) 
2% agar 
0.003% (w/v) Adenin 
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2.5.2 Modified lithium acetate method for yeast transformation 
Y190 yeast cells were cultivated in YEPD-medium at 30˚C overnight. Cells were pelletted 
and following was added to the pellet:   
• 20 µg Salmon sperm DNA 
• 1 µg of Plasmid DNA 
• 500 µl Plate mix 
• 50 µl 1 M DTT 
Next day yeast cells were incubated at 42˚C for 10 min and spun down. The supernatant 
was removed and the cells were resuspended in a small amount of water and plated on the 
appropriate selection plates. Plates were incubated at 30˚C for several days until colonies 
appeared. 
 
Plate-mix 
90 ml 50% PEG-4000 
10 ml 1 M Lithium acetate 
1 ml 1 M Tris-HCl, pH 7.5 
0.2 ml 0.5 M EDTA, pH 8.0 
 
2.5.3 Test of galactosidase activity 
The yeast cells were blotted onto nitrocellulose membrane. The membrane was immersed 
in liquid nitrogen for 10 sec, then allowed to warm up to room temperature. The membrane 
was placed on filter paper pre-wetted with staining solution with cells facing up and 
incubated at 30˚C for 12 h. 
 
Z-buffer, pH 7.0 
0.04 M Na2HPO2·7H2O 
0.04 M NaH2PO4·H2O 
0.01 M KCl 
0.01 M MgSO4·7H2O 
 
 
Staining solution: 
100 ml Z-buffer 
0.27 ml 2-β-Mercaptoethanol 
1.67 ml X-Gal-solution (20 mg/ml 
solution of 5-bromo-4-chloro-3-indolyl-
β-D-galactopyranoside N,N´-dimethyl-
formamide) 
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2.6 Immunohistochemistry 
2.6.1 Fixation and permeabilisation of mammalian cells 
Mammalian cells cultivated on coverslips were fixed with 4% paraformaldehyde in PBS 
for 20 min. After a washing step with PBS, cells were permeabilised with 0.2% Triton X-
100 for 5 min and again washed with PBS.  
 
Phosphate Buffered Saline (PBS), pH 7.4 
1.37 M NaCl 
27 mM KCl 
100 mM Na2HPO4 
18 mM KH2PO4  
  
2.6.2 Immunodetection of proteins in the cells 
To prevent unspecific antibody binding, cells were incubated in 5% FBS in PBG for 
30 min. Primary and secondary antibodies were diluted in 1% FBS in PBG and cells were 
incubated with primary antibody for 1 h and with secondary antibody for 45 min. If DAPI 
staining was required, it was added to the diluted secondary antibody (final concentration 
1 μg/ml). After incubation with each antibody, cells were washed several times with PBS. 
At the end, coverslips were mounted on glass slides with a drop of gelvatol. 
 
PBG pH 7.4 
0.5% (w/v) bovine serum albumin (BSA) 
0.1 % (w/v) gelatine 
in 1x PBS 
 
Gelvatol 
14.3% (v/v) Gelvatol (Polyvinylalcohol)  
28.6% (v/v) Glycerine 
2.5% (w/v) DABCO (1,4-
diazabicyclo[2.2.2] octane) in PBS 
 
2.6.3 Immunostaining of mitochondria 
Cells were washed once with PBS, and then incubated for 45 min at room temperature with 
MitoTracker® Red CMXRos (final concentration 500 nM) in PBS. DMSO was used as 
a negative control. After incubation the staining solution was removed and cells were fixed 
and permeabilised as described above (see section 2.6.1). 
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2.6.4 Immunostaining of microtubules 
Cells were washed with 1× BRB80 buffer and then fixed in 3% paraformaldehyde in 
1× BRB80 buffer for 30 min. Permeabilisation and staining steps were done as described 
above. 
 
5× BRB80 buffer pH 6.8  
80 mM PIPES 
1 mM MgCl2·6H2O 
1 mM EGTA 
 
2.6.5 Immunostaining of actin filaments 
Cells were fixed and permeabilised as described above (see section 2.6.1). To stain 
the actin cytoskeleton, TRITC-labelled phalloidin was used (for 30 min, final 
concentration 5 µg/ml).   
 
2.6.6 Transferrin uptake 
Cells were washed once with PBS and starved in DME medium without antibiotics, 
glutamine and FBS, only with 0.5% BSA for 1 hour. Cells were then incubated for 5 min 
in 200 μl complete medium (without BSA) with 10 μg/ml human transferrin labelled with 
Alexa Fluor 546 for 5 min. Non-internalised transferrin was removed by incubation of the 
cells with trypsin on ice for 5 min. After washing with PBS, cells were fixed with 4% 
paraformaldehyde, washed and incubated with 50 mM NH4Cl for 10 min. Cells were 
permeabilised with 0.5% saponin in PBS for 10 min. For nuclei staining DAPI was diluted 
in 0.1% saponin in PBS and also all washing steps were done with 0.1% saponin in PBS.  
 
2.6.7 Microscopy and image processing 
Images were acquired with conventional fluorescence microscopes (Leica with DC 350 FX 
camera and Nikon with Photometrics CoolSnapTM ES camera) or with Leica SP2 confocal 
laser scanning microscope. Where indicated, images were deconvolved using AutoQuantX 
software. Images were overlaid and processed in Photoshop. 
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2.7 Biochemical methods 
2.7.1 Lysis of mammalian cells 
Cells were scraped into pre-cooled (4˚C) lysis buffer (200 μl for a well of a 6-well plate) 
and transferred to an eppendorf tube. After 30 min incubation on ice, cell debris was 
pelletted by centrifugation for 10 min at 10,000 × g at 4˚C and the supernatant was 
transferred to the fresh tubes. 
 
Lysis buffer 
150 mM NaCl 
1% Triton® X-100 
50 mM Tris-HCl, pH 8.0 
 
2.7.2 Immunoprecipitation of proteins with Myc-epitope or GFP-epitope tag 
Proteins containing Myc or GFP epitope were immunoprecipitated with kits obtained from 
Miltenyi Biotec (µMACS Epitope Tagged Protein Isolation Kit). These kits allow isolation 
of such tagged proteins by binding them to magnetic beads conjugated with anti-Myc or 
anti-GFP antibody.  
170 µl of cell lysate was mixed with 8 μl anti-Myc or anti-GFP MicroBeads and incubated 
on ice for 30 min. μColumns were placed on a μMACS Separator and activated by 
applying lysis buffer. The lysate containing MicroBeads was then applied to the column. 
Magnetic beads remained retained in the column because of the strong magnetic field. 
Unbound proteins were washed out by stringent washing steps (4 times washing with wash 
buffer I, once washing with wash buffer II) and the tagged proteins were finally eluted by 
applying pre-heated (95˚C) elution buffer. First, 20 µl of elution buffer was applied to 
the column and incubated for 5 min. Elution was achieved by subsequent addition of 50 µl 
elution buffer. These eluates were analysed by SDS-PAGE electrophoresis. In case very 
weak interaction between two examined proteins was expected, low stringent conditions 
were used for lysis and washing steps. In that case this is mentioned at the corresponding 
experiments.  
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Wash buffer I 
150 mM NaCl 
1% NP-40 
0.5% sodium deoxycholate 
0.1% SDS 
50 mM Tris-HCl, pH 8.0 
 
Wash buffer II 
20 mM Tris-HCl, pH 7.5 
 
 
Elution buffer 
50 mM Tris-HCl, pH 6.8 
50 mM DTT 
1% SDS 
1 mM EDTA 
0.005% bromophenol blue 
10% glycerol 
 
Low stringency lysis and washing buffer 
1% NP-40 
50 mM Tris-HCl, pH 8.0 
 
2.7.3 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
In order to resolve proteins according to their molecular weight, denaturating SDS-PAGE 
was performed. Samples were mixed with 2× SDS-sample buffer in a 1:1 ratio 
and denatured at 95˚C for 5 min. For casting of the gels and for gel electrophoresis 
the SDS-PAGE system MiniPROTEAN® (Biorad) was used. Resolving gel was prepared 
by mixing components mentioned in the Table 2.1 and left to polymerise for 30 min. 
Isopropanol was applied on the top of the gel. After complete removal of isopropanol, 
stacking gel was loaded on top of the resolving gel and left to polymerise for 30 min. 
The gels were assembled and placed into the Biorad Mini-PROTEAN® Gel Chamber and 
1× SDS running buffer was added. The samples were loaded onto the wells of the gel 
together with a molecular weight marker and were run at 80-120 V until the bromophenol 
blue dye of the samples reached the bottom of the gel. 
 
1× SDS-running buffer, pH 8.3 
25 mM Tris-base 
192 mM Glycine 
0.1% SDS 
 
 
2× SDS-sample buffer 
100 mM Tris-HCl, pH 6.8 
4% SDS 
20% glycerine 
4% β-mercaptoethanol 
0.005% (w/v) bromophenol blue 
 
 
 49
Resolving gel Stacking gel 
10% 15% 18% 5% 
Acrylamide (30%) [ml] 20 30 36 4 
1.5 M Tris-HCl, pH 8.8 [ml] 15.1 15.1 15.1 - 
0.5 M Tris-HCl, pH 6.8 [ml] - - - 2.4 
10% SDS-solution [µl] 590 590 590 240 
deionised H2O [ml] 24.25 14.25 8.25 17.36 
TEMED [µl] (for each 5 ml of gel) 15 15 15 10 
10% APS [µl] (for each 5 ml of gel) 20 20 20 15 
 
Table 2.1: Solution for preparation of polyacrylamide mini gels.  
 
2.7.4 Staining of polyacrylamide gels with Coomassie-Brilliant-Blue R 250 
Proteins separated on polyacrylamide gels were stained with Coomassie-Brilliant-Blue 
R 250 solution for 20 min at room temperature. The excess staining was removed with 
destaining solution. To dry the gel, it was incubated in Gel Dry Buffer for 5 min, then 
wrapped in permeable foil and left to dry overnight.  
 
Staining solution 
0.1% (w/v) Coomassie-Brilliant-Blue 
R 250 
50% (v/v) Methanol 
10% (v/v) Acetic acid 
 
 
Destaining solution 
10% (v/v) Ethanol 
7% (v/v) Acetic acid 
 
Gel dry solution 
50% ethanol 
5% glycerol 
 
2.7.5 Transfer of proteins to membrane (Western blot) 
Polyacrylamide gels were equilibrated in blotting buffer for 20-60 min. Polyvinylidene 
fluoride membrane (PVDF) was pre-wetted by placing in 100% methanol for 15 sec 
and then washed in distilled water for 1-2 min. Nitrocellulose membrane was used without 
any pre-wetting. The membrane was soaked in blotting buffer together with thick blotting 
papers for 5 min. Semi-dry transfer was carried out by using a Biorad Trans Blot SD 
Semidry Transfer Cell. The blotting sandwich was assembled as follows: anode, blotting 
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paper, membrane, gel, blotting paper and cathode. The transfer took 20-60 min at 10-15 V, 
depending on the size of the gel. 
 
Blotting buffer 
25 mM Tris base 
193 mM Glycine 
20% Methanol 
 
2.7.6 Staining of proteins bound to the membranes 
Transferred proteins were visualised with Ponceau S staining. This served as a control of 
protein transfer after the blotting and it also allowed marking the position of the molecular 
weight marker and individual samples. The staining was removed by TBS-T buffer in 
following washing steps.  
 
Ponceau S 
0.1% Ponceau S 
1% Acetic acid 
 
TBS-T buffer 
150 mM NaCl 
10 mM Tris-HCl, pH 8.0 
0.1% Tween 20 
 
2.7.7 Immunodetection of proteins bound to the membrane 
To prevent unspecific binding of proteins, the membrane was blocked by incubation with 
10% skimmed milk in TBS-T for 30-60 min. Milk was shortly washed out and the 
membrane was incubated with primary antibody at the appropriate dilution in TBS-T for 
2 h at room temperature or overnight at 4˚C. The unbound primary antibody was washed 
out with 1× TBS-T buffer (3x 10 min) and the membrane was incubated for 1 h with 
the appropriate peroxidise-coupled secondary antibody (1:10,000 dilution). The secondary 
antibody was washed out similarly as the primary antibody. The chemiluminiscence 
reaction was done using SuperSignal® West Pico solutions. The membrane was exposed to 
X-ray film and developed by using developer and fixer solutions (Kodak). 
 
2.7.8 Subcellular fractionation of mammalian cells 
Cells were harvested by scraping in PBS with 1 mM DTT, 1 mM benzamidin, 
1 mM EGTA and 1 mM PMSF (5 ml for a 10 cm dish). Cells were centrifuged for 5 min at 
1000 × g at 4˚C. The pellet was dissolved in hypotonic lysis buffer and incubated on ice for 
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30 min. The suspension was then pressed through a syringe with a thin needle (0.4 mm in 
the diameter). Nuclei were sedimented at 1000 × g for 15 min at 4˚C and the supernatant 
was subsequently ultracentrifuged for 30 min at 45,000 rpm at 4˚C. The cytosolic fraction 
is in the supernatant and the membranous fraction is in the pellet. The pellets were 
resuspended in 2× sample buffer and boiled at 95˚C for 10 min. The fractions were 
analysed by Western blotting. Anti-emerin antibody was used as a marker for the nuclear 
fraction and anti-GAPDH antibody as a marker for the cytosolic fraction.  
 
Hypotonic lysis buffer 
10 mM HEPES, pH 7.5 
1.5 mM MgCl2 
1.5 mM KCl 
Protease inhibitor cocktail 
0.5 mM DTT 
 
2.7.9 Ubiquitination assay 
6×106 293T HEK cells were seeded the day before transfection on a 10 cm Petri dish. 
Transfection of the appropriate plasmids was done with Lipofectamine 2000. 10 h after 
transfection proteasomal inhibitor MG132 (5 μM) was added for 12 h. Cells were lysed 
and expressed proteins were co-immunoprecipitated using ProFoundTM Mammalian c-Myc 
Tag IP/CoIP Application Set (Pierce). Briefly, the cell lysate was incubated with Myc-
tagged agarose beads overnight at 4°C. Agarose beads were washed 8 times with washing 
buffer and native proteins were eluted with elution buffer. 0.5 μl of 1M Tris-HCl, pH 9.5 
was added to each 10 μl of eluate to neutralise the pH. The ubiquitination reaction was 
setup as follows: 20 μl of purified protein complex was mixed with 500 ng yeast E1 
(BostonBiochem), 850 ng human recombinant UbcH5a E2 (BostonBiochem), 2 μM human 
recombinant ubiquitin aldehyde (BostonBiochem), 0.29 nM GST-Ub (section 2.7.11), 
1 mM ATP, 10 μM MG132, 5 mM MgCl2, 0.5 mM DTT, 1 mM PMSF in 10 mM HEPES, 
pH 7.6. The reaction was incubated at 37˚C for 1 h, then SDS-sample buffer was added 
and samples were denatured (Wilkins et al. 2004). 
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2.7.10 Protein expression and purification 
A single bacterial colony of E. coli XL1-blue was picked from an LB agar plate and pre-
cultured overnight in 30 ml LB medium. 200 ml of fresh LB medium was inoculated with 
the overnight culture to an optical density of OD600 = 0.1 and allowed to grow to an optical 
density of OD600 = 0.7-0.8. The culture was then induced with 0.5 mM IPTG for 4 h. After 
induction, the culture was centrifuged for 10 min at 6000 × g at 4˚C. The pellet was 
resuspended in lysis buffer and incubated for 30 min on ice. Lysis of bacterial cells was 
achieved with a French press. Cell debris was sedimented by centrifugation for 1 h at 
17,300 × g at 4˚C. The supernatant was supplemented with 0.1% Triton X-100 and was 
incubated with glutathione-agarose beads (Amersham, Buckinghamshire, UK) for 2 h at 
4˚C. After incubation, the GST-agarose beads with bound protein were washed twice with 
washing buffer with 0.1% Triton X-100 and twice with washing buffer without Triton X-
100. The purified protein was eluted with elution buffer.   
 
Lysis buffer 
50 mM Tris-HCl, pH 7.0 
300 mM NaCl 
5 mM EDTA 
4 mM DTT 
1 mM PMSF 
1 mg/ml lysozyme 
Washing buffer 
50 mM Tris-HCl, pH 7.0 
1 M NaCl 
5 mM EDTA 
4 mM DTT 
0.1% Triton X-100 
 
Elution buffer 
1 M Tris-HCl, pH 8.0 
100 mM NaCl 
20 mM reduced glutathione 
 
2.7.11 Expression and purification of GST-Ubiquitin (Ub) 
GST-Ub (kind gift of Michael Gmachl, Innsbruck Medical University, Austria) was 
expressed and purified as described above (see section 2.7.10). Several eluates were 
recovered from glutathione-agarose beads that were tested on an SDS gel to determine 
the purity (Figure 2.1). The eluates were joined together and dialysed against 10 mM 
HEPES, pH 7.6. The dialysed protein was concentrated with Ultrafree-MC Centrifugal 
Filters Units (Millipore) and the protein concentration was measured (see section 2.7.12).  
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Figure 2.1: Expression and purification of GST-Ub. Ubiquitin was expressed as a GST fusion in E. coli 
XL1-blue. Bacterial cells were lysed and supernatant was incubated with glutathione agarose beads. After 
purification, lysates were resolved on 18% SDS gel and stained with Coomassie-Brilliant-Blue R 250 (see 
section 2.7.4). 
 
2.7.12 BCA (bicinchoninic acid) protein assay 
Concentration of proteins was measured with a Pierce® BCA Protein Assay Kit according 
to the manufacturers’ recommendations. This method is based on reduction of Cu2+ to Cu1+ 
by protein in an alkaline environment. Two molecules of BCA form a complex with one 
cuprous ion and this complex exhibits absorbance at 562 nm. Briefly, BSA was diluted in 
the same buffer as the sample (concentration range between 2000 μg/ml and 2 μg/ml) 
and served as a standard of protein concentrations. Working reagent was prepared by 
mixing 50 parts of BCA reagent A (containing sodium carbonate, sodium bicarbonate, 
bicinchoninic acid and sodium tartrate) with 1 part of BCA reagent B (containing 
4% cupric sulfate). 25 μl of diluted standard or sample was pipetted into a well in a 96-well 
plate and mixed with 200 μl of working reagent. Plate was incubated in the dark at 37˚C 
for 30 min and absorbance was measured at 562 nm on a plate reader. 
 
2.7.13 GTP binding assay 
Hs Rac1 and the GTPase domain of RhoBTB3 were expressed as GST fusions in E. coli 
XL1-blue along with empty GST vector as a negative control (see section 2.7.10). After 
purification, lysates were resolved with SDS-PAGE electrophoresis and blotted onto 
nitrocellulose membrane. The membrane was rinsed twice with washing buffer followed 
by incubation in binding buffer for 2 h at room temperature. The membrane was then 
washed with washing buffer 4 times for 15 min each and subjected to autoradiography.  
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GTP-washing buffer 
50 mM Tris-HCl, pH 7.4 
0.3% Tween 20 
10 μM MgCl2 
 
 
 
GTP-binding buffer 
50 mM Tris-HCl, pH 7.4 
0.3% Tween 20 
10 μM MgCl2 
100 mM DTT 
100 μM ATP 
1 μCi/ml (α-32P) GTP 
 
2.8 Molecular biology methods 
2.8.1 Isolation of plasmid DNA by the alkaline method (Birnboim and Doly 1979) 
1.5 ml overnight culture was spun down (6000 × g, 5 min, 4˚C) and resuspended in 200 μl 
buffer P1. 200 μl of buffer P2 was added and samples were incubated 2-3 min at room 
temperature. After 200 μl of buffer P3 was added, samples were centrifuged (10 min, 
12,000 × g, room temperature). The supernatant was transferred into a fresh tube 
and plasmid DNA was precipitated with 530 μl of isopropanol and subsequent 
centrifugation (20 min, 12,000 × g, 4˚C). The pelletted DNA was washed with 70% 
ethanol, dried and redissolved in the 5 mM Tris-HCl, pH 8.0 buffer. Contaminating RNA 
was removed from the sample during restriction by adding RNase A (final concentration 
1 μg/µl). 
 
Buffer P1, pH 8.0 
50 mM Tris-HCl 
10 mM EDTA 
 
Buffer S2 
200 mM NaOH 
1% SDS 
Buffer S3, pH 5.5 
3 M Potassium acetate 
 
2.8.2 Isolation of plasmid DNA for transfection of mammalian cells 
To isolate high quality DNA the commercial kit „NucleoBond® AX 100“ was used. 30 ml 
LB medium was inoculated with a single colony of E. coli picked from a plate. The culture 
was grown at 37˚C, 250 rpm overnight until an OD600=3-6 was reached. Cells were then 
centrifuged at 6000 × g for 15 min at 4˚C. The bacterial pellet was resuspended in 4 ml of 
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buffer S1. Cells were lysed by addition of 4 ml of buffer S2 for 2-3 min and the lysate was 
afterwards neutralised with 4 ml of buffer S3 on ice for 5 min. The lysate was clarified by 
filtration and then applied to a column pre-equilibrated with buffer N2. Plasmid DNA 
remained bound to the silica-based anion-exchange resin while proteins, polysaccharides, 
tRNA and 5S RNA flew through the column. rRNA and mRNA were washed out with 
buffer N3 and plasmid DNA was subsequently eluted with 5 ml of elution buffer N5. DNA 
was afterwards precipitated with 3.5 ml of isopropanol and centrifuged at ≥ 15,000 × g at 
4˚C for 30 min. The pellet was washed with 70% ethanol, dried and plasmid DNA was 
redissolved in 5 mM Tris-HCl, pH 8.0. The quality of the isolated plasmid was determined 
by spectrophotometry (see section 2.8.3). 
 
Buffer S1, pH 8.0 
50 mM Tris-HCl 
10 mM EDTA 
100 μg/ml RNase A 
 
Buffer S3, pH 5.1 
2.8 M Potassium acetate 
 
Buffer N2, pH 6.3 adjusted with H3PO4 
100 mM Tris 
15% ethanol  
900 mM KCl 
0.15% Triton X-100 
 
Buffer S2 
200 mM NaOH 
1% SDS 
 
Buffer N3, pH 6.3 adjusted with H3PO4 
100 mM Tris 
15% ethanol 
1.15 M KCl 
 
Buffer N5, pH 8.5 adjusted with H3PO4 
100 mM Tris 
15% ethanol 
1 M KCl 
2.8.3 Determination of plasmid DNA concentration 
DNA concentration was measured by spectrophotometry at wavelength λ = 260 nm 
(absorbance maximum of purine and pyrimidine bases). Optical density OD260 = 1 refers to 
the dsDNA concentration 50 µg/ml. The purity of the sample was determined by 
measuring the OD at wavelength λ = 280 nm (absorbance maximum of proteins). In case 
that A260/A280 is 1.6-2.0 (quotient lower than 1.6 indicates high contamination of DNA 
with proteins) DNA concentration can be calculated as follows: 
DNA concentration [μg/ml] = OD260 × 50 × factor of dilution 
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2.8.4 DNA-agarose gel electrophoresis 
Agarose gels were prepared by melting the appropriate amount of agarose in TAE or TBE 
buffer. After the agarose had cooled down, the gel was poured in a casting chamber 
and ethidium bromide was added (final concentration 0.1 μg/ml). The gel was placed in 
an electrophoresis chamber filled with appropriate buffer and after the samples and marker 
of molecular weight were loaded, electric current was applied that allowed separation of 
DNA fragments according to their molecular weight. The gel was examined under UV 
light and a picture was taken using a gel documentation system.  
 
TAE buffer, pH 8.3 
40 mM Tris base 
20 mM Acetic acid 
2 mM EDTA 
TAE buffer, pH 8.0 
89 mM Tris base 
89 mM Boric acid 
2 mM EDTA 
 
DNA sample buffer (in TE buffer) 
6% (v/v) Glycerine 
0.05% (w/v) Bromophenol blue  
TE buffer, pH 8.0 
10 mM Tris base 
1 mM EDTA 
 
2.8.5 Polymerase chain reaction (PCR) 
Standard polymerase chain reaction was performed in a thermocycler as follows: 
 
~100 ng Plasmid-DNA as a template 
10 µM oligonucleotide 5´-3´  
10 µM oligonucleotide 3´-5´  
500 µM dNTP-Mix  
1× PCR-buffer (100 mM Tris-HCl, pH 8.3; 500 mM KCl; 20 mM MgCl2) 
3-4 U Taq-Polymerase  
 
The usual volume of a PCR reaction was 25 μl. The programmes of the PCR reactions 
differ depending on the primers and template used.   
 
2.8.6 Reverse transcription PCR (RT-PCR) 
RT-PCR was performed using RNA isolated from mouse tissues (kind gift of Dr. W. Lu, 
Center for Biochemistry, Medical Faculty, University of Cologne, Germany) as template. 
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Reverse transcription was performed as follows: 3 μg RNA was mixed with 2 μl p(dN)6 
random hexanucleotide primer and water in 20 μl reaction. The reaction was incubated for 
5 min at 70˚C and then cooled for 2 min on ice. Following was added to the reaction: 
 
5 μl M-MLV RT 5× buffer 
1.25 μl 10mM dNTP 
40 U rRNasin RNase Inhibitor  
200 U M-MLV reverse transcriptase RNase H Minus 
1.75 μl H2O  
 
The reaction was incubated for 1 h at 37˚C. Then PCR was preformed as follows: 
5 μl RT-PCR reaction 
1 μl 100 pmol/μl MUF1/fwd/E5-E6 primer 
1 μl 100 pmol/μl MUF1/rev/E9-E10 primer  
1 μl Reaction ReadyTM Mouse GAPD Internal Normaliser (436 bp)  
1 μl 10 mM dNTP 
1 μl 25 mM MgCl2 
1 μl Taq polymerase 
7 μl H2O 
 
Conditions: 
1. 95˚C 5 min 
2. 95˚C 1 min 
3. 55˚C 1 min 
4. 72˚C 50 sec 
5. Step 2. – 4. repeated 30 times 
6. 72˚C 10 sec 
7. 4˚C for ever 
2.8.7 Elution of DNA-fragment from agarose gel 
To isolate DNA form agarose gels the commercial kit NucleoSpin Extraction Kit was used. 
The DNA fragment of interest was cut out from a TAE agarose gel with a clean scalpel. 
The piece of gel was dissolved in buffer NT (100 mg of the gel was mixed with 200 µl of 
buffer NT) by heating at 50˚C. The sample was loaded into a column, which allows DNA 
binding and centrifuged. DNA bound into the column was washed with buffer NT3. 
Because this buffer contains ethanol that may inhibit subsequent reactions, the silica 
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membrane of the column was dried prior to elution with elution buffer. The quality of the 
eluted DNA was tested again on an agarose gel. 
 
2.8.8 Restriction reaction 
Plasmid DNA was cut with chosen restriction enzyme in a reaction mixture containing 
1× BSA and 1× enzyme buffer suitable for restriction enzyme.  
 
2.8.9 Dephosphorylation of DNA 5´- ends 
The dephosphorylation reaction was prepared as follows: 1-2 µg of linearised plasmid was 
mixed with 1U of SAP (shrimp alkaline phosphatase), 1× SAP buffer, and water to 
the final volume of reaction 20 μl. The reaction was incubated for 10 min at 37˚C and then 
stopped by 65˚C for 10 min. 
 
10× SAP buffer 
0.5 M Tris-HCl, pH 8.5 
10 mM MgCl2 
 
2.8.10 Ligation of vector and DNA-fragment 
A ligation reaction containing 1-3 µg total DNA was mixed in ratio 1:3 vector:insert with 
1U T4-DNA-ligase. The final concentration of T4 ligase buffer was 1×. The reaction was 
incubated over night at 16˚C. 
 
10× Ligase buffer 
660 mM Tris-HCl, pH 7.5  
50 mM MgCl2  
50 mM DTT  
10 mM ATP
 
2.8.11 DNA-sequencing 
All constructs were verified by sequencing with specific primers. Sequencing was 
performed by service laboratory of Centrum for Molecular Medicine Cologne (Germany), 
MWG (Germany) or Yorkshire Biolabs (United Kingdom). 
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3 Results 
 
3.1 Characterisation of RhoBTB proteins  
3.1.1 Subcellular localisation of RhoBTB3 
Little is known about the precise localisation of RhoBTB proteins. Myc-tagged RhoBTB1 
and RhoBTB2 were found localised in vesicles in the cytoplasm (Aspenström et al. 2004). 
Similarly, when GFP-RhoBTB3 is expressed at moderate levels, it localises to vesicles 
found in the perinuclear area and dispersed in the cytoplasm. RhoBTB3 also forms 
aggregates in the paranuclear area when overexpressed. These vesicles are in close 
proximity of the MTOC and partially co-localise with the early endosomal marker EEA1 
and with the marker of the endoplasmic reticulum PDI (protein disulfide isomerase). 
RhoBTB3 positive vesicles were also observed in close proximity of microtubules 
and stress fibres (Berthold et al. 2008b). In order to examine the localisation of RhoBTB3 
in more detail we performed counterstaining with additional cellular markers. 
To prove that the pattern of subcellular localisation described above applies also to other 
cell lines, HeLa cells were transfected with GFP-RhoBTB3 (Figure 3.2 depicts different 
RhoBTB constructs used in this study). In HeLa cells GFP-RhoBTB3 localises to vesicles 
dispersed in the cytoplasm (Figure 3.1), similarly to what has been reported in other cell 
lines (Berthold 2006 dissertation thesis, Berthold et al. 2008b). 
 
 
 
Figure 3.1: RhoBTB3 localises to vesicles dispersed through the cytoplasm in HeLa cells. Cells were 
transfected with GFP-tagged RhoBTB3 or with GFP empty vector. Cells were fixed and stained with DAPI 
(blue). Images were acquired with a fluorescence microscope and overlaid. Bar represents 10 μm.  
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Figure 3.2: Domain architecture of RhoBTB and constructs used in this study.  Where the tag is not 
specified, different tags were used (GFP, Flag, Myc, GST) and are indicated in the particular experiment. In 
RhoBTB3 the GTPase domain appears extensively erased, to the point that it is virtually unrecognisable as 
a GTPase. Only RhoBTB3 ends with a CAAX prenylation motif. G – GTPase; B1 – first BTB domain; B2 – 
second BTB domain; C – C-terminus;  
 
3.1.1.1 RhoBTB3 partially localises at early endosomes through the C-terminal 
domain 
As mentioned above, it was observed previously in our laboratory that GFP-RhoBTB3 
partially co-localises with EEA1, a marker of early endosomes. It was also reported that it 
is the C-terminal domain with its CAAX motif at the very end that is responsible for 
the vesicular pattern of localisation of the protein (Berthold et al. 2008b). Therefore we 
hypothesised that only a shortened fused protein containing the C-terminus of RhoBTB3 
will show co-localisation with the early endosomes. To verify this, COS7 cells were 
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transfected with GFP-RhoBTB3-B1, GFP-RhoBTB3-B2, GFP-RhoBTB3-C or GFP-
RhoBTB3-B2C (Figure 3.2). Fixed cells were stained with anti-EEA1 antibody. In cells 
overexpressing GFP and GFP-tagged subdomains of RhoBTB3 EEA1 vesicles looked 
normal. A disrupted or weaker staining was observed only in a very low proportion of 
cells. GFP-RhoBTB3-B1 and GFP-RhoBTB3-B2 displayed diffused localisation and no 
co-localisation with EEA1 was observed. GFP-RhoBTB3-C and GFP-RhoBTB3-B2C 
localise at vesicles that, as expected, partially co-localise with the early endosome marker 
(Figure 3.3). 
 
3.1.1.2 GFP-RhoBTB3 occasionally co-localises with transferrin 
Another marker of early endosomes is transferrin. It binds to the transferrin receptor and is 
promptly internalised in clathrin-coated vesicles (Olusanya et al. 2001). HeLa cells were 
transfected with GFP-RhoBTB3. 24 h after transfection, cells were treated with 
AlexaFluor 546-labelled transferrin and subsequently fixed. GFP-RhoBTB3 vesicles did 
not significantly influence the localisation and distribution of transferrin containing 
vesicles. To examine whether GFP-RhoBTB3 and transferrin co-localise, confocal images 
were taken. As seen on figure 3.4, GFP-RhoBTB3 and transferrin only occasionally co-
localised. 
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Figure 3.3: Co-localisation of RhoBTB3 domains with early endosomes. COS7 cells were transfected 
with the indicated GFP fusions or empty GFP vector as a control. To visualise early endosomes in fixed cells, 
primary antibody αEEA1 and secondary antibody Alexa Fluor 568 were used. Images were acquired with a 
confocal laser scanning microscope and overlaid. Bar represents 10 μm.  
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Figure 3.4: Co-localisation of RhoBTB3 with transferrin. HeLa cells were transfected with GFP-RhoBTB3 and 24 h after transfection incubated with Alexa 
Fluor 546-labelled human transferrin, fixed and permeabilised with 0.5% saponin. Images were acquired with a conventional fluorescence microscope (first 
and third row) or with a confocal laser scanning microscope (second row) and overlaid. Right hand panel is a magnification of the indicated area. Arrows point 
at RhoBTB vesicles that colocalise with transferrin. Bar represents 10 μm. 
3.1.1.3 Overexpression of RhoBTB3 disrupts the Golgi apparatus 
RhoBTB3 is the only RhoBTB protein that contains a CAAX prenylation motif at the C-
terminus. It is known that proteins with prenylation motif are targeted to the Golgi 
apparatus (GA). Moreover, GFP-RhoBTB3 localises to vesicles in the perinuclear area that 
might be the GA. To examine whether RhoBTB co-localises with the GA, COS7 cells 
were transfected with one of the following constructs: GFP-RhoBTB3, Flag-RhoBTB3, 
GFP-RhoBTB2, Flag-RhoBTB2, GFP-RhoBTB3-B1, GFP-RhoBTB3-B2, GFP-
RhoBTB3-C, GFP-RhoBTB3-B2C and GFP-RhoBTB1-C (Figure 3.2). Fixed cells were 
immunostained with anti-GM130 antibody that stains the GA. Expression of all RhoBTB 
constructs caused a significant disruption of the GA (Figure 3.5): staining of the GA was 
observed in vesicles dispersed through the cytoplasm, or in some cases the GA formed 
aggregates as opposed to cells expressing empty GFP where the GA formed stacks. GFP-
RhoBTB3 only partially co-localised with the disrupted GA. To exclude the possibility that 
this partial co-localisation of GFP-RhoBTB3 is caused by the bulky GFP tag, 
the localisation of Flag-RhoBTB3 was also examined. Similarly, Flag-RhoBTB3 also 
partially co-localised with disrupted GA. GFP-RhoBTB3-C and GFP-RhoBTB3-B2C 
showed co-localisation with disrupted GA to a higher extent. Surprisingly, GFP-RhoBTB2 
and Flag-RhoBTB2 also displayed partial co-localisation with the GA, although RhoBTB2 
does not bear any prenylation motif. Those constructs with a GFP-tag were examined more 
closely and the ratio of cells with disrupted GA was determined. Expression of GFP-tagged 
RhoBTB proteins significantly disrupted GA, in all cases more than 52% of examined cells 
showed altered morphology of the GA in comparison to those expressing only GFP 
(19.9%) (Figure 3.6). 
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Figure 3.5: RhoBTB overexpression disrupts the Golgi apparatus. COS7 cells were transfected with 
the indicated GFP-tagged or Flag-tagged RhoBTB constructs or with empty GFP vector. Cells were fixed 
and immunostained with anti-GM130 antibody followed by Alexa Fluor 568-coupled secondary antibody. 
Flag-tagged proteins were visualised with anti-Flag (anti-ECS) antibody followed by staining with Alexa 
Fluor 488-coupled secondary antibody. Images were acquired with a confocal laser scanning microscope 
and overlaid. Right hand panels are magnifications of the indicated areas. Bar represents 10 μm. The figure 
continues on the next page. 
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Figure 3.6: Disruption of Golgi apparatus by different RhoBTB proteins or domains. COS7 cells were 
transfected with the indicated GFP fusions. Fixed cells were immunostained with αGM130 to visualise the 
GA. The graph shows average and standard deviation of two independent experiments. Approximately 500 
cells were scored for each sample. 
 
3.1.1.4 RhoBTB3 does not localise to the mitochondria  
In order to examine whether RhoBTB3 localises to one more membrane compartment, 
the mitochondria, COS7 cells were transfected with GFP-RhoBTB3. Prior to fixation cells 
were labelled with MitoTracker® Red CMXRos. This is a derivative of X-rosamine that 
passively diffuses across the plasma membrane and accumulates in active mitochondria 
where it reacts with thiols on proteins and peptides. From figure 3.7 it is apparent that 
GFP-RhoBTB3 vesicles showed no co-localisation with the mitochondrial network 
and overexpression of RhoBTB3 did not alter the mitochondrial staining.  
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Figure 3.7: RhoBTB3 does not localise at mitochondria. COS7 cells were transfected with GFP-tagged Mm RhoBTB3 or with 
empty GFP vector as a control. Cells were incubated with 500nM MitoTracker® Red CMXRos prior to fixation. Images were 
acquired with a confocal laser scanning microscope and overlaid. Overexpression of RhoBTB3 does not alter mitochondrial 
staining. Bar represents 10 μm. 
3.1.1.5 Interaction of RhoBTB3 with the cytoskeleton 
3.1.1.5.1 Interaction of RhoBTB3 with microtubules 
RhoBTB3 localises at vesicles that are found in the proximity of the microtubule 
organising centre (MTOC) and these vesicles were also identified in close proximity of 
microtubules (Berthold et al. 2008b).  
To further examine the link between RhoBTB3 and the microtubule network, we used 
drugs that either stabilise (taxol) or disrupt (colchicine) the microtubule network. 
We would expect that if RhoBTB3 is not interacting (directly or indirectly) with 
the microtubule network, stabilisation or disruption of microtubules will have no effect on 
RhoBTB3 distribution.  COS7 cells were transfected with GFP-RhoBTB3 (Figure 3.2). 
20 h after transfection cells were treated with one of the drugs for 4 h (20 μM taxol 
or 25 μM colchicine) and fixed. Microtubules stabilised with taxol show clustered staining 
(Figure 3.8B, C). Stabilisation of microtubules might have some effect on GFP-RhoBTB3 
localisation: it still displayed vesicular localisation but because there is no MTOC, 
the paranuclear localisation was altered and vesicles were more dispersed in the cytoplasm. 
GFP-RhoBTB3 did not co-localise with stabilised microtubules. Colchicine disrupted 
microtubules completely. Disruption of the microtubule network seemed to cause 
aggregation of GFP-RhoBTB3 (Figure 3.8D, E). 
 
3.1.1.5.2 Co-localisation of RhoBTB2 and RhoBTB3 does not depend on an intact 
microtubule network 
It was shown previously that RhoBTB proteins are able to build homo- and heterodimers 
and RhoBTB3 co-localises with RhoBTB2 (Berthold et al. 2008b). To rule out that this 
interaction is indirect through a possible microtubule binding, COS7 cells were transfected 
with GFP-MmRhoBTB3 and Flag-HsRhoBTB2 and treated with colchicine. Disruption of 
the microtubule network neither influenced localisation of RhoBTB2 and RhoBTB3 nor 
prevented their co-localisation (Figure 3.9). 
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Figure 3.8: Microtubule-independent localisation of RhoBTB3. COS7 cells were transfected with GFP-
RhoBTB3. Before fixation, cells were treated with the tubulin-stabilising agent taxol or with the tubulin-
disrupting agent colchicine. Fixed cells were immunostained with anti-α-tubulin antibody followed by Alexa 
Fluor 568-coupled secondary antibody. Nuclei were visualised with DAPI. Images were acquired with 
a conventional fluorescence microscope (A, B, D) or with a confocal laser scanning microscope (C, E) 
and overlaid. A) Non-treated cells. B) and C) Cells treated with 20 μM taxol for 4 h. D) and E) Cells treated 
with 25 μM colchicine for 4 h. Bar represents 10 μm.  
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Figure 3.9: Microtubule independent co-localisation of RhoBTB3 and RhoBTB2. COS7 cells were transfected with GFP-RhoBTB3 and Flag-RhoBTB2. Before fixation, 
cells were treated with the tubulin-disrupting agent colchicine (25 μM) for 4h. Fixed cells were immunostained with anti-Flag (anti-ECS) antibody followed by Alexa Fluor 
568-coupled secondary antibody and anti-α-tubulin antibody followed by Cy5-coupled secondary antibody. Images were acquired with a confocal laser 
scanning microscope and overlaid. A) Non-treated cells. B) Cells treated with colchicine. Right hand panels are magnifications of the indicated areas. Bar represents 10 μm. 
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3.1.1.5.3 Interaction of RhoBTB3 with the actin cytoskeleton 
Ectopic expression of RhoBTB1 and RhoBTB2 has only a moderate influence on 
the organisation of the actin filament system (Aspenström et al. 2004). The influence of 
actin on RhoBTB distribution has not been examined before. To examine this, COS7 cells 
were transfected with GFP-RhoBTB3 (Figure 3.2). Cells were treated with latrunculin B 
and fixed. To visualise actin filaments, cells were stained with TRITC-phalloidin. After 
latrunculin B treatment, actin filaments were completely disrupted and the cell bodies 
appeared retracted. However, the paranuclear clustered distribution of RhoBTB3 was not 
altered (Figure 3.10). 
 
 
 
Figure 3.10: Actin-independent localisation of RhoBTB3. COS7 cells were transfected with GFP-tagged 
RhoBTB3. 30 min before fixation, cells were treated with the actin-disrupting agent latrunculin B (2.5 μM) 
or with ethanol as a control. Fixed cells were immunostained with TRITC-labelled phalloidin. Images were 
acquired with a confocal laser scanning microscope and overlaid. A) Non-treated cells. B) Cells treated with 
latrunculin B. Bar represents 10 μm.  
 
3.1.2 The GTPase domain of RhoBTB3 does not bind GTP 
It has been shown that RhoBTB2 does not bind GTP (Chang et al. 2006). The GTPase 
domain of RhoBTB3 is, in comparison to those of RhoBTB1 and RhoBTB2, broadly 
erased. Therefore it was of great interest to determine whether the GTPase domain of 
RhoBTB3 is still able to bind GTP.  
The GTPase domain of RhoBTB3 (Figure 3.2) was expressed as a GST fusion protein in 
E. coli. The purified GST-tagged protein was resolved on two SDS gels. One gel was 
stained with Coomassie-Brilliant-Blue R 250 and one was blotted onto a nitrocellulose 
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membrane, incubated in buffer containing radioactive GTP and subjected to 
autoradiography. The gel stained with Coomassie-Brilliant-Blue R 250 shows the amount 
of recombinant protein. No binding of radioactive GTP to RhoBTB3 GTPase was 
observed, in contrast to GST-Rac1 that is known for GTP binding. No binding of 
radioactive GTP to GST was observed, which was used as a negative control (Figure 3.11). 
 
 
 
 
Figure 3.11: The GTPase domain of RhoBTB3 does not bind GTP in vitro. The GTPase domain of 
RhoBTB3 (RhoBTB3-G) was expressed as a GST fusion in E. coli, purified and resolved on 15% SDS-
PAGE. One gel was stained with Coomassie-Brilliant-Blue R 250 and one was blotted onto nitrocellulose 
membrane. The membrane was incubated with (α-32P) GTP. Human Rac1 was used as a positive control 
and GST as a negative control. This experiment was done in collaboration with Jessica Berthold. 
 
3.1.3 Interaction of RhoBTB3 with Cul3 
3.1.3.1 RhoBTB3 interacts with endogenous Cul3 
It was shown previously that endogenous Cul3 co-immunoprecipitates RhoBTB2 (Wilkins 
et al. 2004). From previous experiments in our laboratory it was known that Myc-
RhoBTB3 is able to co-immunoprecipitate Flag-Cul3. To confirm this data it was 
necessary to show that Myc-RhoBTB3 can co-immunoprecipitate also endogenous Cul3. 
293T HEK cells were transfected with Myc-RhoBTB1, Myc-RhoBTB2 or Myc-RhoBTB3 
(Figure 3.2). Directly after transfection, proteasomal inhibitor MG132 was added to 
the cells for 24 h. Protein complexes were immunoprecipitated with anti-Myc antibody 
coupled to magnetic beads. Figure 3.12 shows that all three RhoBTB proteins, when 
ectopically expressed, were able to co-immunoprecipitate endogenous Cul3. This result 
confirms previous observations that RhoBTB3 interacts with Cul3 in vivo. The reciprocal 
experiment was not possible, because of a lack of good antibodies recognising endogenous 
RhoBTB proteins. 
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Figure 3.12: All three RhoBTB proteins interact with endogenous Cul3 in vivo. 293T HEK cells were 
transfected with the indicated Myc-RhoBTB or the empty Myc vector and treated with proteasomal inhibitor 
MG132 (5μM) for 24 hours. After lysis complexes were immunoprecipitated with anti-Myc antibody coupled 
to magnetic beads. Boiled lysates or immunoprecipitated samples were resolved on 10% SDS gel and blotted 
onto PVDF membrane. The membrane was incubated with the indicated primary antibodies 
and corresponding peroxidase-conjugated secondary antibodies followed by ECL detection.  
 
3.1.3.2 Dimerisation of RhoBTB is Cul3-independent 
Previous experiments performed in our laboratory showed that RhoBTB proteins are 
capable of assembling homodimers and heterodimers. Because all three RhoBTB proteins 
are able to bind Cul3 through the first BTB domain (Berthold et al. 2008b), it has to be 
ruled out that this dimerisation occurs through interaction with Cul3. To examine this, 
a gene silencing experiment was performed with the goal of downregulating the expression 
of endogenous Cul3. HEK 293T cells were first transfected with siRNA oligonucleotides 
to downregulate Cul3 and the following day with Myc-RhoBTB3 and Flag-RhoBTB2 
(Figure 3.2). Protein complexes were immunoprecipitated with anti-Myc antibody coupled 
to magnetic beads. Immunoprecipitates and lysates were analysed for the presence of 
the tagged proteins by Western blotting. Figure 3.13 shows that although there was still 
some signal of Cul3 present after siRNA treatment, in comparison to the negative control 
Cul3 was significantly downregulated. Myc-RhoBTB3 was still able to co-
immunoprecipitate Flag-RhoBTB2, which indicates that dimerisation of RhoBTB2 
and RhoBTB3 is independent of Cul3.  
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Figure 3.13: Downregulation of Cul3 does not abolish dimerisation of RhoBTB proteins. 293T HEK 
cells were transfected with Cul3 specific siRNA oligonucleotides or random oligonucleotides as a negative 
control. Following day cells were transfected with Myc-RhoBTB3 and either Flag-RhoBTB2 or empty flag 
vector. 24 h after transfection, cells were lysed and Myc-RhoBTB3 was precipitated with anti-Myc antibody 
coupled to magnetic beads. Samples were resolved on 10% SDS gel and blotted onto PVDF membrane. 
The membrane was incubated with the indicated primary antibodies and corresponding peroxidase-
conjugated secondary antibodies followed by ECL detection. Cul3 is visible as two bands, the upper one 
corresponding to the neddylated form.  
 
3.1.4 Proteasomal degradation of RhoBTB3 is prevented by intramolecular 
interaction 
It was shown previously in our laboratory that the GTPase domain of RhoBTB is able to 
bind to the BTB tandem (Berthold et al. 2008b) and the hypothesis was put forward that 
the GTPase prevents binding of Cul3 to the first BTB domain and therefore blocks 
ubiquitination and subsequent degradation of RhoBTB in the proteasome. To test this 
hypothesis, a half life experiment was performed (see section 2.3.5). 293T HEK cells were 
transfected with GFP-RhoBTB3-B1B2C or GFP-RhoBTB3 and Myc-RhoBTB3-G (Figure 
3.2). Lysates were collected at several time points and analysed for the presence of 
the tagged proteins by Western blotting.  Figure 3.14 shows that when GFP-RhoBTB3-
B1B2C was expressed alone, it was degraded very fast. Degradation was prevented by co-
expression of Myc-RhoBTB3-GTPase. When proteasome inhibitor was added, very strong 
stabilisation of the GFP-RhoBTB3-B1B2C was apparent, as expected. Expression of full 
length GFP-RhoBTB3 was more stable and did not depend on the presence of the Myc-
RhoBTB3-GTPase. This data indicates that an intramolecular interaction between 
the GTPase domain of RhoBTB3 and the B1B2C region prevents degradation of 
RhoBTB3.   
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Figure 3.14: Intramolecular interaction between the GTPase and the BTB tandem prevents 
degradation of RhoBTB3.  293T HEK cells were transfected with GFP-RhoBTB3-B1B2C or GFP-
RhoBTB3 and either Myc-RhoBTB3-GTPase or empty Myc vector. 16 h after transfection cells were split 
and treated with 100 μM cycloheximide and either with 10 μM MG132 or DMSO. At the time points 0, 4, 8 
and 12h cells were collected and lysed. Lysates were tested on 10% SDS gel and blotted onto PVDF 
membrane. The membrane was probed with the indicated primary antibodies and corresponding peroxidase-
conjugated secondary antibodies followed by ECL detection. Actin staining served as a loading control. 
The graphs show the amount of the GFP fusion protein normalised to the amount of actin and expressed as 
percentage relative to the 0 time point. 
 
3.1.5 RhoBTB3 is ubiquitinated by a Cul3-dependent ligase 
It was shown that RhoBTB2 is ubiquitinated in the presence of Cul3, Roc1, E1, E2 
and ubiquitin (Wilkins et al. 2004). Because we showed that RhoBTB3 is degraded in 
the proteasome (see section 3.1.4), it was of great interest to test if RhoBTB3 is 
ubiquitinated. 293T HEK cells were transfected with GFP-RhoBTB3, Myc-Cul3 and Myc-
Roc1. Co-immunoprecipitation was performed with anti-Myc antibody coupled to agarose 
beads. The ubiquitination assay was performed as described (see section 2.7.9). Samples 
were analysed for the presence of the indicated tagged proteins by Western blotting. GST-
Ub was visualised with GST antibody. Figure 3.15 shows the high molecular weight smear 
of ubiquitinylated RhoBTB3 confirming that RhoBTB3 was ubiquitinated in the presence 
of Cul3, Roc1, E1, E2 and ubiquitin. Bands of smaller sizes (below 94 kDa) could also be 
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observed that might correspond to degraded protein. Cul3-dependent ubiquitination of 
RhoBTB3 was also shown by Berthold et al. (2008b). 
 
 
 
 
Figure 3.15: Ubiquitinylation of RhoBTB3. A) 293T HEK cells were co-transfected with GFP-RhoBTB3, 
Myc-Cul3 and Myc-Roc1. 10 h after transfection proteasomal inhibitor MG132 (5 μM) was added for 12 h. 
Protein complexes were immunoprecipitated with anti-Myc antibody coupled to agarose beads. 
Ubiquitination assay was performed with purified proteins in the presence of E1, E2 and purified GST-Ub. 
Boiled lysates, immunoprecipitated samples and samples from the ubiquitination assay were resolved on a 4-
20% SDS gradient gel and blotted onto PVDF membrane. The membrane was incubated with the indicated 
primary antibodies and corresponding peroxidase-conjugated secondary antibodies followed by ECL 
detection. The asterisk marks non-specific binding of the antibody. B) Cartoon depicting the model of 
the ubiquitination and degradation of RhoBTB3. 
 
3.2 Characterisation of MUF1/LRRC41, a binding partner of RhoBTB 
GTPases 
To identify binding partners (and possible substrates) of RhoBTB3, a two hybrid screening 
on a mouse brain cDNA library was performed where RhoBTB3-B1B2C served as a bait. 
As a result, 1265 clones were reanalysed and 48 clones sequenced. One of the proteins 
identified in two hybrid screening was MUF1/LRRC41 (leucine rich repeat containing 41) 
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(S. Ramos, personal communication). MUF1, like RhoBTB proteins, is involved in 
processes linked to protein degradation (Kamura et al. 2001) therefore we decided to 
examine this protein more closely. 
 
3.2.1 Computational characterisation of MUF1  
In order to determine how MUF1 protein is conserved and widespread, similar proteins 
were identified by means of a BLAST search with mouse MUF1 protein sequence 
(GeneID 230654) as bait. 113 sequences were obtained and were individually examined. 
Each sequence was aligned with the bait MUF1 protein sequence using BLAST protein 
alignment programme. Many sequences were similar to the leucine-rich repeat region but 
the N-terminal part characteristic of MUF1 was missing. Shortened protein products, 
hypothetical proteins or MUF1-like proteins were excluded and figure 3.16 shows only 
these sequences that are complete. Full length protein sequences of MUF1 were obtained 
from following organisms: human (Hs), orang-utan (Pa), mouse (Mm), rat (Rn) and cow 
(Bt). As seen from figure 3.16., MUF1 is very highly conserved in mammals. Mm MUF1 
is 97% identical and 98% similar to Rn MUF1. Mm MUF1 is 94% identical and 96% 
similar to Hs MUF1, Pa MUF1 and Bt MUF1. The blast search revealed also proteins 
similar to MUF1 that were predicted by automated computational analysis. These proteins 
shared significant similarity with Hs MUF1, but parts of the sequence were missing so they 
are not included in the alignment. Predicted proteins similar to MUF1 were found in 
following organisms: chimpanzee (Pan troglodytes), rhesus macaque (Macaca mulatta), 
dog (Canis familiaris), horse (Equus cabalus), opossum (Monodelphis domestica), 
platypus (Ornithorhynchus anatinus), chicken (Gallus gallus) and zebra finch 
(Taeniopygia guttata). Figure 3.16 also shows the position of the SOCS-box domain with 
the BC-box subdomain and the leucine-rich repeat region. To predict the subcellular 
localisation of MUF1, several programs were used. Two of them - SubLoc v1.0 
and PSORT analysis identified MUF1 as a nuclear protein. With the latter one, three 
putative nuclear localisation signals (NLS) were identified at positions 287 (RRPR), 288 
(RPRR) and 382 (PLKRFKR). 
Figure 3.16 (next page): Alignment of MUF1 sequences. Protein sequences were aligned with ClustalX 
and edited with BioEdit. N terminally is the SOCS-box (A42-P71, marked in red frame) that contains the so-
called BC-box (A45-V54, marked with a red arrow). Putative NLSs (nuclear localisation signals) were 
identified using PSORT programme at position 287 (RRPR), 288 (RPRR) and 382 (PLKRFKR) (marked in 
yellow). The leucine-rich repeat region is marked with a black arrow. Dashes indicate gaps introduced for 
optimal alignment. Identical residues are marked in grey, similar residues are marked in green. Hs: Homo 
sapiens GeneID 10489, Pa: Pongo abelii GeneID 100172869, Mm: Mus musculus GeneID 230654, Rn: 
Rattus norvegicus GeneID 362566, Bt: Bos taurus GeneID 337889.  
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                                                               BC-box (A45-V54)         
HsMUF1  MAAPEAWRARSCWFCEVAAATTMEATSREAAPAKSSASGPNAPPALFELCGRAVSAHMGVLESGVWALPGPILQSILPLL 80   
PaMUF1  MAAPEAWRARSCWFCEVAAATTMEATSREAAPAKSSASGPNAPPALFELCGRAVSAHMGVLESGVWALPGPILQSILPLL 80   
MmMUF1  MAAPEAWRARSCWFCEVAAATTMEATSREAAPAKSSASGPSAPPALFELCGRAVSAHMGVLESGVWALPGPILQSILPLL 80   
RnMUF1  MAAPEAWRARSCWFCEVAAATTMEATSREAAPAKSSASGPSAPPALFELCGRAVSAHMGVLESGVWALPGPILQSILPLL 80   
BtMUF1  MAAPEAWRARSCWFCEVAAATTMEATSREAAPAKSSASGPSAPPALFELCGRAVSAHMGVLESGVWALPGPILQSILPLL 80   
      
 
HsMUF1  NIYYLERIEETALKKGLSTQAIWRRLWDELMKTRPSSLESVTCWRAKFMEAFFSHVLRGTIDVSSDRRLCDQRFSPLLHS 160  
PaMUF1  NIYYLERIEETALKKGLSTQAIWRRLWDELMKTRPSSLESVTCWRAKFMEAFFSHVLRGTIDVSSDRRLCDQRFSPLLHS 160  
MmMUF1  NIYYLERIEETALKKGLSTQAIWRRLWDELMKTRPSSLESVTCWRAKFMEAFFSHVLRGTIDVSSDKRLCDQRFSPLLHS 160  
RnMUF1  NIYYLERIEETALKKGLSTQAIWRRLWDELMKTRPSSLESVTCWRAKFMEAFFSHVLRGTIDVSSDKRLCDQRFSPLLHS 160  
BtMUF1  NIYYLERIEETALKKGLSTQAIWRRLWDELMKTRPSSLESVTCWRAKFMEAFFSHVLRGTIDVSSDRRLCDQRFSPLLHS 160  
 
 
HsMUF1  SRHVRQLTICNMLQGATELVAEPNRRVLETLASSLHTLKFRHLLFSDVAAQQSLRQLLHQLIHHGAVSQVSLYSWPVPES 240  
PaMUF1  SRHVRQLTICNMLQGATELVAEPNRRVLETLASSLHTLKFRHLLFSDVAAQQSLRQLLHQLIHHGAVSQVSLYSWPVPES 240  
MmMUF1  SRHVRQLTICNMLQGATELVAEPNRRVLETLASSLHTLKFRHLLFSDVAAQQSLRQLLHQLIHHGAVSQVSLYSWPVPES 240  
RnMUF1  SRHVRQLTICNMLQGATELVAEPNRRVLETLASSLHTLKFRHLLFSDVAAQQSLRQLLHQLIHHGAVSQVSLYSWPVPES 240  
BtMUF1  SRHVRQLTICNMLQGATELVAEPNRRVLETLASSLHTLKFRHLLFSDVAAQQSLRQLLHQLIHHGAVSQVSLYSWPVPES 240  
 
 
HsMUF1  ALFILILTMSAGFWQPGPGGPPCRLCGEASRGRAPSRDEGSLLLGSRRPRRDAAERCAAALMASRRKSEAKQMPRAAPAT 320  
PaMUF1  ALFILILTMSAGFWQPGPGGPPCRLCGEASRGRAPSRDEGSLLLGSRRPRRDAAERCAAALMASRRKSEAKQMPRAAPAA 320  
MmMUF1  ALFILILTMSAGFWQPGPGSLPCRLCGEASRGRAPSRDEGSLLLGSRRPRRDAAERCAAALMATRRKSEVKQMPRAVPPT 320  
RnMUF1  ALFILILTMSAGFWQPGPGSLPCRLCGEASRGRAPSRDEGSLLLGSRRPRRDAAERCAAALMATRRKSEVKQVPRALPTS 320  
BtMUF1  ALFILILTMSAGFWQPGPGGPPCRLCGEASRGRAPSRDEGSLLLGSRRPRRDAAERCAAALMASRRKSEAKQTARAAPAT 320  
 
 
HsMUF1  RVTRRSTQESLTAGGTDLKRELHPPATSHEAPGTKRSPSAPAATS--SASSSTSSYKRAPASSAPQPKPLKRFKRAAGKK 398  
PaMUF1  RVTRRSTQESLTAGGTDLKRELHPPATSHEAPGTKRSPSAPAATS--SASSSTSSYKRAPASSAPQPKPLKRFKRAAGKK 398  
MmMUF1  RVTRRSTQESLAIGGTDSK--LYLPATSYEASGTKQ-PSAPAA---ASA-SSSTSSKRAPASSASQPKPLKRFKRAAGKK 393  
RnMUF1  RVTRRSTQESLTIGGTDSKRELYPPATSYEASGTKQ-PSS-APT--A-A-SSSTSSKRAPASSVSQPKPLKRFKRATGKK 394  
BtMUF1  RVTRRSTQESLTAGGTDSKREPLPPATSHEAPGTKRPPSAPATTSSASASSSTSSSKRAPASSAPQPKPLKRFKRAAGKK 400       
                                
                                     LRR                                
HsMUF1  GARTRQGPGAESEDLYDFVFIVAGEKEDGEEMEIGEVACGALDGSDPSCLGLPALEASQRFRSISTLELFTVPLSTEAAL 478  
PaMUF1  GARTRQGPGAESEDLYDFVFIVAGEKEDGEEMEIGEVACGALDGSDPSCLGLPALEASQRFRSISTLELFTVPLSTEAAL 478  
MmMUF1  GPRTRQGSGAESEDLYDFVFIVAGEKEDGEEMEIGEVACGALDGSDPSCLGLPALEASQRFRSISTLELFTVPLSTEAAL 473  
RnMUF1  GPRTRQGSGAESEDLYDFVFIVAGEKEDGEEMEIGEVACGALDGSDPSCLGLPALEASQRFRSISTLELFTVPLSTEAAL 474  
BtMUF1  GARTRQGCGAESEDLYDFVFIVAGEKEDGEEMEIGEVACGALDGSDPSCLGLPALEASQRFRSISTLELFTVPLSTEAAL 480  
                 
 
HsMUF1  TLCHLLSSWVSLESLTLSYNGLGSNIFRLLDSLRALSGQAGCRLRALHLSDLFSPLPILELTRAIVRALPLLRVLSIRVD 558  
PaMUF1  TLCRLLSSWVSLESLTLSFNGLGSNIFRLLDSLRALSGQAGCRLRALHLSDLFSPLPILELTRAIVRALPLLRVLSIRVD 558  
MmMUF1  TLCHLLSSWVSLESLTLSYNGLGSNIFRLLDSLRALSGQAGCRLRALHLSDLFSPLPILELTRAIVRALPLLRVLSIRVD 553  
RnMUF1  TLCHLLSSWVSLESLTLSYNGLGSNIFRLLDSLRVLSGQAGCRLRALHLSDLFSPLPILELTRAIVRALPLLRVLSIRVD 554  
BtMUF1  TLCHLLSSWVSLESLTLSYNGLGSNIFRLLDSLRALSVQAGCRLRALHLSDLFSPLPILELTRAIVRALPLLRVLSIRVD 560  
 
 
HsMUF1  HPSQRDNPGVPGNAGPPSHIIGDEEIPENCLEQLEMGFPRGAQPAPLLCSVLKASGSLQQLSLDSATFASPQDFGLVLQT 638  
PaMUF1  HPSQRDNPGVPGNAGPPSHIIGDEEIPENCLEQLEMGFPRGAQPAPLLCSVLKASGSLQQLSLDSATFASPQDFGLVLQT 638  
MmMUF1  HPSQRDNPAVPENAGPPGHIVGDEEIPENCLEQLEMGFPRGAQPAPLLCSVLKASGSLQQLSLDSATFASPQDFGLVLQT 633  
RnMUF1  HPSQRDNPAVPENAGPPGHIIGDEEIPENCLEQLEMGFPRGAQPAPLLCSVLKASGSLQQLSLDSATFASPQDFGLVLQT 634  
BtMUF1  HPSQRDNPAVPGNAGPPSNVIGDEEIPENCLEQLEMGFPRGAQPAPLLCSVLKASGSLQQLSLDSATFASPQDFGLVLQT 640  
 
 
HsMUF1  LKEYNLALKRLSFHDMNLADCQSEVLFLLQNLTLQEITFSFCRLFEKRPAQFLPEMVAAMKGNSTLKGLRLPGNRLGNAG 718  
PaMUF1  LKEYNLALKRLSFHDMNLADCQSEVLFLLQNLTLQEITFSFCRLFEKRPAQFLPEMVAAMKGNSTLKGLRLPGNRLGNAG 718  
MmMUF1  LKEHNLSLKRLSFHDMNLADCQSEVLFLLKNLTLQEITFSFCRLFEKRPVQFLPEMVAAMKGNSTLKGLRLPGNRLGNAG 713  
RnMUF1  LKEYNLSLKRLSFHDMNLADCQSEVLFLLKNLTLQEITFSFCRLFEKRPAQFLPEMVAAMKGNSTLKGLRLPGNRLGNAG 714  
BtMUF1  LKEYNLTLKRLSFHDMNLADCQSEVLFLLQNLTLQEITFSFCRLFEKRPAQFLPEMVAAMKGNSTLKGLRLPGNRLGNAG 720  
 
 
HsMUF1  LLALADVFSEDSSSSLCQLDISSNCIKPDGLLEFAKRLERWGRGAFGHLRLFQNWLDQDAVTAREAIRRLRATCHVVSDS 798  
PaMUF1  LLALADVFSEDSSSSLCQLDISSNCIKPDGLLEFAKRLERWGRGAFGHLRLFQNWLDQDAVTAREAIRRLRATCHVVSDS 798  
MmMUF1  LLALADVFSEDSSSSLCQLDISSNCIKPDGLLEFAKRLERWGRGAFGHLRLFQNWLDQDAVTAREAIRRLRATCHVVSDS 793  
RnMUF1  LLALADVFSEDSSSSLCQLDISSNCIKPDGLLEFAKRLERWGRGAFGHLRLFQNWLDQDAVTAREAIRRLRATCHVVSDS 794  
BtMUF1  LLALADVFSEDSSSSLCQLDISSNCIKPDGLLEFAKRLERWGRGAFGHLRLFQNWLDQDAVTAREAIRRLRATCHVVSDS 800  
 
 
HsMUF1  WDSSQAFADYVSTM 812  
PaMUF1  WDSSQAFADYVSTM 812  
MmMUF1  WDSTQAFADYVSTM 807  
RnMUF1  WDSTQAFADYVSTM 808  
BtMUF1  WDSSQAFADYVSTM 814  
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3.2.2 Lrrc41 mRNA is ubiquitously expressed 
To examine the expression profile of Lrrc41 in mouse, RT-PCR was performed. As 
a template RNA isolated from various mouse tissues was used. The position of the Lrrc41 
primers for RT-PCR relative to the Lrrc41 gene is shown in figure 3.17B. The primers 
were designed in a way that they amplified a 690 bp fragment only from cDNA and not 
from genomic DNA. Figure 3.17A shows that Lrrc41 was expressed in all the tissues 
tested with the exception of skeletal muscle. The highest expression level was observed in 
testis. Other tissues expressing Lrrc41 were brain, heart, liver and lung. This data support 
previous observations that human LRRC41 is also ubiquitously expressed (Kopp 2006 
diploma thesis). 
 
 
 
 
 
 
Figure 3.17: Expression of Lrrc41. A) RNA isolated from the indicated mouse tissues was reverse 
transcribed into cDNA and amplified with specific primers sitting on intron/exon boundaries. A 436 bp 
fragment of the housekeeping gene GAPDH was amplified simultaneously and was used as a positive 
control. Samples were tested on an agarose gel. B) Cartoon depicting the position of the primers.  
 
3.2.3 Localisation of MUF1 
To examine the subcellular localisation of MUF1, MUF1 GFP-fusion proteins (see figure 
3.18) were expressed in COS7 cells and their localisation was examined using florescence 
microscopy. GFP-MUF1, GPF-MUF1(L46P,C50F) and GFP-MUF1ΔSOCS localised 
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almost solely to the nucleus (85.5% to 94.5% of cells), in some cases they could be found 
in both cytoplasm and nucleus (5% to 13.3%) and only a very small fraction of 
the transfected cells showed exclusively cytoplasmic localisation (1.2% and less). GFP-
MUF1-LRR does not contain any putative NLS and in 86.6% of the cells this fusion 
protein localised in both cytoplasm and nucleus. 2.6% of the cells showed only nuclear 
localisation of GFP-MUF1-LRR and in 8.8% cells only cytoplasmic localisation (Figure 
3.19). 
 
 
 
 
 
Figure 3.18: Domain architecture of MUF1 protein and constructs used in this study.  Where the tag is 
not specified, different tags were used (GFP, Flag, Myc) as specified in the corresponding experiment.  
SOCS: SOCS (suppressor of cytokine signalling) box domain, LRR: leucine-rich repeat domain. GFP-
MUF1(L46P,C50F) is full length protein containing two point mutations within SOCS-box that abolish 
interaction with Cul5. GFP-MUF1ΔSOCS has deleted the entire SOCS box. 
 
 
 
 
 
 
 
Figure 3.19 (next page): GFP-MUF1 localises to the nucleus and requires the putative NLSs for 
nuclear targeting. COS7 cells were transfected with the indicated GFP-tagged MUF1 constructs. 
Transfected cells were fixed with paraformaldehyde and stained with the DNA dye DAPI. Images were 
acquired with a confocal microscope. Bar represents 10 μm. For statistic evaluation, approximately 1000 
cells were scored for each sample. The graph shows average and standard deviation of two independent 
experiments.  
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To support these results, subcellular fractionation was performed. As expected, GFP-
MUF1-LRR was found in the nuclear and cytoplasmic fractions. GFP-MUF1, GPF-
MUF1(L46P,C50F) and GFP-MUF1ΔSOCS were found in the nuclear fraction 
and surprisingly, also in a membranous fraction. The possible explanation for this 
phenomenon could be that because staining with anti-emerin antibody showed signal not 
only in nuclei fraction, but also in the membranous fraction, possibly there was some 
contamination of membranous fraction with nuclei (Figure 3.20). 
 
 
 
Figure 3.20: GFP-MUF1 localises to the nucleus and requires the putative NLSs for nuclear targeting. 
COS7 cells were transfected with indicated GFP-tagged MUF1 constructs. Cell lysates were separated into 
nuclear, cytosolic and membranous fractions by centrifugation and analysed by Western blotting. Blots were 
probed with anti-GFP antibody. Ratio of nuclear : cytoplasmic : membranous fraction is 1:0.5:2. MUF1, 
MUF1(L46P,C50F) and MUF1ΔSOCS were found in nuclear and membranous fractions. MUF1-LRR was 
found in nuclear and cytosolic fractions. An empty GFP vector was used as a control. Anti-emerin antibody 
was used as a marker for the nuclear fraction and anti-GAPDH antibody as a marker for the cytosolic 
fraction.  
 
Because GFP is a bulky tag, it may be affecting the cellular localisation of GFP-MUF1. To 
confirm the subcellular localisation of MUF1 with another tag, we generated an expression 
vector with the I-Plastin (IPl) tag. This tag consists of the 18 N-terminal amino acids of I-
Plastin (IPl) sequence, for which a polyclonal antibody is available in our laboratory. 
A MUF1 construct with an N-terminal IPl-tag was prepared and DNA was transfected into 
COS7 cells. Fixed cells were immunostained with anti-I-Plastin antibody. Consistent with 
previous results, IPl-MUF1 localised predominantly in the nucleus indicating that GFP did 
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not affect the distribution of the GFP fusions and that the endogenous protein is most 
probably predominantly nuclear (Figure 3.21).  
 
 
3.2.4 MUF1 interacts with all three RhoBTB proteins in vivo 
To confirm that MUF1 interacts with RhoBTB3 in vivo, a series of co-
immunoprecipitation experiments were performed. 293T HEK cells were transfected with 
MUF1 and RhoBTB1, 2 or 3. Co-immunoprecipitation was performed with anti-Myc 
antibody coupled to magnetic beads. Immunoprecipitates and lysates were analysed for the 
presence of the indicated tagged proteins by Western blotting. In a first experiment Myc-
Figure 3.21: Subcellular 
localisation of MUF1. COS7 cells 
were transfected with IPl-tagged 
MUF1 or with empty vector with 
IPl-tag. Transfection with the empty 
plasmid served as a control to show 
that the I-Plastin antibody does not 
recognise any cellular structure. 
Transfected cells were fixed with 
paraformaldehyde 
and immunostained with I-Plastin 
antibody followed by Alexa Fluor 
568-coupled secondary antibody. 
Nuclei were stained with the DNA 
dye DAPI. Images were acquired 
with a conventional fluorescence 
microscope. Bar represents 10 μm 
(B,D) and 100 μm (A,C). For 
statistic evaluation, approximately 
1000 cells were scored. The graph 
shows average and standard 
deviation of two independent 
experiments. 
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MUF1 and Flag-RhoBTB1, 2 and 3 were used. Figure 3.22A shows that Myc-MUF1 
specifically co-immunoprecipitated all three RhoBTB proteins. To confirm this result, the 
experiment was repeated with swapped tags. Myc-RhoBTB2 and Myc-RhoBTB3 co-
immunoprecipitated Flag-MUF1. Interestingly, Myc-RhoBTB1 did not co-
immunoprecipitate Flag-MUF1 (Figure 3.22B). It is possible that RhoBTB1 binds to 
MUF1 with lower affinity than RhoBTB2 and RhoBTB3. We performed a co-
immunoprecipitation experiment using low stringency lysis and washing conditions. 
However, unspecific binding of Flag-MUF1 was observed (Figure 3.22C). The observation 
that Myc-RhoBTB1 did not co-immunoprecipitate Flag-MUF1 was very surprising and 
contradictory to the observation that Myc-MUF1 co-immunoprecipitated Flag-RhoBTB1. 
A possible explanation for this is that there might be some alterations in protein folding 
due to the tag that abolish protein interactions. In conclusion, these results demonstrate that 
all three RhoBTB proteins interact with MUF1 in vivo.  
Because RhoBTB3 is a cytoplasmic protein (Berthold et al. 2008b) and MUF1 localises 
predominantly to the nucleus (see section 3.2.3), it was of great interest to examine their 
mutual localisation in mammalian cells. COS7 cells were co-transfected with Flag-
RhoBTB3 and GFP-MUF1 constructs. Interestingly, when GFP-tagged MUF1 proteins and 
Flag-RhoBTB3 were co-expressed, GFP-tagged MUF1 proteins retained partially in the 
cytoplasm where they co-localise with Flag-RhoBTB3 in a paranuclear cluster (Figure 
3.23). Figure 3.23 shows only co-localisation of GFP-MUF1 and GFP-MUF1-LRR with 
Flag-RhoBTB3. GFP-MUF1(L46P,C50F) and GFP-MUF1ΔSOCS behaved similarly to 
GFP-MUF1 (only statistic data are shown). 
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Figure 3.22: Interaction of MUF1 with RhoBTB proteins. 293T HEK cells were transfected with the indicated MUF1 and either RhoBTB1, RhoBTB2 or RhoBTB3. 
Empty Myc or Flag vectors were used as controls. Protein complexes were immunoprecipitated with anti-Myc antibody coupled to magnetic beads. Boiled lysates or 
immunoprecipitated samples were resolved on 10% SDS gels and blotted onto PVDF membrane. The membrane was incubated with the indicated primary antibodies 
and corresponding peroxidase-conjugated secondary antibodies followed by ECL detection. A) Interaction of Myc-MUF1 and Flag-RhoBTB1/2/3, high stringency lysis 
and washing conditions. B) Interaction of Flag-MUF1 and Myc-RhoBTB1/2/3, high stringency lysis and washing conditions. C) Interaction of Flag-MUF1 and Myc-
RhoBTB1/2/3, low stringency lysis and washing conditions. Asterisk marks non-specific binding of the antibody.  
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Figure 3.23: MUF1 retains in the cytoplasm in a RhoBTB3-dependent manner. COS7 cells were transfected with GFP-tagged MUF1 constructs and Myc-RhoBTB3, 
fixed and immunostained with anti-Flag (anti-ECS) antibody. Nuclei were visualised with DAPI.  Images were acquired with a confocal laser scanning microscope 
and overlaid. RhoBTB3 caused MUF1 to be partially retained in the cytoplasm in a paranuclear pattern where they co-localised. Only MUF1 and MUF1-LRR are shown 
here as an example. The graphs show average and standard deviation of two independent experiments. Scale represents 10 μm. For statistic evaluation, approximately 
1000 cells were scored in two independent experiments. Compare with the localisation of the same constructs in the absence of RhoBTB3 (Figure 3.19). Note that 
the effect of RhoBTB3 does not require the presence of the SOCS-box.  
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3.2.5 RhoBTB3 has probably multiple binding sites on MUF1 
To identify the binding site of RhoBTB3 within MUF1 protein, different shortened MUF1 
constructs were used (Figure 3.18). 293T HEK cells were co-transfected with Flag-
RhoBTB3-FL and one of the Myc-MUF1 C-terminal constructs. Myc-MUF1/C (609-
807AA) contains the MUF1 sequence that was identified in the two-hybrid screening. 
Myc-MUF1/C (609-735) and Myc-MUF1/C (724-807) constructs were used to narrow 
down the interaction. Co-immunoprecipitation was performed with anti-Myc antibody 
coupled to magnetic beads. Immunoprecipitates and lysates were analysed for the presence 
of the indicated tagged proteins by Western blotting. Figure 3.24A shows that all three C-
terminal Myc-tagged proteins co-immunoprecipitated Flag-RhoBTB3. Apparently, binding 
to RhoBTB3 occurs through multiple binding sites.  
To examine if also the N-terminal part of MUF1 can bind to RhoBTB3, 293T HEK cells 
were co-transfected with Flag-RhoBTB3 and Myc-MUF1/N. Co-immunoprecipitation was 
performed with anti-Myc antibody coupled to magnetic beads. Immunoprecipitates 
and lysates were analysed for the presence of the indicated tagged proteins by Western 
blotting. Surprisingly, the N-terminal part of MUF1 also co-immunoprecipitated Flag-
RhoBTB3 (Figure 3.24B). This observation can be explained by the fact that this N-
terminal fusion protein contains also part of the leucine-rich repeat region (131 amino 
acids) that is a well known motif for mediating protein-protein interactions (Bella et al. 
2008). 
 
 
Figure 3.24: Myc-MUF1/N and Myc-MUF1/C co-immunoprecipitate RhoBTB3.  293T HEK cells were 
transfected with Flag-RhoBTB3 or empty Flag vector and the indicated Myc-tagged MUF1 constructs or 
empty Myc vector as a control. Protein complexes were immunoprecipitated with anti-Myc antibody coupled 
to magnetic beads. Boiled lysates or immunoprecipitated samples were resolved on 10% SDS gel and blotted 
onto PVDF membrane. The membrane was incubated with the indicated primary antibodies 
and corresponding peroxidase-conjugated secondary antibodies followed by ECL detection. A) Interaction of 
C-terminal fragments of MUF1 and RhoBTB3. B) Interaction of N-terminal fragment of MUF1 
and RhoBTB3. 
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3.2.6 MUF1 has probably multiple binding sites on RhoBTB3 
To map the binding of MUF1 on RhoBTB3, co-immunoprecipitation experiments were 
performed using different GFP-tagged RhoBTB3 constructs (Figure 3.2). 293T HEK cells 
were co-transfected with Myc-MUF1 and GFP-tagged RhoBTB3 deletion constructs. Co-
immunoprecipitation was performed with anti-GFP antibody coupled to magnetic beads. 
Immunoprecipitates and lysates were analysed for the presence of the indicated tagged 
proteins by Western blotting.  
In the first experiment, 293T HEK cells were co-transfected with Myc-MUF1 and GFP-
RhoBTB3-GTPase or GFP-RhoBTB3-PB1B2C. Figure 3.25A shows that both GFP-
RhoBTB3-GTPase and GFP-RhoBTB3-PB1B2C co-immunoprecipitated Myc-MUF1, 
although the interaction between RhoBTB3-PB1B2C and MUF1 seemed to be stronger.  
To further map the binding of MUF1 on RhoBTB3-PB1B2C, 293T HEK cells were co-
transfected with Myc-MUF1 and GFP-RhoBTB3-B1, GFP-RhoBTB3-B2 or GFP-
RhoBTB3-C. Figure 3.25B shows that all three GFP-tagged RhoBTB3 proteins co-
immunoprecipitated Myc-MUF1. This result indicates that MUF1 might have multiple 
binding sites on RhoBTB3. 
 
Figure 3.25: Interaction of MUF1 with different domains of RhoBTB3. 293T HEK cells were transfected 
with Myc-MUF1 or empty Myc vector and indicated GFP-tagged RhoBTB3 constructs or empty GFP vector 
as a control. Protein complexes were immunoprecipitated with anti-GFP antibody coupled to magnetic beads. 
Boiled lysates or immunoprecipitated samples were resolved on 10% SDS gel and blotted onto PVDF 
membrane. The membrane was incubated with the indicated primary antibodies and corresponding 
peroxidase-conjugated secondary antibodies followed by ECL detection. A) Interaction of MUF1 with 
RhoBTB3-GTPase and RhoBTB3-PB1B2C. B) Interaction of MUF1 with RhoBTB3-B1, RhoBTB3-B2 
and RhoBTB3-C.  
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3.2.7 MUF1 interacts with RhoBTB3 in a Cul3 and Cul5 independent manner 
As already mentioned in the introduction (see section 1.4.3), the first BTB domain of 
RhoBTB3 interacts with Cul3 (Berthold et al. 2008b) and MUF1 binds Cul5 through the 
SOCS box domain (Kamura et al. 2001). To rule out that RhoBTB3 binds MUF1 indirectly 
through possible heterodimerisation of Cul3 and Cul5 (see section 3.2.11), a RhoBTB3 
mutant that does not bind Cul3 and a MUF1 mutant that does not bind Cul5 were prepared 
and their interaction was examined.  
First, a RhoBTB3 mutated in one residue (histidine 270) within first BTB domain was 
prepared (H270L). This histidine residue was chosen because it is necessary for interaction 
of the BTB/POZ domain protein Btb3p with S. pombe Cul3 (Pcu3p) (Geyer et al. 2003) 
and is also present in the first BTB domain of RhoBTB3. To test whether this point 
mutation is sufficient to abolish Cul3 interaction with RhoBTB3, 293T HEK cells were 
transfected with Flag-Cul3 and either Myc-RhoBTB3 or  Myc-RhoBTB3(H270L). Co-
immunoprecipitation was performed with anti-Myc antibody coupled to magnetic beads. 
Immunoprecipitates and lysates were analysed for the presence of the indicated tagged 
proteins by Western blotting. Figure 3.26 shows that while Myc-RhoBTB3 still co-
immunoprecipitated Flag-Cul3, Myc-RhoBTB3(H270L) did not. The single point mutation 
H270L localised in the first BTB domain is therefore sufficient to abolish interaction of 
RhoBTB3 with Cul3.  
 
 
Figure 3.26: RhoBTB3(H270L) mutant does not bind Cul3. HEK 293T cells were transfected with Flag-
Cul3 or empty Flag vector and either Myc-RhoBTB3, Myc-RhoBTB3-H270L or empty Myc vector. Protein 
complexes were immunoprecipitated with anti-Myc antibody coupled to magnetic beads. Boiled lysates or 
immunoprecipitated samples were resolved on 10% SDS gel and blotted onto PVDF membrane. 
The membrane was incubated with the indicated primary antibodies and corresponding peroxidase-
conjugated secondary antibodies followed by ECL detection. Asterisk marks non-specific binding of the 
antibody.  
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Second, a MUF1 construct with deleted SOCS box domain was prepared to prevent 
binding of MUF1 to Cul5. 293T HEK cells were transfected with Flag-MUF1ΔSOCS and 
Myc-RhoBTB3(H270L). As a positive control, cells were transfected with Flag-MUF1 and 
Myc-RhoBTB3. Co-immunoprecipitation was performed with anti-Myc antibody coupled 
to magnetic beads. Immunoprecipitates and lysates were analysed for the presence of the 
indicated tagged proteins by Western blotting. Myc-RhoBTB3(H270L) was still able to co-
immunoprecipitate Flag-MUF1ΔSOCS (Figure 3.27). This result shows that the interaction 
of RhoBTB3 and MUF1 is not mediated by a possible dimerisation of Cul3 and Cul5, 
which is addressed below (see section 3.2.11). 
 
 
 
Figure 3.27: MUF1 interacts with RhoBTB3 in a Cul3 and Cul5 independent manner. HEK 293T cells 
were transfected with Myc-RhoBTB3(H270L) or empty Myc vector and Flag-MUF1-ΔSOCS or empty Flag 
vector. As positive control, cells were co-transfected with Myc-RhoBTB3 and Flag-MUF1. Protein 
complexes were immunoprecipitated with anti-Myc antibody coupled to magnetic beads. Boiled lysates or 
immunoprecipitated samples were resolved on 10% SDS gel and blotted onto PVDF membrane. The 
membrane was incubated with the indicated primary antibodies and corresponding peroxidase-conjugated 
secondary antibodies followed by ECL detection. The cartoon on the right hand side represents RhoBTB3-
H270L and MUF1ΔSOCS that are not able to bind to their corresponding cullins. 
 
3.2.8 MUF1 is degraded in the proteasome in a Cul5 independent manner 
The observation that MUF1 interacts with RhoBTB proteins raised the question of 
the relationship between these two proteins in cullin-multiprotein complexes. We 
envisioned two possible models: a) MUF1 is ubiquitinated by a Cul3 complex dependent 
on RhoBTB, which acts as the substrate specific adaptor; b) RhoBTB is ubiquitinated by 
a Cul5 complex dependent on MUF1, which acts as the substrate specific adaptor. To test 
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this hypothesis, a half life experiment was performed (see section 2.3.5). 293T HEK cells 
were transfected with Myc-MUF1ΔSOCS and GFP-RhoBTB3 or Myc-RhoBTB3(H270L) 
and GFP-MUF1. Lysates were collected at several time points and analysed for 
the presence of the tagged proteins by Western blotting.  Figure 3.28A shows that Myc-
MUF1ΔSOCS was very fast degraded in the presence of GFP-RhoBTB3. Addition of 
the proteasomal inhibitor MG132 stabilised MUF1ΔSOCS, confirming that degradation is 
proteasomal specific. When co-expressed with GFP, no significant degradation of 
MUF1ΔSOCS was observed. MUF1ΔSOCS lacks the SOCS-box that mediates interaction 
with Cul5 therefore this degradation is Cul5-independent and occurs probably through 
Cul3 by binding to RhoBTB3. To mediate this effect, the C-terminal part of RhoBTB3 
(B1B2C) is sufficient (data not shown).  As shown above (see section 3.2.7), Myc-
RhoBTB3(H270L) did not bind Cul3. Figure 3.28B shows that although 
RhoBTB3(H270L) was also degraded, this effect was clearly less dramatic as it was for 
MUF1ΔSOCS. Degradation of RhoBTB3(H270L) is not enhanced in the presence of 
MUF1.  To conclude, these experiments provide evidence that MUF1 is degraded in the 
proteasome in a Cul5 independent manner probably by Cul3-RhoBTB3 ligase complex. 
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Figure 3.28: MUF1 is degraded in the proteasome by Cul3-RhoBTB3 ligase complex. 293T HEK cells 
were transfected with indicated plasmids. 16 h after transfection cells were split and treated with 100 μM 
cycloheximide and either with 10 μM MG132 or DMSO. At the time points 0, 4, 8 and 12h cells were 
collected and lysed. Lysates were tested on 10% SDS gel and blotted onto PVDF membrane. The membrane 
was probed with indicated primary antibodies and corresponding peroxidase-conjugated secondary antibodies 
followed by ECL detection. Actin staining served as a loading control. The graphs show the amount of 
the GFP fusion protein normalised to the amount of actin and expressed as percentage relative to the 0 time 
point. A) Cells were co-transfected with Myc-MUF1ΔSOCS and either GFP-RhoBTB3 or empty GFP vector 
as a control. B) Cells were co-transfected with Myc-RhoBTB3(H270L) and either GFP-MUF1 or empty GFP 
vector. C) Cartoon depicting possible relationship between MUF1 and RhoBTB3 in Cul3-dependent 
complex. RhoBTB3 is a substrate specific adaptor that targets MUF1 for proteasomal degradation. 
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3.2.9 MUF1 is able to homodimerise 
Proteins containing a leucine-rich repeats form very often homo- and heterodimers or even 
larger assemblies like tetramers (Bella et al. 2008). To examine if MUF1 is also able to 
build homodimers, Flag-MUF1 and Myc-MUF1 were co-transfected into 293T HEK cells. 
Co-immunoprecipitation was performed with anti-Myc antibody coupled to magnetic 
beads. Immunoprecipitates and lysates were analysed for the presence of the indicated 
tagged proteins by Western blotting. Figure 3.29 shows that Myc-MUF1 co-
immunoprecipitated Flag-MUF1. To prove that this homodimerisation was not mediated 
by interaction with Cul5, Flag-MUF1ΔSOCS was also used. This shorter protein did not 
bind Cul5 (Kamura et al. 2001). Figure 3.29 shows that Myc-MUF1 also co-
immunoprecipitated Flag-MUF1ΔSOCS, therefore homodimerisation of MUF1 is not 
mediated by Cul5. 
 
 
 
Figure 3.29: Homodimerisation of MUF1. HEK 293T cells were transfected with Myc-MUF1 and either 
Flag-MUF1 or Flag-MUF1ΔSOCS. Empty Myc or Flag vectors were used as a control. Protein complexes 
were immunoprecipitated with anti-Myc antibodies coupled to magnetic beads. Boiled lysates or 
immunoprecipitated samples were resolved on 10% SDS gel and blotted onto PVDF membrane. 
The membrane was incubated with the indicated primary antibodies and corresponding peroxidase-
conjugated secondary antibodies followed by ECL detection. 
 
3.2.10 Characterisation of MUF1 interaction with potential binding partners 
To understand the function of MUF1 protein, it is of a great interest to identify possible 
interaction partners. Large scale screenings that reveal a list of protein-protein interactions 
constitute a great help to study this issue. Stelzl et al. (2005) performed large scale yeast 
two-hybrid screening and identified MyoIXb as an interaction partner of MUF1 with a 
score medium confidence of interaction. Another large scale screenings revealed RBPMS 
protein as a potential binding partner of MUF1 (Rual et al. 2005).  
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3.2.10.1 MyoIXb as a potential binding partner of MUF1 
Myosins are molecular motors that convert chemical energy stored in ATP into direct 
mechanical force along actin filaments. Human myosin IXb is an unconventional myosin 
that comprises a RhoGAP (RhoGTPase-activating protein) domain (Reinhard et al. 1995). 
MyoIXb exhibits increased GAP activity for Rho proteins (Müller et al. 1997) and is 
recruited to the extending lamellipodia, ruffles and filopodia where it acts as a motorised 
RhoGAP molecule (van den Boom et al. 2007). 
To verify the possible interaction between MUF1 and MyoIXb, co-immunoprecipitation 
analysis was performed. 293T HEK cells were transfected with MyoIXb-Flag and Myc-
MUF1. One sample transfected with Flag-MUF1 and Myc-RhoBTB3 was used as 
a positive co-immunoprecipitation control. Co-immunoprecipitation was performed with 
anti-Myc antibody coupled to magnetic beads. Immunoprecipitates and lysates were 
analysed for the presence of the indicated tagged proteins by Western blotting. 
No interaction of MyoIXb and MUF1 was observed despite the fact that co-
immunoprecipitation of MUF1 with RhoBTB3 was successful (Figure 3.30).  
 
 
 
Figure 3.30: MUF1 does not co-immunoprecipitate MyoIXb. 293T HEK cells were transfected with 
MyoIXb-Flag and Myc-MUF1 or with the corresponding empty vectors as a negative control. Flag-MUF1 
and Myc-RhoBTB3 co-transfection was used as a positive control. Protein complexes were 
immunoprecipitated with anti-Myc antibody coupled to magnetic beads. Boiled lysates or 
immunoprecipitated samples were resolved on 4-20% SDS gradient gel and blotted onto PVDF membrane. 
The membrane was incubated with the indicated primary antibodies and corresponding peroxidase-
conjugated secondary antibodies followed by ECL detection. Asterisks mark non-specific binding of the 
antibody.  
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Because binding of MyoIXb and MUF1 might be weak and the lysis buffer commonly 
used may disrupt this interaction, a low stringency buffer was used for the cell lysis and 
washing steps in a new experiment (see section 2.7.2). However, despite the mild lysis and 
washing conditions, an interaction between MyoIXb and MUF1 was not observed (not 
shown).  
 
3.2.10.2 RBPMS as a potential binding partner of MUF1 
RBPMS (RNA Binding Protein with Multiple Splicing) proteins belong to the large family 
of RNA-binding proteins. Alternative splicing of the single copy of the RBPMS gene gives 
rise to at least twelve transcripts, nine of them encoding an RNA-recognition motif at 
the N-terminus (Shimamoto et al. 1996). RBPMS is involved in transforming growth 
factor-β (TGF-β) signalling by increasing Smad-mediated transcriptional activity (Sun 
et al. 2006). 
Most of the RBPMS transcripts encode the same N-terminus containing the RNA-binding 
motif, but differ in their C-terminus. For testing the interaction between RBPMS 
and MUF1, we have chosen mouse variant 1 (NP_062707.1), which is the most frequently 
occurring transcript and variant 3 (NP_001036140.1), which has a distinct C-terminus 
compared to isoform 1 and we subcloned their cDNAs to the expression vectors. 293T 
HEK cells were transfected with Flag-RBPMS1 or Flag-RBPMS3 and Myc-MUF1. One 
sample transfected with Flag-MUF1 and Myc-RhoBTB3 was used as a positive co-
immunoprecipitation control. Co-immunoprecipitation was performed with anti-Myc 
antibody coupled to magnetic beads. Immunoprecipitates and lysates were analysed for 
the presence of the indicated tagged proteins by Western blotting. As figure 3.31A shows, 
Myc-MUF1 did not co-immunoprecipitate neither Flag-RBPMS1 nor Flag-RBPMS3. 
To confirm this, another co-immunoprecipitation was performed this time with anti-GFP 
antibody coupled to magnetic beads. 293T HEK cells were transfected with Flag-RBPMS1 
or Flag-RBPMS3 and GFP-MUF1-LRR. One sample transfected with GFP-RhoBTB3 
and Flag-RhoBTB2 was used as a positive co-immunoprecipitation control. 
Immunoprecipitates and lysates were analysed for the presence of the indicated tagged 
proteins by Western blotting. As figure 3.31B shows, GFP-MUF1-LRR did not co-
immunoprecipitate neither Flag-RBPMS1 nor Flag-RBPMS3. Low stringency buffer was 
used for the cell lysis and washing steps in both experiments. 
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Figure 3.31: MUF1 does not co-immunoprecipitate RBPMS1 or RBPMS3. 293T HEK cells were 
transfected with the indicated plasmids. Protein complexes were immunoprecipitated and boiled lysates or 
immunoprecipitated samples were resolved on 10% SDS gel and blotted onto PVDF membrane. 
The membrane was incubated with the indicated primary antibodies and corresponding peroxidase-
conjugated secondary antibodies followed by ECL detection. A) Myc-MUF1 did not co-immunoprecipitate 
Flag-RBPMS1 or Flag-RBPMS3. Protein complexes were immunoprecipitated with anti-Myc antibody 
coupled to magnetic beads. B)  GFP-MUF1-LRR did not co-immunoprecipitate Flag-RBPMS1 or Flag-
RBPMS3. Protein complexes were immunoprecipitated with anti-GFP antibody coupled to magnetic beads. 
 
3.2.11 Dimerisation of cullins  
As already mentioned in the introduction (see section 1.4.3), RhoBTB3 is an adaptor of 
cullin 3-based ligases (Berthold et al. 2008b) and MUF1 is an adaptor of cullin 5-based 
ligases (Kamura et al. 2001). This raises the question whether MUF1 and RhoBTB3 are 
together involved in multiprotein complexes containing Cul3 and Cul5 simultaneously. 
That would indicate that there is cross-talk among cullin-dependent ubiquitin ligases. 
It was shown recently that several cullins can make homodimers, e.g. Cul1 (Chew et al. 
2007), Cul3 (Chew et al. 2007, Wimuttisuk and Singer 2007), Cul4A (Chew et al. 2007) 
and Cul7 (Skaar et al. 2005), although homodimersation of Cul2 and Cul5 was not 
observed (Chew et al. 2007). Cul3 can also heterodimerise with Cul1 (Wimuttisuk 
and Singer 2007). To examine whether Cul3 can also heterodimerse with Cul5, two 
different approaches were used – yeast two-hybrid and co-immunoprecipitation.  
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Cul3-pGADT7 and Cul5-pGBKT7 were transformed into yeast cells in order to perform 
yeast two-hybrid experiments. These experiments were performed several times but 
brought inconsistent and irreproducible results. 
As a second approach, co-immunoprecipitation studies in mammalian cells were 
performed. 293T HEK cells were transfected with Myc-Cul3 or Myc-Cul5 and Flag-Cul3. 
Co-immunoprecipitation was performed with anti-Myc antibody coupled to magnetic 
beads. Immunoprecipitates and lysates were analysed for the presence of the indicated 
tagged proteins by Western blotting. Figure 3.32A shows that both Myc-Cul3 as well as 
Myc-Cul5 co-immunoprecipitated Flag-Cul3, therefore Cul3 is able to make homodimers 
as well as heterodimers with Cul5. 
Wimuttisuk and Singer (2007) claimed that dimerisation of Cul3 is mediated by a single 
Nedd8 molecule in a way that one neddylated Cul3 and one non-neddylated Cul3 form 
a dimer. To examine whether this is also the case for heterodimerisation of Cul3 and Cul5, 
293T HEK  cells were transfected with Myc-Cul3 or Myc-Cul5 and a dominant negative 
mutant of  Cul3 (Cul3-DN-Flag). Cul3-DN-Flag lacks the C-terminus, therefore is unable 
to bind Roc1. This mutant also lacks the lysine residue that is neddylated (K719). Co-
immunoprecipitation was performed with anti-Myc antibody coupled to magnetic beads. 
Immunoprecipitates and lysates were analysed for the presence of the indicated tagged 
proteins by Western blotting. Figure 3.32B shows that both Myc-Cul3 as well as Myc-Cul5 
co-immunoprecipitated Cul3-DN-Flag. These data imply that the dimerisation of 
the examined cullins does not depend on the C-terminal part of Cul3. 
Apart from cullin dimerisation, there is increasing evidence that substrate specific adaptors 
can form homo- and heterodimers and this interaction is crucial for substrate 
ubiquitination. This was shown for example for yeast F-box proteins Pop1p and Pop2p 
(Seibert et al. 2002, Wolf et al. 1999) or the BTB domain containing protein Kelch 
(McMahon et al. 2006). To examine whether Cul3 and Cul5 heterodimerise through 
substrate specific adaptors, Cul5ΔNΔC mutant was prepared. This mutant lacks the N-
terminal part of Cul5 necessary for interaction with substrates (Xu et al. 2003), and also 
the C-terminal part that is neddylated (Wimuttisuk and Singer 2007). 293T HEK cells were 
transfected with Myc-Cul3 and GFP-Cul5ΔNΔC. Co-immunoprecipitation was performed 
with anti-GFP antibody coupled to magnetic beads. Immunoprecipitates and lysates were 
analysed for the presence of the indicated tagged proteins by Western blotting. Figure 
3.32C shows that GFP-Cul5ΔNΔC co-immunoprecipitated Myc-Cul3 therefore 
heterodimerisation of Cul3 and Cul5 is not mediated through substrate specific adaptors. 
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Figure 3.32: Dimerisation of Cul3 and Cul5. 293T HEK were transfected with the indicated constructs or empty Flag and Myc vectors as controls. Protein complexes 
were immunoprecipitated with anti-Myc antibody coupled to magnetic beads. Boiled lysates or immunoprecipitated samples were resolved on 10% SDS gel and blotted 
onto PVDF membrane. The membrane was incubated with the indicated primary antibodies and corresponding peroxidase-conjugated secondary antibodies followed by 
ECL detection. Asterisks mark non-specific binding of the antibody. A) Interaction of Myc-Cul3 and Myc-Cul5 with Flag-Cul3. B) Interaction of Myc-Cul3 and Myc-
Cul5 with Cul3-DN-Flag. C) Interaction of GFP-Cul5ΔNΔC with Myc-Cul3. D) Cartoon depicting the possible mechanism of binding of Cul3 and Cul5.  
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3.3 Kindlin, an interaction partner of RhoBTB3 
Kindlin-2/Mig-2 is one of several proteins identified previously in our laboratory during 
attempts to identify binding partners (and possible substrates) of RhoBTB3 (S. Ramos, 
personal communication). It was the C-terminus of kindlin-2 that was identified (554-
680AA). To confirm this interaction, several co-immunoprecipitation studies were 
performed in mammalian cells. Figure 3.33 depicts the constructs used in the following 
studies.  
 
 
Figure 3.33: Domain architecture of kindlin-1 and kindlin-2 and constructs used in this study. Kindlins 
are composed of FERM (4.1, ezrin, radixin, moesin) domain, which is subdivided into four subdomains 
named F0, F1, F2 and F3. The F2 subdomain is interrupted by a pleckstrin homology domain (PH). NLS 
represents nuclear localisation signal.  
 
3.3.1 RhoBTB2 and RhoBTB3 interact with kindlin-1 and kindlin-2 
293T HEK cells were transfected with kindlin-1-Flag or kindlin-2-Flag and either Myc-
RhoBTB3 or Myc-RhoBTB2. Co-immunoprecipitation was performed with anti-Myc 
antibody coupled to magnetic beads. Immunoprecipitates and lysates were analysed for 
the presence of the indicated tagged proteins by Western blotting. Figure 3.34A shows that 
Myc-RhoBTB3 co-immunoprecipitated kindlin-2-Flag thus confirming observations from 
the two-hybrid screening that RhoBTB3 interacts with kindlin-2. Moreover, Myc-
RhoBTB3 co-immunoprecipitated also kindlin-1-Flag (Figure 3.34A) and similarly, Myc-
RhoBTB2 also co-immunoprecipitated both kindlin-1-Flag and kindlin-2-Flag (Figure 
3.34B). 
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Figure 3.34: RhoBTB2 and RhoBTB3 co-immunoprecipitate kindlin-1 and kindlin-2. 293T HEK cells 
were transfected with kindlin-1-Flag, kindlin-2-Flag or empty Flag vector and Myc-RhoBTB2, Myc-
RhoBTB3 or empty Myc vector. Protein complexes were immunoprecipitated with anti-Myc antibody 
coupled to magnetic beads. Boiled lysates or immunoprecipitated samples were resolved on 10% SDS gels 
and blotted onto PVDF membrane. The membrane was incubated with the indicated primary antibodies 
and corresponding peroxidase-conjugated secondary antibodies followed by ECL detection. A) Interaction of 
Myc-RhoBTB3 with kindlin-1-Flag and kindlin-2-Flag. B) Interaction of Myc-RhoBTB2 with kindlin-1-Flag 
and kindlin-2-Flag. 
 
3.3.2 RhoBTB3 has probably multiple binding sites on kindlin-1 
We obtained two splicing variants of human kindlin-1, one of them is missing the C-
terminal part – kindlin-1 (1-495) and another one is missing the N-terminal part – kindlin-1 
(258-677) (Figure 3.33). To test which splicing variant binds to RhoBTB3, co-
immunoprecipitation was performed. 293T HEK cells were transfected with Flag-kindlin-1 
(1-495) or Flag-kindlin-1 (258-677) and Myc-RhoBTB3. Co-immunoprecipitation was 
performed with anti-Myc antibody coupled to magnetic beads. Immunoprecipitates 
and lysates were analysed for the presence of the indicated tagged proteins by Western 
blotting. Both Flag-kindlin-1 (1-495) and Flag-kindlin-1 (258-677) were co-
immunoprecipitated with Myc-RhoBTB3 (Figure 3.35). Interestingly, it was the C-terminal 
part of kindlin-2 (residues 554-680) that was identified in the two-hybrid screening. This 
region corresponds to the region 551-677 AA in kindlin-1. This indicates that RhoBTB3 
may have multiple binding sites on kindlins. To confirm this, two additional constructs 
were used – GFP fusions of the N-terminal part and the C-terminal part of kindlin-1 
(Figure 3.33). 293T HEK cells were transfected with GFP-kindlin-1/N or GFP-kindlin-1/C 
and Myc-RhoBTB3. Co-immunoprecipitation was performed with anti-GFP antibody 
coupled to magnetic beads. Immunoprecipitates and lysates were analysed for the presence 
of the indicated tagged proteins by Western blotting. Both, GFP-kindlin-1/N and GFP-
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kindlin-1/C, co-immunoprecipitated Myc-RhoBTB3 supporting the hypothesis that 
RhoBTB3 may have multiple binding sites on kindlins (Figure 3.36).   
 
 
Figure 3.35: RhoBTB3 co-immunoprecipitates kindlin-1 (1-495) and kindlin-1 (258-677). 293T HEK 
cells were transfected with Flag-kindlin-1 (1-495) or Flag-kindlin-1 (258-677) or empty Flag vector 
and Myc-RhoBTB3 or empty Myc vector. Protein complexes were immunoprecipitated with anti-Myc 
antibody coupled to magnetic beads. Boiled lysates or immunoprecipitated samples were resolved on 10% 
SDS gel and blotted onto PVDF membrane. The membrane was incubated with the indicated primary 
antibodies and corresponding peroxidase-conjugated secondary antibodies followed by ECL detection.  
 
 
 
 
Figure 3.36: Kindlin-1/N and kindlin-1/C co-immunoprecipitate RhoBTB3. 293T HEK cells were 
transfected with GFP-kindlin-1/N or GFP-kindlin-1/C or empty GFP vector and Myc-RhoBTB3 or empty 
Myc vector. Protein complexes were immunoprecipitated with anti-Myc antibody coupled to magnetic beads. 
Boiled lysates or immunoprecipitated samples were resolved on 10% SDS gels and blotted onto PVDF 
membrane. The membrane was incubated with the indicated primary antibodies and corresponding 
peroxidase-conjugated secondary antibodies followed by ECL detection. A) Interaction of GFP-kindlin-1/N 
with Myc-RhoBTB3. B) Interaction of GFP-kindlin-1/C with Myc-RhoBTB3. This part of the experiment 
was done in collaboration with Julia Lutz. 
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3.3.3 RhoBTB3 partially co-localises with kindlin-1 and kindlin-2 
To examine if kindlin also co-localises with RhoBTB3, COS7 cells were co-transfected 
with either GFP-kindlin-1 or GFP-kindlin-2 and Flag-RhoBTB3. Fixed cells were 
immunostained with anti-Flag (anti-ECS) antibody. In COS7 cells GFP-kindlin-1 
and GFP-kindlin-2 localised in the cytoplasm and stronger signal was observed in the 
paranuclear area where it partially co-localises with RhoBTB3 (Figure 3.37).  
 
 
 
Figure 3.37: Kindlin-1 and kindlin-2 partially co-localise with RhoBTB3. COS7 cells were transfected 
with Flag-RhoBTB3 and either GFP-kindlin-1, GFP-kindlin-2 and or with empty GFP vector. Cells were 
fixed and immunostained with anti-Flag (anti-ECS) antibody followed by staining with Alexa Fluor 568-
coupled secondary antibody. Images were acquired with a conventional fluorescence microscope, 
deconvolved and overlaid. Right hand panels are magnifications of the indicated areas. Bar represents 10 μm. 
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3.4 Uev1a, an interaction partner of RhoBTB3 
Uev1a (ubiquitin-conjugating E2 enzyme variant) is another potential binding partner of 
RhoBTB3 identified in a two hybrid screening (S. Ramos, personal communication). 
Interaction between Uev1a and RhoBTB2-B1B2C and RhoBTB3-B1B2C has been 
confirmed by yeast two-hybrid analysis (Berthold 2006 dissertation thesis). However, it 
has not been confirmed that RhoBTB3 binds Uev1a in vivo. To examine this, 293T HEK 
cells were transfected with Myc-Uev1a and GFP-RhoBTB3. Co-immunoprecipitation was 
performed with anti-GFP antibody coupled to magnetic beads. Immunoprecipitates 
and lysates were analysed for the presence of the indicated tagged proteins by Western 
blotting. Figure 3.38 shows that GFP-RhoBTB3 co-immunoprecipitated Myc-Uev1a 
therefore confirming the interaction between Uev1a and RhoBTB3. 
 
 
 
Figure 3.38: RhoBTB3 co-immunoprecipitates Uev1a. 293T HEK cells were transfected with GFP-
RhoBTB3 or empty GFP vector and Myc-Uev1a or empty Myc vector. Protein complexes were 
immunoprecipitated with anti-GFP antibody coupled to magnetic beads. Boiled lysates or 
immunoprecipitated samples were resolved on 10% SDS gels and blotted onto PVDF membrane. 
The membrane was incubated with the indicated primary antibodies and corresponding peroxidase-
conjugated secondary antibodies followed by ECL detection. 
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To examine if Uev1a also co-localises with RhoBTB3, COS7 cells were co-transfected 
with GFP-Uev1a and Flag-RhoBTB3. Fixed cells were immunostained with anti-Flag 
(anti-ECS) antibody. GFP-Uev1a localised in the nucleus and the cytoplasm. Additionally, 
GFP-Uev1a positive vesicles were observed in the paranuclear area, where they partially 
co-localise with RhoBTB3 (Figure 3.39). 
 
 
Figure 3.39: Uev1a partially co-localises with RhoBTB3. COS7 cells were transfected with GFP-Uev1a 
and Flag-RhoBTB3 or with empty GFP or Flag vectors. Cells were fixed and immunostained with anti-Flag 
(anti-ECS) antibody followed by staining with Alexa Fluor 568-coupled secondary antibody. Images were 
acquired with a conventional fluorescence microscope, deconvolved and overlaid. Right hand panel is 
magnification of the indicated area. Bar represents 10 μm. 
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4 Discussion 
4.1 Subcellular localisation of RhoBTB3 
The major obstacle that hampers the study of the subcellular localisation of RhoBTB3 is 
a lack of good antibodies recognising the endogenous protein. Although the available 
antibodies recognise endogenous RhoBTB3 on Western blot under certain conditions, 
probably low cellular levels of RhoBTB3 is the major cause that it cannot be detected 
using immunofluorescence techniques. We have therefore resorted to the use of tagged 
proteins in our studies. 
RhoBTB3 localises to vesicles dispersed in the cytoplasm and accumulation of the vesicles 
is observed in the paranuclear area around the MTOC in COS7 and PAE (porcine aortic 
endothelial) cells (Berthold 2006 dissertation thesis, Berthold et al. 2008b). In this study, 
we extended this observation also to HeLa cells. RhoBTB3 is the only RhoBTB protein 
containing a prenylation motif at the C-terminus. Prenylation is a post-translational 
modification that targets the protein to membranous structures. It was shown that the C-
terminus of RhoBTB3 is necessary and sufficient for the vesicular localisation of 
RhoBTB3 (Berthold et al. 2008b).  
To identify the nature of these vesicles various stainings of RhoBTB3-transfected cells 
were performed. Counterstaining with different cellular markers revealed that RhoBTB3 
(at least partially) co-localises with the markers of the endocytic pathway. RhoBTB3 
positive vesicles occasionally co-localise with the early endosomal marker transferrin and 
with the early endosomal marker EEA1. It is the C-terminus that is responsible for 
RhoBTB3 localisation to early endosomes. The co-localisation with GM130 (GA marker) 
is more extensive and here again, the C-terminus is responsible for this localisation. These 
data are consistent with previous observations from our laboratory showing that RhoBTB3 
co-localises with another GA marker, namely mannosidase II (Berhold 2006 dissertation 
thesis). Surprisingly, RhoBTB2 also showed a vesicular localisation and partial co-
localisation to the GA. A vesicular localisation of RhoBTB2 was also reported before 
(Chang et al. 2006). However, because RhoBTB2 lacks a prenylation motif, it is possible 
that RhoBTB2 is associated with vesicular structures by interaction with other yet 
unidentified protein(s).  
Overexpression of all RhoBTB proteins or only single RhoBTB domains altered 
the structure of the GA causing formation of aggregates or vesicles dispersed in 
the cytoplasm. Based on our co-localisation observations, it is possible that most of 
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the RhoBTB proteins localise primarily to the GA within the cell and overexpression of 
large amount of exogenous proteins just cause GA disruption. The localisation of 
RhoBTB3 and the dramatic effect of RhoBTB3 overexpression on GA morphology 
suggest that this protein might participate in vesicle transport, a role already proposed for 
RhoBTB2. In the study performed by Chang et al. (2006), knockdown of endogenous 
RhoBTB2 hindered the ER to GA transport and resulted in altered distribution of 
the vesicular stomatitis virus glycoprotein. While this thesis was in progress, Espinosa et 
al. (2009) reported the localisation of RhoBTB3 in the GA by counterstainig with two 
different GA markers, TGN46 and GCC185, which is in agreement with our own results. 
In support of a function of RhoBTB3 in vesicular transport, it was shown that this protein 
interacts with Rab9 through B2C domains. Espinosa et al. (2009) also showed that 
RhoBTB3 is required for recycling of MPRs to the GA and proposed that Rab9 activates 
RhoBTB3 on GA, which removes the cargo selection protein TIP47 from the vesicles 
and permits membrane fusion of vesicles with the GA. These authors also suggest that 
binding of Rab9 to the C-terminus of RhoBTB3 frees the GTPase domain that is then able 
to hydrolyse ATP. 
GFP-RhoBTB3 vesicles were also observed in close proximity of microtubules and, as 
mentioned above, around the MTOC (Berthold et al. 2008b). We performed taxol or 
colchicine treatment that promoted microtubule stabilisation or disruption, respectively. 
Although RhoBTB3 vesicles were still dispersed in the cytoplasm, the MTOC localisation 
was not observed anymore. Furthermore, disruption of the microtubule network caused 
aggregation of RhoBTB3. Thus it seems that an intact microtubule network is necessary 
for proper RhoBTB3 localisation and possibly also function. Consistent with this 
observation, RhoBTB2 vesicles appeared also adjacent to microtubules and an intact 
microtubule network seemed required for the mobility of RhoBTB2 positive vesicles 
(Chang et al. 2006). GFP-RhoBTB3 vesicles were also observed adjacent to actin filaments 
(Berthold et al. 2008b). However, disruption of the actin cytoskeleton did not significantly 
influence the localisation of RhoBTB3 positive vesicles, as these were still observed 
dispersed in the cytoplasm and in the paranuclear area. Although the precise function of 
RhoBTB3 needs to be examined in more details, the evidence gathered so far indicates that 
RhoBTB proteins are involved in vesicular trafficking. 
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4.2 RhoBTB3 is an adaptor of Cul3-dependent ligase complexes 
RhoBTB proteins are very atypical members of the Rho family of small GTPases. Unlike 
in most Rho GTPases, the GTPase domain does not function as a switch, at least for GTP. 
This was first documented for RhoBTB2 by Chang et al. (2006) who observed that the 
GTPase domain of RhoBTB2 does not bind GTP using a blot overlay approach. We show 
in this work that this feature is also shared by RhoBTB3, as its GTPase domain did not 
bind (α-32P) GTP. Interestingly, it was shown recently, that RhoBTB3 can bind 
and hydrolyse ATP (Espinosa et al. 2009).  
In comparison to the classical Rho GTPases, RhoBTB proteins also possess additional 
domains beyond the GTPase domain and these domains can mediate interaction with other 
cellular proteins. The BTB-domain, which has been found in about 200 proteins in 
humans, binds to Cul3. The BTB-Cul3 complex resembles the structure of the well 
characterised SCF and ECV/ECS complexes (Krek 2003) that link the substrate to 
the catalytical core of the ubiquitin ligase and facilitate ubiquitination and degradation of 
the substrate protein. In fact, this has been shown for several BTB-containing proteins 
(Furukawa et al. 2003, Geyer et al. 2003, Pintard et al. 2003, Xu et al. 2003), including 
RhoBTB2 (Wilkins et al. 2004). RhoBTB3, similarly to RhoBTB2, binds Cul3 through its 
first BTB domain (Berthold et al. 2008b) and in this work we confirmed the interaction of 
all three RhoBTB proteins with endogenous Cul3 by co-immunoprecipitation. Our 
laboratory has shown that RhoBTB3 is, similarly to RhoBTB2, ubiquitinated in the 
presence of Cul3 and degraded in the proteasome (Berthold et al. 2008b).  
The BTB domains of RhoBTB proteins contain each an N-terminal extension that in other 
BTB domains folds into one α-helix and one β-strand and mediates the formation of 
oligomers (Stogios et al. 2005). It was shown experimentally that RhoBTB proteins exist 
as homo- and heterodimers, and both BTB domains participate in dimerisation (Berthold et 
al. 2008b). Since both, RhoBTB2 and RhoBTB3, can interact with Cul3 (which itself 
dimerises), one might suspect that Cul3 mediates RhoBTB dimerisation. However, we 
were able to show by co-immunoprecipitation analysis that almost complete abrogation of 
Cul3 expression by siRNA does not have any effect on heterodimerisation of RhoBTB2 
and RhoBTB3. This observation is supported by many examples of proteins that dimerise 
through the BTB domain (Aravind and Koonin 1999, Stogios et al. 2005), and several are 
recognised Cul3 adaptor proteins, like the promyelocytic leukaemia zinc finger (PLZF) 
protein (Furukawa et al. 2003) and Keap1 (Zhang et al. 2004). Based on these and other 
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studies, dimerisation has been proposed as a general feature of Cul3 substrate adaptors 
(McMahon et al. 2006).  
We show here that the GTPase domain, which is able to bind to the C-terminal region of 
the protein that comprises the BTB tandem (Berthold et al. 2008b), could be responsible 
for an intramolecular interaction that either blocks the formation of a Cul3-dependent 
complex or otherwise hinders its ubiquitination activity. An experiment determining 
the stability of RhoBTB3 showed that the C-terminal region of RhoBTB3 (B1B2C) is 
degraded very fast in the proteasome and this degradation is prevented by simultaneous co-
expression of the GTPase domain. Consistent with this observation, full length RhoBTB3 
is more stable than its C-terminal region (B1B2C) expressed alone.  
Autoinhibition of RhoBTB3 has been reported recently by Espinosa et al. (2009). Authors 
of this study have observed that the GTPase domain, which has an ATPase activity, 
displays approximately the double rate of ATP hydrolysis when expressed alone in 
comparison to the full length RhoBTB3. Binding of Rab9 to the C-terminal (B2C) part of 
RhoBTB3 relieves the autoinhibition of the GTPase domain and restores ATP hydrolysis. 
Therefore it is possible that the interaction of cellular proteins with other domains than the 
GTPase also mediates the activation of RhoBTB3. It needs to be established whether this 
particular interaction exposes also the Cul3 binding site or if this process is a part of a 
different pathway.   
Our results strongly support the hypothesis that RhoBTB3 serves as an adaptor in Cul3-
dependent ligase complexes. Based on this observations, we proposed a model (Figure 4.1) 
in which interaction of the GTPase domain with unknown proteins would relieve 
the autoinhibitory mechanism. The GTPase and other domains, as well as the insertion of 
the first BTB domain could function as substrate recognition domains. In this process 
RhoBTB proteins become ubiquitinated and degraded.  
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Figure 4.1: Model of the mechanism of action of RhoBTB proteins. RhoBTB proteins recruit Cul3 
(regulated by attachment of Nedd8), Roc1 and the E2 (ubiquitin-conjugating enzyme), components of the 
ubiquitination pathway to constitute an ubiquitin ligase. E1 is the ubiquitin-activating enzyme. RhoBTB 
proteins probably exist as homo- and heterodimers. RhoBTB is depicted as a parallel dimer, but it remains to 
be established whether the dimer is parallel or antiparallel. An intramolecular interaction between the 
GTPase domain and the BTB region would maintain the dimer in an inactive state. Although we have 
depicted the GTPase interacting with the BTB tandem of the same molecule, an interaction with the tandem 
of the partner molecule is equally possible. Interaction of the GTPase domain with unknown proteins would 
relieve the autoinhibition, allowing recruitment of the Cul3 scaffold to the first BTB domain. The GTPase 
and other domains, as well as the insertion of the first BTB domain could function as substrate recognition 
domains. The proline-rich region is a potential SH3 domain-binding domain. RhoBTB proteins also become 
ubiquitinated. Taken from Berthold et al. (2008b).  
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4.3 Characterisation of MUF1 
Using BLAST search analysis, complete MUF1 proteins from different organisms (human, 
orang-utan, mouse, rat and cow) were identified and aligned. All five MUF1 proteins show 
a very high degree of similarity. This indicates a conserved function of MUF1. The SOCS-
box localised in the N-terminal part of the protein was in all aligned sequences identical, 
implying its importance for interaction with Cul5 (Kamura et al. 2001). Putative nuclear 
localisation signals predicted by the PSORT analysis programme were also identical in all 
five examined sequences. Our findings therefore indicate that MUF1 is very well 
conserved in Mammalia class. Using BLAST search, we also identified predicted proteins 
similar to MUF1 in number of other organisms. Interestingly, all MUF1 proteins obtained 
from BLAST search are from Mammalia class, except from two representatives belonging 
to the Aves class.  
In conclusion, MUF1 is present apparently only in some vertebrate classes where it may 
have a specific function. Due to the presence of two widely spread domains, we speculate 
that the gene encoding MUF1 protein arose by a fusion of a gene encoding the LRR region 
with some gene encoding a protein bearing a SOCS-box domain. 
 
4.4 Expression and subcellular localisation of MUF1 
Murine MUF1 is encoded by the Lrrc41 gene. In this study we demonstrate that the Lrrc41 
gene is ubiquitously expressed. RT-PCR performed on mRNA isolated from different 
mouse tissues revealed that Lrrc41 is present in almost all samples tested with exception of 
skeletal muscle. Lrrc41 was detected in brain, heart, liver, lung and the highest expression 
was observed in testis. This result is in agreement with previous observations from our 
laboratory. Using a Human Multiple Tissue Expression Array it was shown that human 
LRRC41 is ubiquitously expressed (Kopp 2006 diploma thesis). This was very important to 
determine in order to confirm that MUF1 and RhoBTB proteins do actually ‘meet’ in the 
same tissue.  
Both in humans and mice, all three RHOBTB genes are rather ubiquitously expressed, 
although with notable differences in the pattern of tissue levels among the three genes 
(Nagase et al. 1998a, Nagase et al. 1998b, Ramos et al. 2002). 
In human, expression of Lrrc41 overlaps with expression of RHOBTB1 in testis, of 
RHOBTB2 in brain and heart and of RHOBTB3 in testis, brain and heart. Expression of 
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Lrrc41 overlaps with expression of mouse Rhobtb1 in heart, testis, liver and lung, of 
Rhobtb2 in brain and of Rhobtb3 in brain and heart.  
Immunofluorescence studies showed that MUF1 localises predominantly in the nucleus, 
independently of the used tag (GFP, I-Plastin tag). This effect is not mediated by the 
SOCS-box of MUF1, as proteins with mutation in the SOCS-box or with the SOCS-box 
deletion are still predominantly localised in the nucleus. Predicted putative nuclear 
localisation signals might be responsible for MUF1 targeting to this compartment. GFP-
tagged MUF1 containing only leucine-rich repeat region shows both nuclear 
and cytoplasmic localisation. These observations were also confirmed by subcellular 
fractionation. Our attempt to verify the subcellular localisation of MUF1 by detecting 
endogenous protein failed, as a polyclonal antibody raised against a peptide encompassing 
residues 771-784 was very unspecific both on the fixed cells as well as on Western blot. 
Since MUF1 is predominantly a nuclear protein, it was of a great interest to examine 
the mutual localisation of RhoBTB3 and MUF1 in the cell. There is no experimental 
evidence that RhoBTB proteins localise in the nucleus. Chang et al. (2006) claim, that 
endogenous RhoBTB2 can be seen in the nucleus in some cells, but this is presented as not 
shown. To date, only cytoplasmic localisation of RhoBTB proteins has been documented. 
We observed that upon co-expression of MUF1 and RhoBTB3, MUF1 still localises 
mainly in the nucleus, but interestingly, part of the protein is retained in the cytoplasm, 
where it co-localises with RhoBTB3 in the paranuclear area. The LRR region of MUF1 is 
sufficient for mediating this effect. The possible relevance of MUF1 re-localisation to the 
cytoplasm in dependence of RhoBTB3 will be discussed below. 
 
4.5 MUF1 as an adaptor for Cul5 ubiquitin ligases 
Adaptor specific subunits of cullin-dependent ubiquitin ligases are very often capable of 
forming dimers. F-box proteins, substrate-specific adaptors in SCF complexes, dimerise 
through the D-domain just N-terminally from the F-box (Tang et al. 2007). Dimerisation 
was shown for example for the yeast F-box proteins Pop1p and Pop2p (Seibert et al. 2002, 
Wolf et al. 1999), βTRCP1 (Suzuki et al. 2000) and a number of other F-box proteins. 
Dimerisation was also observed in case of the von Hippel-Lindau (VHL) tumour 
suppressor gene, a substrate-specific adaptor in ECV complexes (Chung et al. 2006). 
As already mentioned, BTB-domain containing proteins dimerise through the BTB domain 
(Stogios et al. 2005).  Given that a large number of substrate-binding adaptors are dimeric 
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and the fact that proteins with LRR domains exist as dimers (Bella et al. 2008), we tested 
the ability of MUF1 to form homodimers. We confirmed that MUF1 homodimerises 
and proved that this homodimerisation is not mediated by Cul5. Dimerisation is most 
probably achieved through interaction of LRRs. Because MUF1 shows predominantly 
nuclear localisation and nuclear localisation has been reported for Cul5 as well (Furukawa 
et al. 2000), we favour the hypothesis that Cul5-MUF1 complex is involved in 
ubiquitination and degradation of nuclear proteins. MUF1 might recognise these substrates 
by the LRR, as this is a common protein-protein interaction domain (Bella et al. 2008). 
Substrates for the Cul5-MUF1 complex are unknown. Our attempt to confirm 
the interaction of MUF1 with MyoIXb and RBPMS by co-immunoprecipitation was not 
successful. These two proteins were identified in large scale yeast-two hybrid screenings 
(Rual et al. 2005, Stelzl et al. 2005); however it is possible that these interactions do not 
take place in mammalian cells in vivo.  
 
4.6 MUF1 is a binding partner of RhoBTB proteins 
MUF1 was identified as a putative binding partner of RhoBTB3 and is therefore a possible 
substrate for RhoBTB3-Cul3 ligase complexes. We have verified the interaction of MUF1 
with all three RhoBTB proteins using an immunoprecipitation approach. The interaction of 
MUF1 and RhoBTB3 is not mediated by heterodimerisation of Cul3 and Cul5, as shown 
by co-immunoprecipitation of mutated proteins unable to bind their respective cullin. 
Interestingly, it seems that MUF1 may have multiple binding sites on RhoBTB3 
and similarly, RhoBTB3 may have multiple binding sites on MUF1 as well. This 
observation did not come as a complete surprise. It has been shown recently that adaptor 
proteins can have multiple binding sites on their substrates. SPOP, a MATH-BTB domains 
containing protein, forms dimers and is in complex with two molecules of Cul3 (Zhuang 
et al. 2009). HIB/Roadkill, the Drospohila SPOP orthologue, controls degradation of 
the MAPK phosphatase Puc involved in TNF signalling in the fly eye (Liu et al. 2009). 
Crystallographic studies demonstrated that Puc has multiple SPOP binding sites 
and dimeric SPOP binds only one molecule of Puc in vitro. The SPOP-Cul3 complex 
ubiquitinates Puc in the presence of E1 and E2 and all three SPOP binding sites of Puc 
contribute to proper ubiquitination of the substrate (Zhuang et al. 2009). This is in 
agreement with previous observations that cyclin E, a substrate protein that is recognised 
by an F-box protein Fbw7 in an SCF complex, contains one optimal and one suboptimal 
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degron (Hao et al. 2007). It is possible that multiple binding sites on the substrate increase 
the efficiency of substrate-adaptor interaction.  
MUF1 was identified as a binding partner of RhoBTB3 in a bacterio-match screening 
and this would strongly suggest that the interaction is likely to be direct. It was the C-
terminal part of MUF1 (609-807 AA) that was identified in this screening to interact with 
the B1B2C region of RhoBTB3. It is possible that additional binding sites uncovered in 
our immunoprecipitation studies are not direct binding sites, as during co-
immunoprecipitation additional proteins may be present in the complex that might mediate 
the interaction. Attempts to confirm a direct interaction using recombinant proteins were 
hampered by poor solubility of GST fusions of RhoBTB3 and its domains.  
 
4.7 MUF1 as a substrate of Cul3-RhoBTB3 ubiquitin ligase 
We show that MUF1 is apparently degraded by a Cul3-RhoBTB3 ubiquitin ligase 
complex. MUF1ΔSOCS, a mutant that lacks the entire SOCS-box and therefore cannot 
associate with Cul5, is rapidly degraded in the presence of RhoBTB3. We also found that 
the C-terminal part of RhoBTB3 (B1B2C) is sufficient to mediate this effect. MUF1 
contains 27 lysine residues that in theory can serve as acceptor sites for ubiquitin. Now 
the question is in which subcellular compartment the degradation takes place. Some of 
the components of the proteasomal degradation system, like E1 and the proteasomes, have 
nuclear localisation signals and have been identified in the nucleus (McGrath et al. 1991, 
Schwartz et al. 1992, Wójcik and DeMartino 2003). The presence of the ubiquitin in 
the nucleus has also been reported (Schwartz et al. 1988) and in fact, it has been shown 
that Far1, a protein required for cell cycle arrest and establishing cell polarity during yeast 
mating, is degraded exclusively in the nucleus by an SCF-ubiquitin ligase complex after it 
has been phosphorylated (Blondel et al. 2000). Other proteins shuttle from the nucleus to 
the cytoplasm prior degradation, as it was shown for β-catenin, a transcriptional activator 
regulated by the Wnt signalling pathway (Henderson 2000). 
MUF1 and RhoBTB3, when expressed alone, localise to different cellular compartments. 
MUF1 is predominantly nuclear and we did not observe its presence in cytoplasmic 
vesicles. The presence of RhoBTB3 in the nucleus has not been confirmed and most of 
the protein accumulates in the paranuclear area. Interestingly, when co-expressed with 
RhoBTB3, MUF1 is observed in the cytoplasm in vesicles and aggregates that overlap with 
RhoBTB3 localisation. Therefore it is possible that RhoBTB3 causes MUF1 to be partially 
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retained in the cytoplasm and degradation of MUF1 occurs here. It is not clear yet whether 
MUF1 is captured by RhoBTB3 before being transported into the nucleus or whether 
MUF1 shuttles from the nucleus to the cytoplasm where it binds RhoBTB3, in which case 
cellular stimuli that might mediate this event remain unknown.  
Substrates of SCF and ECS/ECV ubiquitin ligases usually require post-translational 
modification before they can be recognised for proteasomal degradation. This modification 
is usually phosphorylation or prolyl-hydroxylation (Krek 2003). One of the many examples 
is cyclin D1 that must be phosphorylated prior to its transport to the cytoplasm. Once in 
the cytoplasm cyclin D1 is recognised by FBX4/αB-crystallin, an F-box protein that 
functions as a substrate-specific adaptor of the SCF ligase complex, and after 
ubiquitination cyclin D1 is degraded in the proteasome (Diehl et al. 1997, Lin et al. 2007). 
Interestingly, FBX4/αB-crystallin-SCF activity also requires FBX4 dimerisation that is 
mediated by phosphorylation of the D-domain of FBX4 (Barbash et al. 2008). To our 
knowledge, post-translational modifications that trigger substrates degradation via BTB-
protein containing Cul3-ubiquitin ligases have not been identified yet. In the case of 
the already mentioned MATH-BTB domain containing protein SPOP, phosphorylation of 
SPOP-binding sites on the substrate abrogates binding to SPOP (Zhuang et al. 2009). On 
the other hand, the KBTBD2 (Kelch-repeat and BTB/POZ domain containing 2) protein 
was identified as a binding partner of phosphorylated ezrin (Heiska and Carpén 2005). 
Proteins containing simultaneously Kelch-repeats and BTB-fold serve as substrate-specific 
adaptors in Cul3-based ubiquitin ligase complexes, as has been shown for Keap1, which 
mediates the degradation of Nrf2, a protein implicated in the response to oxidative stress 
(Cullinan et al. 2004). However, involvement of KBTBD2 protein in Cul3-dependent 
ubiquitin ligase complexes has not been examined so far.  
Large scale proteomic analysis of proteins phosphorylated by ATM (ataxia telangiectasia 
mutated) and ATR (ATM and Rad3 related) protein kinases revealed that MUF1 is 
phosphorylated upon DNA damage and the phosphorylation site was mapped to the region 
upstream to the LRR (Matsuoka et al. 2007). The relevance of MUF1 phosphorylation has 
not been examined so far. It is possible, that MUF1 plays specific roles in maintaining cell 
homeostasis in the DNA damage response. However, on the other hand, phosphorylation 
of MUF1 might be a signal for its export out of the nucleus and degradation in 
the cytoplasm, as has been proved for cyclin D1 (Diehl et al. 1997, Lin et al. 2007). 
Another option is that phosphorylation regulates MUF1 dimerisation, similarly to the F-
box protein FBX4/αB-crystallin (Barbash et al. 2008). 
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4.8 Heterodimerisation of Cul3 and Cul5 
Cullin-dependent ubiquitin ligases exist in the cell as dimers. The importance of these 
interactions might be in accumulation of the local concentration of substrate or E2, or in 
facilitating their optimal orientation (Tang et al. 2007). Evidence is accumulating 
indicating that both cullins and substrate-specific adaptors can dimerise.  
Homodimerisation of cullins has been reported for Cul1 (Chew et al. 2007), Cul3 (Chew 
et al. 2007, Wimuttisuk and Singer 2007), Cul4A (Chew et al. 2007) and Cul7 (Skaar et al. 
2005) but has not been confirmed for Cul2 and Cul5 (Chew et al. 2007). 
Heterodimerisation of cullins is also possible, as was shown for Cul1 and Cul3 
(Wimuttisuk and Singer 2007). Based on these observations, we assumed that other cullins 
can also exist as heterodimers and we tested the interaction between Cul3 and Cul5. Using 
co-immunoprecipitation we show that Cul3 interacts with Cul5. It was proposed by 
Wimuttisuk and Singer (2007), that this interaction is mediated by Nedd8. Nedd8 is 
an ubiquitin like protein that is covalently attached to the C-terminus of cullin (K712) in 
a process called neddylation. Nedd8 conjugation to the cullin positively regulates ubiquitin 
ligase activity of cullin complexes by releasing the autoinhibition of cullin C-terminus, 
allowing structural flexibility of these complexes (Merlet et al. 2009).  A point mutation of 
the Nedd8 binding site did not prevent Cul3-Cul3 interaction, however multiple mutations 
of the C-terminal region of both cullins completely abrogate dimerisation. Based on this 
and other data, Wimuttisuk and Singer (2007) proposed that dimerisation of Cul3 is 
mediated by a single Nedd8 molecule. Nedd8 covalently binds to one Cul3 molecule 
and non-covalently to the C-terminus of a second Cul3 molecule to form a Cul3 dimer . 
Our results do not support these observations. A Cul5 that lacks a substantial part of the C-
terminus was successfully co-immunoprecipitated by both, Cul3 and Cul5, therefore it 
seems that the C-terminal part is not necessary for dimerisation. To our knowledge there is 
no structural evidence addressing the dimerisation of cullins that would identify 
the dimerisation interface.  
As already mentioned (see section 4.5), substrate-specific adaptors in cullin-based ubiquitn 
ligases very often dimerise. Whether dimerisation of the adaptor subunits constitutes 
a prerequisite for cullin dimerisation is not clear. Chew et al. (2007) showed by co-
immunoprecipitation analysis that dimerisation of Cul3, but not Cul1, is dependent on 
the substrate recognition adaptor. In this work we observed that heterodimerisation of Cul3 
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and Cul5 is not mediated by adaptor dimerisation as a Cul5 mutant lacking the N-terminus 
was still able to pull-down full length Cul3. Therefore heterodimerisation of Cul3 and Cul5 
seems to be direct and not dependent on the N- or C-terminal part of the protein. 
The physiological relevance of cullin heterodimerisation still needs to be elucidated. We 
hypothesise that heterodimeric cullin complexes that engage different substrate-specific 
adaptors will function as a big catalytical centre for processing of diverse substrates.  
 
4.9 A possible model of MUF1 function and degradation  
Based on the observations mentioned above we proposed following model (Figure 4.2). 
MUF1 protein exists as a homodimer in a Cul5-ubiquitin ligase complex and would 
predominantly regulate the turnover of nuclear proteins by targeting them to 
the proteasome (Figure 4.2A). Although homodimerisation of Cul5 has not been 
demonstrated (Chew et al. 2007), it is possible that Cul5-MUF1 complex exists in 
the nucleus as a tetramer. Under some conditions (it may be e.g. phosphorylation in 
response to the DNA damage) MUF1 would shuttle to the cytoplasm. In the cytoplasm 
the Cul3-RhoBTB3 ubiquitin ligase exists as a tetrameric complex and binds MUF1 in 
order to mediate its proteasomal degradation (Figure 4.2B). We have not determined 
the precise dimerisation interface of MUF1 and the exact interaction sites of MUF1 
and RhoBTB3; the binding sites depicted on figure 4.2 are hypothetical.  
 
. 
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Figure 4.2: Model of MUF1 function and degradation. See text for details. Ub – ubiquitin, E1 – ubiquitin 
activating enzyme, E2 – ubiquitin conjugating enzyme, EloC – Elongin C, EloB – Elongin B, SOCS – 
SOCS-box of MUF1, LRR – leucine-rich repeat domain of MUF1, P – phosphorylation. 
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4.10 Kindlin is a binding partner of RhoBTB proteins 
Kindlin-2 was another protein identified in a two-hybrid screening as a potential binding 
partner of RhoBTB3. Kindlins have received increased interest in the last decade, because 
it has been shown that they bind directly to the cytoplasmic tails of β1 and β3 subunits of 
integrins (Harburger et al. 2009, Moser et al. 2008, Ussar et al. 2008) and together with 
talin are key regulators of integrin activation (Moser et al. 2009). Using co-
immunoprecipitation we confirmed the interaction of RhoBTB3 with kindlin-2 and showed 
that kindlin-1 as well as kindlin-2 interacts with RhoBTB2 and RhoBTB3. Similarly to 
MUF1, RhoBTB proteins have probably multiple binding sites on kindlins, at least on 
kindlin-1.  
Kindlin-1 and kindlin-2 localises predominantly to focal adhesions in keratinocytes 
(Kloeker et al. 2004, Siegel et al. 2003, Tu et al. 2003, Ussar et al. 2006). However, 
cytoplasmic (including perinuclear) and nuclear localisation was observed for both kindlins 
depending on the cell type used (Kato et al. 2004, Kloeker et al. 2004, Lai-Cheong et al. 
2008, Siegel et al. 2003). COS7 fibroblasts form focal adhesions and have been used for 
the study of proteins in these structures (Schmalzigaug et al. 2007). 
In immunofluorescence studies we examined mutual localisation of RhoBTB3 and kindlin-
1 or kindlin-2 in COS7 cells. Both kindlin proteins were observed in the cytoplasm in 
the paranuclear area where they partially co-localised with RhoBTB3. In this cell line we 
did not observe any localisation of kindlins to focal adhesions. However, it is possible, that 
part of the RhoBTB vesicles that are dispersed through the whole cytoplasm might co-
localise with kindlin in focal adhesions in a more suitable cell line (e.g. keratinocytes). 
The relationship between RhoBTB and kindlin is currently unknown. Preliminary results 
from our laboratory showed that endogenous kindlin-1 maintains constant expression 
levels in HaCaT cells (a human keratinocyte cell line). Similarly in 293T HEK cells, 
exogenous kindlin-1 is not destabilised upon overexpression of RhoBTB3 and the cellular 
levels of kindlin-1 are not altered even in the presence of proteasomal inhibitor (Julia Lutz, 
personal communication). It is possible that the relationship between kindlins and RhoBTB 
proteins is different than it is in the case of MUF1 and that the function of RhoBTB 
proteins in complex with kindlin is other than ubiquitination and degradation. 
The potential relevance of kindlin-RhoBTB3 interaction might lay in recruitment of 
the Cul3-ubiquitin ligase complex to the sites of focal adhesions. A number of plasma 
membrane proteins (e.g. growth factor-activated receptor tyrosine kinases, transporters 
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and ion channels as well as surface complexes involved in formation of cell junctions) are 
downregulated predominantly by clathrin-dependent endocytosis upon monoubiquitination 
or Lys-63 polyubiquitination. Internalised membrane proteins are either recycled back to 
the plasma membrane or targeted to multivesicular bodies (MVBs) for subsequent 
degradation in lysosomes. Downregulation of plasma membrane proteins serves as 
an important mechanism for terminating signalling. Ubiquitin ligases of the HECT- 
and RING- classes are involved in ubiquitination of plasma membrane proteins either upon 
direct binding to the substrate or through adaptor proteins (d'Azzo et al. 2005, Léon 
and Haguenauer-Tsapis 2009). It is tempting to speculate that kindlin might serve here as 
an adaptor protein bringing RhoBTB-Cul3 ligase complexes to the close proximity of 
integrins. In this scenario, a RhoBTB-Cul3 ubiquitin ligase would regulate internalisation 
and turnover of activated integrins by their ubiquitination. However, it is equally possible 
that Cul3 is not present in the RhoBTB3-kindlin complex. In fact, there is no evidence 
describing involvement of cullin ubiquitin-ligases in internalisation processes so far.  
Supporting the possible role of RhoBTB proteins in this endocytic pathway, RhoBTB3 was 
recently identified in a proteomic screen as a binding partner of Hrs (hepatocyte growth 
factor-regulated tyrosine kinase substrate) (Pridgeon et al. 2009). Hrs recognises 
ubiquitinated membrane cargo proteins through ubiquitin-interacting motifs and is one of 
the subunits of the so-called ESCRT (endosomal sorting complex required for transport) 
complex. The ESCRT complex is cellular machinery that recognises ubiquitinated 
membrane cargo proteins at early endosomes and facilitates their sorting into MVBs for 
lysosomal degradation (Raiborg and Stenmark 2009). However, the importance of 
RhoBTB3-Hrs interaction has not been investigated yet.  
Further investigations must be carried out to determine the link between RhoBTB proteins 
and kindlins and their involvement on integrin activation or turnover. Elucidation of 
the role of RhoBTB proteins with respect to kindlins will undoubtedly contribute to better 
understanding of RhoBTB function.  
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4.11 Uev1a is a binding partner of RhoBTB proteins 
The last potential binding partner of RhoBTB3 that was investigated here is Uev1a. We 
confirmed that Uev1a interacts with RhoBTB3 using co-immunoprecipitation. This is in 
agreement with previous observations obtained by yeast-two hybrid analysis (Berthold 
2006, dissertation thesis). Additionally, RhoBTB3 co-localises with Uev1a in 
the paranuclear area. When expressed in COS7 cells Uev1a localises to the nucleus 
and part of the signal is observed also in the cytoplasm in the paranuclear area. Early 
studies attempting to study the localisation of Uev1a revealed nuclear localisation of HA-
tagged Uev1a in COS7 cells (Rothofsky and Lin 1997). Similarly, myc-Uev1a localises 
also to the nucleus in 3T3 (mouse fibroblasts) and HepG2 (hepatocellular carcinoma) cells, 
but some signal was also observed in the cytoplasm. A deletion mutant lacking the first 
30 amino acids displays nuclear as well as cytoplasmic localisation (Andersen et al. 2005). 
Uev1a is expressed in the cells as four different transcript variants, at least two of them are 
generated by alternative splicing (Sancho et al. 1998). These variants share the same C-
terminus including the domain homologous to the Ubc domain of E2 enzymes, but posses 
unique N-termini. We found that the Uev1a transcript variant used in our study is different 
form that one used by Rothofsky and Lin (1997) and Andersen et al. (2005). It lacks first 
30 amino acids and in addition contains extra 8 amino acids N-terminally. This explains 
nuclear and cytoplasmic localisation that we observed in COS7 cells, similarly to 
Uev1aΔ30 used in the study by Andersen et al. (2005).     
The significance of the interaction of RhoBTB3 with Uev1a is not clear so far. Both 
RhoBTB3 and Uev1a are involved in ubiquitination pathways, although their effectors 
seem to meet different fates. It is therefore tempting to speculate that these proteins might 
function in a completely novel pathway within the ubiquitination system. We propose two 
different hypotheses to explain the relevance of the RhoBTB3-Uev1a interaction. 
Since the Uev1-Ubc13 complex is the only ubiquitin-conjugating enzyme that mediates 
the assembly of Lys63-linked poly-Ub chains (Hofmann and Pickart 1999), one of 
the possibilities is that RhoBTB3, together with Uev1a, is involved in substrate 
degradation in a Lys63 polyubiquitin dependent manner. Degradation of proteins modified 
by Lys63 polyubiquitin chains has been reported recently. Yeast Rsp5, a HECT-type E3 
that catalyses the formation of Lys63 ubiquitin chains, ubiquitinates its substrate Mga-p120 
and Lys63 ubiquitin chains are sufficient for recognition by the proteasome and Mga-p120 
degradation (Saeki et al. 2009). In the RhoBTB3-Uev1a complex the interaction between 
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RhoBTB3 and Uev1a might be mediated by Cul3. This mode of interaction has been 
reported for example for RCBTB1, a BTB-domain containing protein linked to 
lymphocytic neoplasias. RCBTB1 binds together with UbcM2 (ubiquitin-conjugating 
enzyme) to the N-terminal substrate-binding region of Cul3 in a RING-finger protein 
independent manner and these interactions are not mutually exclusive. The physiological 
relevance of this interaction has not been clarified yet, although it has been shown that 
UbcM2 monoubiquitinates Cul3 (Plafker et al. 2009). In support of our observation that 
RhoBTB3 interacts with Uev1a, Plafker et al. (2009) reported interaction of RhoBTB1 
with another ubiquitin-conjugating enzyme UbcM2. 
The second possibility is even more attractive. RhoBTB3, in complex with Cul3-ubiquitin 
ligase, might ubiquitinate Uev1a in order to target it to the proteasome for degradation. 
Uev1a has been proposed as a candidate proto-oncogene as its expression is up-regulated 
in many cancer cell lines (Ma et al. 1998, Xiao et al. 1998). Moreover, Uev1a alone is 
capable of evoking NFκB signalling that results in anti-apoptotic response and Uev1a 
seems to be sufficient to drive cells toward tumourigenesis. Downregulation of the cellular 
pool of Uev1a by RhoBTB3 therefore might contribute to maintain the constant levels of 
Uev1a in the cell, thus RhoBTB3 would have proapoptotic and anti-cancerogenic effect in 
this complex. Downregulation of RhoBTB3 might disrupt this balance and direct cells for 
their cancer destiny. Since expression of RhoBTB proteins is decreased in many types of 
tumours, it might be interesting to examine if downregulation of RhoBTB3 correlates with 
upregulation of Uev1a in different types of tumours and cancer cell lines.   
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5 Abstract 
RhoBTB proteins constitute a subfamily of atypical Rho GTPases represented by three 
isoforms in vertebrates. They serve as adaptors in the formation of Cul3-dependent 
ubiquitin ligase complexes. Although reports about the function of RhoBTB proteins are 
accumulating, their significance in cellular processes is far from being understood. Using 
markers for different subcellular compartments we examined the localisation of RhoBTB3 
and found that this protein is localised in part at the GA and to a less extent at early 
endosomes. Overexpression of RhoBTB proteins significantly disrupted the GA 
morphology. Disruption of the microtubule, but not of the actin, network caused 
delocalisation of RhoBTB3 positive vesicles. Connecting to previous observations from 
our laboratory, we investigated more deeply the function of RhoBTB3 in multiprotein 
Cul3-dependent ubiquitin ligase complexes. Using immunoprecipitation we observed that 
RhoBTB3 interacts with endogenous Cul3 and is ubiquitinated by Cul3-dependent 
ubiquitin ligase complexes for subsequent degradation in the proteasome. This degradation 
is prevented by an intramolecular interaction between the GTPase domain and the C-
terminus of RhoBTB3. We confirmed that RhoBTB proteins, similarly to other adaptors 
involved in Cul-dependent degradation, are able to dimerise and this interaction is not 
mediated by Cul3. We propose a model in which RhoBTB proteins play roles in targeting 
of substrates for ubiquitination and degradation via Cul3-dependent ubiquitin ligase 
complexes. In order to identify binding partners (and possible substrates) of RhoBTB3 a 
two-hybrid screening on a mouse brain cDNA library was performed previously in our 
laboratory. We confirmed the interactions with three potential binding partners, namely 
MUF1, kindlin-2 (that we further extended also to kindlin-1) and Uev1a by co-
immunoprecipitation and co-localisation studies. We focused on MUF1, a largely 
uncharacterised protein that consist of a leucine-rich repeat region and a BC-box that 
serves as a linker in multicomponent, Cul5-based ubiquitin ligases. We found that MUF1 
interacts with all three RhoBTB proteins and that the interaction between MUF1 and 
RhoBTB3 is direct and does not depend on Cul3 and Cul5. MUF1 localises in the nucleus 
but RhoBTB3 causes it to be partially retained in the cytoplasm where both proteins co-
localise. MUF1 is able to make homodimers, a feature shared by many leucine-rich repeat 
containing proteins, and this homodimerisation is not mediated by Cul5. RhoBTB is an 
adaptor of Cul3-based ubiquitin ligases and MUF1 is an adaptor of Cul5-based ubiquitin 
ligases. This raises the question whether MUF1 and RhoBTB3 are together involved in 
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multiprotein complexes containing Cul3 and Cul5 simultaneously. It has been reported that 
cullins can assemble into dimers, and consistent with this, we found that Cul3 and Cul5 are 
able to heterodimerise. Our results suggest that MUF1 is degraded in the proteasome in a 
Cul5 independent manner by a Cul3-RhoBTB3 ligase complex. Our data shows that there 
is extensive cross-talk among cullin-dependent ubiquitin ligases. We envision a model in 
which MUF1 exists in a Cul5-ubiquitin ligase complex and predominantly regulates 
turnover of nuclear proteins by targeting them to the proteasome. RhoBTB3 may be able to 
regulate MUF1 functions by targeting it for proteasomal degradation in the cytoplasm.  
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6 Zusammenfassung 
Die RhoBTB Proteine gründen eine Unterfamilie der atypischen Rho GTPasen und 
kommen in Vertebraten in drei Isoformen vor. Sie wirken ursprünglich als Adaptoren am 
Aufbau von Cul3-abhängigen Ubiquitin Ligase Komplexen. Obwohl es mittlerweile viele 
Berichte zu den Funktionen der RhoBTB Proteine gibt, ist ihre Bedeutung in zellulären 
Prozessen bislang kaum geklärt. Wir haben die subzelluläre Lokalisation von RhoBTB3 
mit Hilfe von Markern für unterschiedliche subzelluläre Kompartimente untersucht und 
zeigen, dass RhoBTB3 teilweise am GA und in kleinerem Umfang an frühen Endosomen 
lokalisiert ist. Die Überexpression der RhoBTB Proteine führt zu signifikanten Störungen 
in der GA-Morphologie. Störungen des Mikrotubuli-, nicht aber des Aktinnetzwerks 
führten zu einer Delokalisation von RhoBTB3 positiven Vesikeln. Anknüpfend an frühere 
Beobachtungen unseres Labors, haben wir die Funktion von RhoBTB3 im Multiprotein 
Cul3-abhängiger Ubiquitin Ligase Komplexe genauer untersucht. Mit Hilfe von 
Immunopräzipitionsstudien haben wir bestätigt, dass RhoBTB3 mit endogenem Cul3 
interagiert und vom Cul3-abhängigen Ubiquitin Ligase Komplex für den darauffolgenden 
Abbau im Proteasom ubiquitiniert wird. Dieser Abbau wird durch intramolekulare 
Wechselwirkungen zwischen der GTPase Domäne und dem C-Terminus von RhoBTB3 
verhindert. Wir konnten bestätigen, dass RhoBTB Proteine dimerisieren können, 
vergleichbar mit anderen Adaptoren die am Cul-abhängigen Abbau beteiligt sind. Dieser 
Vorgang wird nicht von Cul3 vermittelt. Wir schlagen ein Modell vor, bei dem RhoBTB 
Proteine an der Markierung von Substraten für eine Ubiquitinierung und am Abbau durch 
Cul3-abhängige Ubiquitin Ligase Komplexe beteiligt sind. Um Bindungspartner (und 
potenzielle Substrate) von RhoBTB3 zu identifizieren, wurde in unserem Labor bereits 
früher ein two-hybrid screening mit einer cDNA Bibliothek aus murinem Gehirn 
durchgeführt. Wir konnten eine Wechselwirkung zu drei potenziellen Bindungspartnern 
durch Koimmunopräzipitations- und Kolokalisationsstudien bestätigen: MUF1, kindlin-2 
(wir erweiterten es später zusätzlich auf kindlin-1) und Uev1a. Wir haben den 
Schwerpunkt auf MUF1 gelegt, ein kaum charakterisiertes Protein, dass aus einer 
leucinreichen Wiederholungsregion und einer BC-Box besteht, die als Verbindungsstelle in 
multikomponenten Cul5 basierenden Ubiquitin Ligasen dient. Wir bestätigten die 
Interaktion zwischen MUF1 und allen drei RhoBTB Proteinen, und konnten zeigen, dass 
eine direkte Interaktion zwischen MUF1 und RhoBTB3 auftritt, die nicht von Cul3 und 
Cal5 abhängt. MUF1 lokalisiert im Kern, wobei es von RhoBTB3 im Zytoplasma zurück 
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gehalten wird, indem beide Proteine kolokalisieren. Wir konnten beobachten, dass MUF1 
in der Lage ist Homodimere zu bilden - eine Eigenschaft, die es mit vielen Proteinen, die 
leucinreiche Wiederholungen enthalten ,teilt. Diese Homodimerisation wird nicht von Cul5 
vermittelt. RhoBTB ist ein Adaptor der Cul3-basierenden Ubiquitin Ligasen und MUF1 
ein Adaptor der Cul5-basierenden Ubiquitin Ligasen. Dies führt zu der Frage, ob MUF1 
und RhoBTB3 zusammen in Multiproteinkomplexen, die sowohl Cul3 als auch Cul5 
enthalten, involviert sind. Es wurde berichtet, dass sich Culline zu Dimeren 
zusammenfügen können. Übereinstimmend damit fanden wir heraus, dass Cul3 und Cul5 
in der Lage sind Heterodimere zu bilden. Unsere Ergebnisse zeigen, dass MUF1 im 
Proteasom in einer Cul5-unabhängigen Weise von einem Cul3-RhoBTB3 Ligase Komplex 
abgebaut wird. Dies deutet auf ein umfangreiches Zusammenspiel zwischen den Cullin-
abhängigen Ubiquitin Ligasen untereinander hin. Wir stellen uns ein Modell vor, in dem 
MUF1 in einem Cul5-abhängigen Ubiquitin Ligase Komplex eingebunden ist, und 
hauptsächlich den turnover der Zellkernproteine beeinflusst, indem es sie für das 
Proteasom markiert. RhoBTB3 wäre in der Lage die Funktionen von MUF1 zu regulieren, 
indem RhoBTB3 MUF1 für den Abbau im Proteasom im Zytoplasma markiert. 
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8 Abbreviations 
 
% Percent 
˚C Celsius degree 
AA Amino acid(s) 
APS Ammonium persulfate 
ATP Adenosine triphosphate 
bp Baise pair(s) 
BSA Bovine serum albumin 
cDNA Complementary DNA  
Cul cullin 
DAPI 4´, 6´- diamidino - 2 phenylindol 
DME medium Dulbeccos´ Modified Eagle Medium 
DMSO Dimethylsulfoxide 
DNA Deoxyribonucleic acid 
dNTP Desoxyribonucleotide triphosphate 
DTT Dithiothreitol 
E1 Ubiquitin-activating enzyme 
E2 Ubiquitin-conjugating enzyme 
E3 Ubiquitin ligase 
E. coli Escherichia coli 
ECS EloB/C-Cul5-SOCS-box protein 
ECV EloB/C-Cul2-VHL-box protein 
EDTA Ethylen-Diamine-Tetra-Acetate 
ER Endoplasmic reticulum 
FBS Fetal bovine serum 
g relative centrifugation force 
GA Golgi apparatus 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GFP Green fluorescent protein of Aequorea victoria 
GTP Guanosine triphosphate 
HEPES 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid  
h hours 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
KDa Kilodalton 
λ Wave length 
LRR Leucine-rich repeat 
M Molar 
min minute 
MTOC Microtubule organising center 
MPR Mannose 6-phosphate receptor 
mRNA Messenger ribonucleic acid 
NP-40 Nonidet P-40  
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PIPES Piperazine-N,N‘-bis (2-ethanesulfonic acid) 
Ponceau S  3-Hydroxy-4-[2-sulfo-4-(sulfo-phenylazo)phenylazo]-
2,7-naphthalindisulfonacid  
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RT-PCR Reverse transcription polymerase chain reaction 
SAP Shrimp alkaline phosphatase 
SCF Skp1/Cul1/F-box complex 
SDS Sodium dodecyl sulphate 
sec Second 
TAE Tris-Acetate-EDTA 
Taq Thermus aquaticus 
TBE Tris-Borate-EDTA 
TBS-T Tris buffered saline with Tween 
TE Tris-EDTA 
TEMED N,N,N´,N´-Tetramethyl-ethylendiamin  
Tris Trishydroxyaminomethan 
U Unit 
Ub Ubiquitin 
Uev Ubiquitin-conjugating E2 enzyme variant 
UV Ultraviolet light 
V Volt 
v/v Volume per volume 
w/v Weight per volume 
X-Gal 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
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